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Spinocerebellar ataxias (SCAs) are hereditary neurodegenerative disorders that are united 
by their autosomal dominant inheritance and their common clinical feature: cerebellar ataxia.  
Cerebellar ataxia is a disorder of impaired motor coordination, and in many SCAs the cause of 
degraded motor coordination is understood to be degeneration of cerebellar Purkinje neurons.  
The degeneration of Purkinje neurons in many SCAs is thought to progress from degeneration of 
the elaborate Purkinje neuron dendrite arbor to eventual cell death.  Although it is likely that the 
early dendrite degeneration contributes substantially to motor impairment, the cellular processes 
which drive dendrite degeneration remain very poorly understood.   
It is known that synaptic inputs and intrinsic excitability shape Purkinje neuron dendrites 
during development, and several studies in different SCA models have suggested that altered 
synaptic input or action potential firing contributes to Purkinje neuron degeneration.  Not yet 
explored in any of the SCA models is whether the physiology of the Purkinje neuron dendritic 
shaft are altered.  In a mouse model of spinocerebellar ataxia type 1 (SCA1), we tested the 
hypothesis that SCA1 Purkinje neurons would show an increase in intrinsic dendritic excitability 
that promotes dendrite degeneration.  Our studies identified an increase in intrinsic dendritic 
excitability throughout the course of dendritic degeneration, and we showed that this increased 
dendritic excitability was associated with changes in expression of several channels that regulate 
dendritic excitability. Subsequently, we demonstrated that normalizing dendritic excitability 
xi 
 
exerts a dendro-protective effect in SCA1 Purkinje neurons, supporting the hypothesis that 
increased intrinsic dendritic excitability drives SCA1 Purkinje neuron dendrite degeneration.  
In our attempts to uncover the pathway(s) by which increased dendritic excitability drives 
SCA1 Purkinje neuron dendrite degeneration, we uncovered a large increase in phosphorylation 
of protein kinase C (PKC) enzyme targets in SCA1 mice and SCA1 patient tissue.  PKC activity 
is an important regulator of Purkinje neuron dendritic structure, and we hypothesized that 
increased PKC activity downstream of increased excitability promotes dendritic 
degeneration.  Surprisingly, suppression of PKC activity in SCA1 mice resulted in accelerated 
dendritic degeneration, suggesting that the increased PKC activation is dendro-protective.  A 
similar dendro-protective effect was observed in a model of a different cerebellar ataxia, 
Spinocerebellar ataxia type 2 (SCA2).  Studies from the SCA1 mice suggest that PKC enzymes 
may be exerting their dendro-protective effect by counteracting (although incompletely) 
increases in dendritic excitability, further supporting the role that dendritic excitability plays as a 
driver of Purkinje neuron dendritic degeneration. 
This thesis establishes both intrinsic dendritic excitability and PKC activity as important 
regulators of Purkinje neuron dendrite degeneration in SCA1 and beyond.  The results provide 
clinically-relevant therapeutic targets, and also provide a novel conceptual framework for 
understanding Purkinje neuron dendrite remodeling in health and disease.  Together, these 
findings establish that Purkinje neuron dendrite degeneration is in fact a regulated process, with 










1.1 Purkinje neuron dendritic degeneration: a poorly-understood 
neuropathologic feature of cerebellar ataxia 
1.1.1 Cerebellar ataxia: an overview 
Cerebellar ataxia is a neurologic syndrome characterized by degraded motor 
coordination, unsteady gait, and slurred speech.  Ataxia is a clinical entity rather than a discrete 
disease, and there are a large number of causes of ataxia, including ischemic, toxic, metabolic, 
paraneoplastic, or genetic etiologies.  In many cases, the underlying cause of a patient’s ataxia 
cannot be addressed with existing therapies, meaning that management is symptomatic and 
supportive.  Limited understanding of the diverse disease processes that produce ataxia have 
hampered the development of effective therapies for either discrete indications or more 
widespread applications. 
Among the many causes of ataxia, there is a large and very diverse subset of progressive 
neurodegenerative diseases that affect the cerebellum and its associated pathways.  The 
concurrent observation of cerebellar neurodegeneration and impaired motor coordination in these 
conditions is consistent with the cerebellum’s undisputed importance in the performance of 
smooth and goal-directed movements
1
. Although most cases of neurodegenerative ataxia are 
sporadic, there are a subset of cases that can be attributed to genetic causes, and within that a 
smaller subset of monogenic diseases showing autosomal dominant inheritance
2
.  These 
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autosomal dominant cerebellar ataxias, referred to as spinocerebellar ataxias (SCAs), are 
estimated to have a prevalence as a group of about 3 cases per 100,000
3
. 
The SCAs are a clinically and genetically heterogeneous group of progressive 
neurodegenerative diseases, typically presenting in the third, fourth, or fifth decade of life.  SCAs 
are named and numbered (SCA1, SCA2, etc.) according to the order in which the pathogenic 
gene for that specific SCA was identified. While ataxia is a cardinal feature of the SCAs, many 
SCAs present with additional symptoms in association with neurodegeneration outside the 
cerebellar circuit
2
.  It is nevertheless widely understood that for most of the SCAs, the ataxia is 
principally attributable to cerebellar pathology.  
1.1.2 Purkinje neuron dendrite degeneration in cerebellar ataxia 
Autopsy studies of cerebellar microcircuitry in many SCAs have revealed significant 
involvement of cerebellar Purkinje neurons
4-7
, for some SCAs occurring to the exclusion of any 
other neurons in the central nervous system
6
.  The pattern of Purkinje neuron pathology is similar 
to that which has been observed in other neurodegenerative diseases: significant Purkinje neuron 
loss, with surviving Purkinje neurons showing dramatic simplification of their dendritic arbor 
and pathological axonal swelling
4, 5, 8
. While these studies suggested a progressive cellular 
degenerative process which begins with neuritic degeneration and ends with cell loss, they did 
not by themselves identify the time course or relative importance of Purkinje neuron loss in 
terms of its effect on patients’ motor performance.  With the development of the first SCA 
mouse model, a transgenic model of spinocerebellar ataxia type 1 (SCA1), researchers identified 
symptom onset well before detectable cell loss
9
.  Similarly, a knock-in SCA1 model
10
 and 
transgenic models of spinocerebellar ataxias type 2, 6, and 7 (SCA2, SCA6, and SCA7) also 
found that ataxia precedes cell loss
11-13
, with the study of the SCA2 transgenic model 
3 
 
demonstrating that motor impairment was fully penetrant by the age at which cell loss was first 
detected
11
, suggesting that cell loss by itself makes no significant contribution to symptoms.  
These findings suggested that early histopathologic changes in Purkinje neurons might be 
particularly important for understanding motor impairment. 
An important caveat for interpreting these data should be drawn from the Huntington 
disease (HD) mouse model literature.  While HD in humans is an adult-onset neurodegenerative 
disease arising from CAG tract expansion in a single allele of the HTT gene, several types of HD 
mouse models have been developed where symptoms are observed within the short (~2 year) 
lifespan of the mouse, namely transgenic models expressing the N-terminal fragment of CAG-
expanded HTT
14, 15
,  transgenic models expressing full-length CAG-expanded HTT
16, 17
, and 
models where a CAG tract expansion has been knocked into the endogenous CAG tract of mouse 
Htt
18, 19
.  Each model diverges from the human case in an effort to produce symptoms within the 
mouse’s lifespan, with the transgenic models expressing under strong promoters while the 
knock-in models have CAG tract expansions much longer than what is observed in humans.  For 
the different models, there is a broad range in how well cell death correlates with the onset of 
motor symptoms, with some models showing symptoms without detectable cell death
20
 while 
other models show substantial cell loss by the time symptoms are first detected
18
.  Although it 
remains consistently true in mouse models of any SCA that symptoms are observed before cell 




 models of SCA1 or the 
Purkinje cell-specific transgenic
11
 vs. BAC transgenic
21
 models of SCA2), the spectrum of 
neuropathology-to-symptom relationships observed in HD mouse models and the fact that this 
spectrum depends heavily on model design raises important questions about the validity of 
mouse models in studying human adult-onset neurodegenerative diseases.   
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Despite the caveats, mice represent the only available models for studying SCA Purkinje 
neuron pathology in Purkinje neurons demonstrating primate-like properties and residing within 
a human-like cellular context.  Within the SCA mouse model literature, one factor has emerged 
as being consistently correlated with motor impairment: degeneration of Purkinje neuron 






, dendritic degeneration is temporally-
correlated with the onset of rota-rod deficits, although the strength of the correlation may depend 
on the method by which dendrite degeneration is measured.  Studies using subjective assessment 
of dendrite structure in SCA1 transgenic mice
9
 or measurement of dendrite capacitance in SCA1 
knock-in mice
10
 detected dendrite degeneration which coincides with motor impairment, 
suggesting that at least in these models there is a tight correlation between the onset of dendrite 
degeneration and motor impairment.  In the studies of the SCA2 and SCA6 transgenic models 
the thickness of the molecular layer (the layer of the cerebellar cortex where Purkinje neuron 
dendrites reside) was used as a measure of dendrite structure, and these studies showed that 
molecular layer thinning weeks after symptom onset.  It is worth noting that the SCA1 knock-in 
mouse has reduced Purkinje neuron dendrite capacitance but never has a detectable change in 
molecular layer thickness, suggesting that molecular layer thickness is a relatively crude measure 
of dendrite surface area.  This is further supported by our own work (see section 3.3.1), which 
shows that dendrite capacitance it substantially reduced in the transgenic model of SCA1 before 
at a time point where there is no detectable reduction in molecular layer thickness. 
The apparent correlation between dendrite degeneration and symptom onset in these SCA 
models raises the possibility that dendritic degeneration might account for symptomatic 
impairment.  This conclusion is supported by several lines of evidence.  The first is a finding in a 
study of lurcher aggregation chimera mice, which are formed by combining an embryo from the 
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lurcher mouse and a wild-type embryo to produce a mouse with a mixed population of neurons, 
some of which express the lurcher mutation while others do not.  The lurcher mouse is a 
spontaneous mutant in the C57/BL6 background strain of mice that develops rapid ataxia with 
Purkinje neuron degeneration. The mutation was identified as being in Grid2
22
, a gene encoding 
the GluRδ2 glutamate receptor subunit that is highly expressed in Purkinje neurons. Lurcher 
Purkinje neurons undergo rapid cell-autonomous neurodegeneration and death
23
, such that 
chimeric mice lose a subset of their Purkinje neurons while the remaining Purkinje neurons are 
unaffected.  Rota-rod performance is normal in lurcher chimeras unless they have fewer than 
surviving 15,000 Purkinje neurons
24
, which is less than 10% of total Purkinje neurons based on 
stereological estimates in C57/BL6 mice
25
.  It is worth noting that relatively subtle changes in the 
dendritic morphology of wild-type Purkinje neurons in lurcher chimeras have been described
26
.  
Nevertheless, these data demonstrate that there is significant Purkinje neuron reserve with the 
mouse cerebellum, such that the comparably modest cell loss in SCA mouse models is not 
sufficient to explain ataxia. 
SCA1 is caused by an expanded glutamine-encoding CAG tract in the ATXN1 gene.  As 
in other degenerative cerebellar ataxias, progressive Purkinje neuron dendritic degeneration 
precedes cell death, a feature modeled in a transgenic mouse model of SCA1 expressing a human 
ATXN1 cDNA with 82 glutamine-encoding CAG repeats (“ATXN1[82Q]”)
9, 27
.  
Phosphorylation of ATAXIN-1 (the protein product from ATXN1) at a particular serine (Ser776) 
regulates its interaction with other proteins and influences diseases pathogenesis
28
, such that 
mice expressing polyglutamine-expanded ATAXIN-1 with an S776A mutation (“ATXN1[82Q]-
A776”) show limited Purkinje neuron pathology
29
 while mice expressing non-expanded ATXN1 





.  The ATXN1[30Q]-D776 mouse shows profound ataxia comparable to the 
ATXN1[82Q] mouse, but ATXN1[30Q]-D776 Purkinje neuron pathology does not progress 
beyond dendritic degeneration to cell loss, suggesting that cell loss is not necessary for motor 
impairment in SCA1 mice.  It is worth noting that none of these studies definitively demonstrates 
that dendritic degeneration is the cause for ataxia in these mice.  Nevertheless, these studies 
demonstrate that Purkinje neuron dendritic degeneration is a much stronger structural correlate of 
motor impairment than cell loss, and they motivate exploration of the mechanisms behind 
Purkinje neuron dendritic degeneration in cerebellar ataxia. 
Despite the experimental evidence suggesting that dendritic degeneration might be a 
clinically meaningful phase in Purkinje neuron degeneration, it remains very poorly understood.  
This is in large part due to the fact that dendritic pathology is seldom studied as an independent 
phenomenon.  Several studies that have looked at dendritic pathology in different models of 





 that are normally localized to the dendrite, suggesting a 
model where dendritic degeneration arises because a cell fails to supply the dendritic arbor with 
necessary metabolic components.  Another study of an ataxia model identified misfolded protein 
aggregates in neuronal dendrites, raising the possibility that local proteotoxic stress might 
contribute to dendritic pathology
33
.  Based on these data, one might infer the observed structural 
changes reflect a dendritic arbor overwhelmed by a toxic challenge. 
While these studies provide one framework for understanding dendritic pathology in the 
SCAs, the lack of rescue studies targeting metabolism or protein quality control specifically in 
the dendritic compartment makes it difficult to assess whether the proposed mechanism is in fact 
responsible for structural changes in dendrites.  I take seriously a different hypothesis: that 
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Purkinje neuron dendritic degeneration is in fact a regulated process of atrophic remodeling, 
mediated by pathways that regulate dendritic structure in wild-type Purkinje neurons.  This 
hypothesis has been put forth for other disease states
34-36
, although it has not been explored 
specifically in ataxia.  Below I will provide a broad overview about what is known regarding the 
pathways that regulate dendritic structure in developing and mature neurons, with a specific 
focus on Purkinje neurons. 
 
1.2 Purkinje neuron dendrite structure: an overview 
1.2.1 General principles of dendrite structure in the brain 
A substantial literature exists exploring the structure of neuronal dendrites.  From this, a 
few broad principles can be generalized.  The first is that neuronal dendrite shape regulation can 
be divided roughly into two phases: development and maintenance, with large-scale structural 
decisions being made during a developmental critical period, after which dendrites enter a 
maintenance phase where dendrite arbor structure is relatively stable
37-39
 while spines continue to 
be added, removed, or undergo structural changes
40-42
.  The second is that regulators of dendritic 
structure operate within a nested hierarchy, with the earliest and in many cases most 
comprehensive shape decisions being determined through cell-autonomous transcriptional 
programs
43-46
, while later and smaller-scale decisions regarding dendritic shape and organization 
are achieved through interactions between the neuron and extrinsic signals
47-49
.  The third is that 
neuronal activity, including both neurotransmission
50-53
 and intrinsic excitability
46, 54, 55
,  can 
influence developing dendrites, with a host of activity-dependent intracellular signaling cascades 
operating downstream to regulate dendritic structure
56-58
.   
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Although there are many qualifiers to the principles described above, those that are most 
germaine to this thesis involve the idea of dendritic structure being stable in adult neurons.  
While it is true that long-term in vivo imaging of select neurons has confirmed critical periods for 
dendrite structural flexibility
37
 and demonstrated that dendritic structure is stable over a period of 
months in adult mice in some neuronal subtypes
59, 60
, molecules such as delta-catenin
61
 and the 
Pten tumor suppressor
62
 have been identified as being regulators of dendrite stability in adult 
neurons.  What these findings suggest is that while dendrite structure is relatively stable in adult 
neurons, it is not that adult neurons have lost the capacity for dendritic remodeling, but that it 
remains latent and is instead constrained by active regulatory processes.  Given the dramatic 
impact that neuronal activity has in shaping dendritic structure during development
53, 63
, one 
might expect that there are circumstances where alterations in activity have been demonstrated to 
impact adult neurons’ dendritic structure.   In fact, studies of learning in the motor-sensory 
forelimb cortex have suggested that certain forms of intensive training in adult rats are 
accompanied by circuit-specific changes in dendritic architecture of cortical pyramidal neurons
64, 
65
.  Similarly, studies of adult rodents exposed to systemic amphetamine or cocaine have 
repeatedly shown that these drugs promote dendritic outgrowth in the prefrontal cortex and 
nucleus accumbens
66-68
, and for medium spiny neurons of the nucleus accumbens shell the 
process is prevented  when c-fos expression is prevented
69
, a finding that mechanistically links 
structural changes in those neurons to drug-induced changes in their activity.   
These findings complicate the idea that dendritic structure is stable in adult neurons.  I 
propose that these data suggest that dendrite arbor structure remains flexible into adulthood (as is 
well-described in spines), but that the threshold for activity-dependent changes in structure is 
significantly higher such that “typical” activity seldom perturbs dendrite structure.  If this were 
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the case, one would predict that pathologic states where neuronal activity is altered might trigger 
dendritic structural remodeling, particularly in neuronal subtypes where dendritic structure is 
heavily determined by activity.   In fact, studies of Purkinje neuron dendrite development suggest 
that Purkinje neurons might represent one such neuronal population. 
1.2.2 Purkinje neuron dendritic architecture: a product of activity 
In Purkinje neuron dendrite development, it appears that dendritic structure is governed 
by the principles outlined above, but with the final dendritic architecture depending almost 
entirely on extrinsic signals and neuronal activity (see below).  Purkinje neurons acquire their 
mature dendritic phenotype through a multi-stage process that begins after migration is 
completed.  Starting as bipolar cells, Purkinje neurons develop a stellate phenotype with multiple 
neuritic protrusions, most of which retract to give rise to one or perhaps two apical dendrites
70, 71
.  
From there, the dendritic tree grows substantially, such that mouse Purkinje neurons achieve 
their mature, monoplanar dendritic structure by P20
72
. 
The earliest stages of Purkinje neuron dendritic differentiation depend heavily on 
intrinsic programs.  This was demonstrated using cerebellar slice cultures where specific genes 
were overexpressed or silenced in only a subset of cells using lentiviral transfection, and the 
impact of both overexpression and knockdown on dendrite development could be assessed.  One 
such study revealed that the nuclear receptor RORα controls the retraction of neurites during the 
stellate phase and that it also drives the progression of the subsequent outgrowth of the apical 
dendrite
73
.  A study using the same strategy also revealed that SCLIP, a protein of the 
microtubule-interacting stathmin family, was necessary for any neuritic outgrowth and also 
supported subsequent outgrowth of the apical dendrite
74
.  Although these early events in Purkinje 
neuron dendritic differentiation remain poorly understood, the lentiviral slice culture strategy 
10 
 
employed in these studies is likely to identify additional intrinsic regulators of early Purkinje 
neuron dendritic specification.  
Past these early stages, Purkinje neuron dendrite development depends on extrinsic 
signals.  Several diffusible ligand systems have been identified as being important for Purkinje 






) and patterning 
(Slit/Robo
78
).  Similarly, contact-mediated ligand-receptor systems have been identified as 
important for Purkinje neuron dendrite outgrowth (cadherins
79
) and patterning (proto-cadherins
80
 
and the adhesion-GPCR BAI3
81
). 
In addition to these dendrite guidance cues, Purkinje neuron activity has been 
demonstrated to be critical for the establishment of mature Purkinje neuron dendrite structure. 
Input from cerebellar granule cells is essential, as cerebellar granule cell loss in vivo causes a 
halting of Purkinje neuron apical dendrite development
82
 and Purkinje neurons are only able to 
grow mature dendrites in vitro when co-cultured with granule cells
83
.  It seems that synaptic 
transmission from granule cells onto Purkinje neurons is particularly important
84
, although a role 
for intrinsic excitability cannot be excluded
85
.  It is also well-established that a variety of 
activity-dependent signaling molecules play an important role in regulating Purkinje neuron 
dendrite structure (discussed in section 1.3.4).  These data suggest that the robust and 
characteristic dendritic arbor observed in adult Purkinje neurons is largely a product of synaptic 
inputs, electrophysiologic activity, and downstream signaling, provided that more fundamental 
dendrite specification pathways remain intact.  This suggests that Purkinje neuron dendrites 
might be particularly susceptible to perturbations in electrophysiologic activity. 
In fact, several spontaneous mouse mutants exist where mutations in ion channel genes 
produce profound effects on Purkinje neuron dendritic development.  The lurcher mutation is a 
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gain-of-function mutation in the GluRδ2 glutamate receptor subunit that produces a channel with 
constitutive inward current
22
 and results in cell-autonomous Purkinje neuron dendrite atrophy
86
.  
The moonwalker mutation is a gain-of-function mutation in the transient receptor potential cation 
channel, type C3 (TRPC3) that results in increased responsiveness to mGluR stimulation, and 
moonwalker mice similarly display Purkinje neuron dendrite stunting
87
 with early changes in 
Purkinje neuron spiking
88
.  These studies suggest that changes in Purkinje neuron activity are 
capable of producing profound changes in dendritic structure.   
It is worth noting that the observed changes in these models appear to be developmental, 
and do not by themselves suggest that adult Purkinje neuron dendrites would undergo dramatic 
activity-dependent structural remodeling, as is being proposed in SCA models.  Nevertheless, the 
literature outlining dendritic remodeling in response to intensive training or psychoactive drugs 
(see section 1.2.1) suggests that dendritic remodeling can occur in adult neurons when there is 
late-onset aberrant activity.  We propose that such a mechanism may be involved in dendritic 
remodeling in ataxia, consistent with the age of symptom onset in patients and mouse models.  
There is a growing literature pointing to adult-onset changes in Purkinje neuron activity as being 
a common feature of ataxia correlated with both neuropathology and symptom progression, and 
several studies demonstrate mechanistically that changes in activity actually drive the 
degenerative process. 
 
1.3 Alterations in Purkinje neuron electrophysiology and their potential role 
in dendrite degeneration in models of spinocerebellar ataxias 
Altered neuronal activity has been observed in many SCA models, such that changes in 
neuronal activity could play a role in dendritic remodeling.  For any neuron, the activity of that 
12 
 
neuron is dictated by three interlinked processes: the synaptic inputs and their properties, the 
intrinsic spiking characteristics, and the electrical characteristics of the neuron’s dendrite.  Each 
of these processes will be discussed separately below, with a specific focus on Purkinje neurons 
and the ways in which these processes are affected in models of spinocerebellar ataxia.  At the 
end of this section I will provide an overview of what is known about signaling systems 
downstream of excitability that mediate dendritic remodeling, with a specific focus on those 
systems that might be involved in Purkinje neuron dendritic remodeling in ataxia. 
1.3.1 Purkinje neuron spiking in models of spinocerebellar ataxias 
Purkinje neurons are tonic repetitively firing cells whose firing frequency changes during 
repetitive movement
89
. It is important to note that bistability characterized by “up” states of 
repetitive firing and “down” states of quiescence have been observed in vivo in anesthetized 
mice
90
, although these are likely a byproduct of the anesthesia
91
. Purkinje neurons exert their 
effect on movement through their GABAergic projections to neurons of the deep cerebellar 
nuclei, which represent the sole outputs of the cerebellum (with the exception of direct 
projections from the cerebellar flocculonodular lobe onto the vestibular nuclei).  Individual 
Purkinje neurons encode information in their firing frequency
92
 and converge on individual 
nuclear neurons with inputs that facilitate nuclear neuron recognition of synchronous spikes from 
multiple Purkinje neuron afferents
93
.   
The repetitive action potential firing of Purkinje neurons is autonomous, such that acutely 
dissociated Purkinje neurons (which maintain the axon initial segments
94
 from which action 
potentials are known to initiate in Purkinje neurons
95
) spike at ~60 Hz in the absence of synaptic 
input or injected current
96
.  Purkinje neurons’ autonomous action potential firing, referred to as 
pacemaking, depends on a precise sequence of currents, with each firing cycle involving 1) 
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, 2) repolarizing outward current mediated by KV3 channels
99
, 3) after-hyperpolarization 





, respectively) coupled to P/Q-type voltage-gated calcium channels
103
, and 4) resurgent 
inward sodium current through NaV1.6
97
 that depolarizes the neuron towards threshold for the 
next spike.  The autonomous spiking produced by the orchestrated function of these channels is 
essential for appropriate participation of Purkinje neurons in the cerebellar system, such that the 




The impact that dysfunctional Purkinje neuron spiking has on motor performance 
suggests that among the many genetic causes of ataxia, one might identify a number of disorders 
caused by mutations in ion channels that participate in pacemaking.  In fact, there are a number 
of SCAs and other degenerative ataxias that are caused by mutations in Purkinje neuron 











.  Additionally, studies in mouse models of SCAs not caused by primary 
mutations in ion channel genes have revealed dysfunctional pacemaking correlates with the onset 
of motor symptoms and neurodegeneration
11, 114-119
.  Many of these studies showed that 
symptoms of ataxia in SCAs that were not primary channelopathies could be improved by 
improving Purkinje neuron spiking
114-116, 118-120
.   
In SCAs caused by ion channel mutations, it is not necessarily clear that Purkinje neuron 
dendritic degeneration observed in these patients is a product of altered Purkinje neuron spiking.  
Although SCA13 and SCA19/22 mutations are known to impair function of the mutant channel 
gene product (KV3.3 and KV4.3, respectively)
121, 122
, mice lacking functional kcnc3 (the gene 
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mutated in SCA13) do not show obvious signs of Purkinje neuron dendritic degeneration
108
, and 
Purkinje neuron pathology has not been described in mice lacking functional kcnd3 (the gene 
mutated in SCA19/22)
123
.  Knock-in models do not exist, making it difficult to assess how the 
mutations produce neurodegeneration. 
Importantly, several studies in spinocerebellar ataxia type 1 (SCA1) have demonstrated 
that therapeutic strategies which target Purkinje neuron spiking can prevent dendritic 
degeneration.  SCA1 is caused by expansion of the CAG tract within ATXN1
30
, a gene whose 
protein product is thought to play important roles in regulating transcription
124
 and RNA 
splicing
125
.  Although not a primary channelopathy, studies in the ATXN1[82Q] transgenic 
mouse model of SCA1 have revealed reduced firing frequency, depolarization block, and altered 
input-output functions in response to injected current
114, 116
.  These studies also found that when 
agents found to improve these spiking abnormalities in vitro were administered in vivo, Purkinje 
neuron dendritic surface area was preserved relative to vehicle-treated controls.  These data were 
the first to implicate spiking abnormalities in the neuropathology observed in degenerative 
cerebellar ataxia.  Importantly, they validate the principle that Purkinje neuron dendrites can 
undergo remodeling in response to significant perturbations in intrinsic excitability during 
adulthood. 
1.3.2 Alterations in synaptic inputs onto Purkinje neurons in spinocerebellar ataxia models 
Purkinje neurons reside within the cerebellar cortex in a characteristic monolayer, sitting 
superficial to the granule cell layer and extending their elaborate dendrites towards the pial 
surface through the molecular layer.  Each Purkinje neuron receive two types of glutamatergic 
inputs: 1) tens to hundreds of thousands of parallel fiber synapses
126
 originating from cerebellar 
granule cells, which are themselves targets of mossy fiber inputs to the cerebellum, and 2) a 
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single climbing fiber originating from principal neurons in the inferior olive.  In addition these 
glutamatergic inputs, there are two subclasses of GABAergic interneurons in the molecular layer 
which synapse onto Purkinje neurons and themselves receive both parallel fiber and climbing 
fiber input
127
.  Finally, Bergmann glia have cell bodies near the Purkinje neuron layer and extend 
radial processes expressing glutamate transporters and glutamine synthetase that allow them to 
modulate parallel fiber input
128
. 
The principle glutamatergic inputs onto Purkinje neurons produce very distinct effects on 
spiking.  Parallel fiber inputs are thought to adjust Purkinje neuron spiking in a linear fashion, 
with recruitment of more parallel fibers resulting in higher Purkinje neuron firing frequencies
129
.  
The single climbing fiber onto each Purkinje neuron has many individual synaptic contacts onto 
that Purkinje neurons’ soma and proximal dendrite
130
, such that climbing fiber activation 
interrupts pacemaking and produces a high-frequency burst of spikes
131
.  The role of the complex 
spike remains somewhat unclear, although it is important for several forms of Purkinje neuron 
plasticity
132




As discussed in section 1.2.2, establishment of mature Purkinje neuron dendritic 
architecture requires synaptic input (specifically from granule cells).  This suggests that changes 
in the synaptic inputs onto Purkinje neurons might participate in dendritic remodeling observed 
in SCA models.  In fact, alterations in synaptic function have been described in many SCA 
models. 
In SCA models where transgene expression is limited to Purkinje neurons using the Pcp2 
(L7) promoter, changes at the synapse have been identified which are most likely attributable to 
cell-autonomous changes in the Purkinje neuron.  In the ATXN1[82Q] model of SCA1, reduced 
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climbing fiber responsiveness is observed in vivo at the onset of symptoms and reduced parallel 
fiber responsiveness is observed in advanced disease
134
, while in vitro studies of climbing fiber 
or parallel fiber-induced AMPA currents reveal no difference
135
 or reduced parallel fiber-induced 
AMPA current
114
.  Altered metabotropic glutamate receptor signaling has also been reported in 
this model of SCA1, and the studies of parallel fiber-induced mGluR1 responses suggest a 
reduced amplitude
135
 with slower decay
136
.  In the ATXN2[127Q] transgenic model of SCA2, 




In addition, studies of SCA models have suggested changes on the pre-synaptic side of 
Purkinje neuron inputs, with Bergmann glia emerging as a potentially important participant in 
Purkinje neuron pathology.  In studies of SCA7, an SCA7 model where transgene expression 
was restricted to Bergmann glia showed significant Purkinje neuron pathology
137
,  while an 
SCA7 model where the transgene was expressed in all neurons and then conditionally deleted in 
Bergmann glia showed behavioral improvement but no rescue of Purkinje neuron pathology
13
.  
Although these data conflict somewhat, both studies suggest that the role for Bergmann glia in 
Purkinje neuron pathology involves reduced expression of the glutamate transporter GLAST.  
Studies in a model of spinocerebellar ataxia type 5 (SCA5) similarly identify an important role 
for Bergmann glia GLAST expression, as they found that deletion of GLAST in an SCA5 model 
accelerated Purkinje neuron pathology
138
. 
1.3.3 Alterations in dendritic excitability and their potential role in spinocerebellar ataxia 
dendrite degeneration 
Sitting physically and mechanistically between the synapse and the spike is the dendrite.  
Dendrites are not simply electrical conduits connecting the synapse to the axon initial segment; 
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instead, an abundant literature from many neuronal subtypes demonstrates that dendrites are full 
of ion channels that play an important and regulated role in neuronal information processing.  
The ways in which dendritic ion channels and structure regulate membrane depolarization and 
signal propagation along the dendritic shaft will be referred to as intrinsic dendritic excitability, 
in an effort to distinguish these properties from membrane potential characteristics depending 
directly on the function of ionotropic receptors in the synapse.  Using this terminology, more 
faithful propagation of depolarization along the dendritic shaft would be a condition of increased 
dendritic excitability, while a degradation of depolarization spread along the dendritic shaft 
would be a condition of decreased dendritic excitability.  It is important to note that there is 
significant cross-talk between the synapse, dendritic shaft, and cell body
139
. 
Propagation of depolarization along dendritic segments is described by the cable 
equation, which models the dendritic shaft as a pipe whose walls have an electrical capacitance 
and resistance to current flow and which also has a resistance to current flow along the length of 
the pipe.  Although there are several forms of the cable equation, I will discuss the steady-state 
form of the equation for an infinite cable, in order to outline some general principles of signal 
propagation along a dendrite-like cable: 




Here Vx is the membrane potential at a distance x along the dendritic cable from where 
depolarization V0 is imposed.  In this equation λ represents the length constant, which is a 
constant dictated by the physical properties of the dendritic cable using an equation described 
below:  






The Rm is the membrane resistance to current flow across the wall of the cable, while Ra is the 
internal resistance to current flow down the axis of the cable.  Rm and Ra in a cylindrical neuronal 
dendrite are described by the equation below: 
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1.3             𝑅𝑚 =
𝑅𝑀
𝜋𝑙𝑑




Rm will be determined by the surface area of available membrane (πld) and the resistance per 
unit area (RM), which is a function of the number and type of channels open, which will itself be 
determined by parameters that regulate the function of those channels (membrane potential, 
ligand concentration, etc.).  Ri will be determined by the cross-sectional area of the dendrite (πr
2
) 
and the resistivity of the dendritic cytoplasm (RI), which is a measure of how readily electric 
current will travel through the cytoplasm. 
From equation 1.1, it is clear that with increasing distance the measured voltage will 
attenuate.  In addition, the other equations demonstrate that two features significantly impact 
signal propagation through the dendritic arbor: dendrite arbor shape and ion channel behavior.  
Ion channel behavior is collectively summed up in RM above, but in general more open channels 
will result in a lower RM and ultimately less depolarization at position x in equation 1.1, a 
property referred to as dendritic shunting.  Changes in dendrite shape will vary depending on the 
specific change, but for a single cable a reduction in axial surface area will increase the axial 
resistance and reduce the measured depolarization at position x in equation 1.1. 
The importance of dendritic structure and dendritic ion channel function for signal 
propagation through the dendritic arbor has been extensively studied, and different neuronal 
subtypes have employed the principles outlined above to confer unique computational properties.  
There is also substantial evidence that neurons change the properties of the dendritic cable to 







 and creating changes in spine neck structure
141
. For the remainder of this section, I 
will focus on what is known about Purkinje neuron dendritic signal integration, ending with the 
evidence suggesting that changes in Purkinje neuron dendritic excitability might be a feature of 
spinocerebellar ataxias. 
In some neuronal subtypes, somatic action potentials back-propagate into the dendritic 
arbor and play an important role in regulating dendritic signal processing
142
 and synaptic 
plasticity
143
.  Purkinje neuron show comparatively poor backpropagation of action potentials into 
the dendritic arbor
95
, likely due to the relative absence of functional dendritic voltage-gated 
sodium channels
144
 and their highly-branched dendritic morphology.  As such, Purkinje neuron 
dendrites are best thought of as receiving and shaping synaptic inputs that ultimately exerts its 
impact on somatic spiking.  Modeling studies have suggested that this occurs through a 
mechanism where synaptic conductances in the Purkinje neuron dendrite exert a partial “voltage 
clamp” on dendritic membrane potential that then influences somatic spike frequency and 
irregularity
145
, and in vivo studies have supported this model and demonstrated that dendritic 
membrane potential influences somatic spiking in response to a linear integration of excitatory 
granule cell inputs and inhibitory interneuron inputs
146
. 
Purkinje neurons are similar to some other types of neurons in that they show locally-
generated dendritic spikes, which for Purkinje neurons are mediated by voltage-gated calcium 
channels
147
 .  Much like an action potential, dendritic calcium spikes are voltage-dependent 
events that likely involve a positive feedback loop of channel recruitment after dendritic 
membrane potential has reached a certain threshold. Dendritic calcium spikes have been found to 
be an important mechanism by which Purkinje neuron dendrites can shape synaptic input to 
influence action potential output
148
.  Dendritic calcium spikes are seen in response to strong 
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parallel fiber stimulation, and they produce supralinear integration of parallel fiber input in 
somatic spiking immediately after the spike and then producing a temporary slowing of spiking 
rate
149
. Climbing fiber stimulation also produces dendritic calcium spikes, a process which is 
itself influenced by mGluR-dependent changes in dendritic A-type potassium currents
150
, and the 
dendritic calcium spikes triggered during a complex spike appear to influence transitions in 
action potential firing measured from the soma between silent down-states and spiking up-
states
148
 that have been described under specific anesthetic conditions in vivo
90
.  The presence or 
absence of a dendritic calcium spike during a somatic complex spike has also been demonstrated 
to determine whether somatic spike undergoes a pause following the complex spike itself
148
.  
These studies all highlight the ways in which dendritic calcium spikes influence Purkinje neuron 
dendritic integration. 
Beyond the voltage-gated calcium channels which produce dendritic calcium spikes, 
Purkinje neuron dendrites express a host of potassium channels that regulate generation of those 
calcium spikes and more broadly participate in dendritic shunting.  KV3 and KV4 channels appear 
to be the predominant voltage-gated potassium channel in Purkinje neuron dendrites
150, 151
, and 
both types of KV channels dampen action potential backpropagation and shape dendritic calcium 






 are both abundant in the dendritic tree 
of Purkinje neurons, and both have been shown to regulate coupling between the dendritic and 
somatic compartments
101, 154
.  Other potassium channels are expressed in Purkinje neuron 
dendrites, such as subthreshold-activated potassium channels
155
 and two-pore potassium 
channels
156
, although their role in Purkinje neuron dendrite shunting is not well-studied. 
The dendritic shaft, as discussed during the introduction to section 1.3, represents a third 
“compartment” whose activity could influence dendritic structure.  In fact, a study in Drosophila 
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C4da sensory neurons revealed that large-scale dendritic remodeling during the fly’s 
metamorphic transition into adulthood is triggered by regulated changes in dendritic excitability, 
rather than changes in spiking or synaptically-driven events
157
.  In considering potential causes 
of Purkinje neuron dendrite remodeling in spinocerebellar ataxias, I will be focusing in this 
thesis on the potential role that altered dendritic excitability might play.   
Unlike spiking or synaptic activity, dendritic excitability has not been explored in any 
SCA models.  Nevertheless, it is likely that changes in dendritic excitability are present in 
multiple forms of spinocerebellar ataxia.  SCA13 is caused by mutations in the KV3.3 channel 
and SCA19/22 is caused by mutations in KV4.3 channel, both of which are important in Purkinje 







, and these channels mediate important dendritic shunting conductances in 
addition to their role in somatic spiking.  Perhaps most importantly, both studies in SCA1 mice 
where therapies designed to normalize action potential firing were able to preserve dendrite 
structure were using drugs that target potassium channels important to both the soma and the 
dendrite.  These studies raise the possibility that the effect of these drugs on dendritic excitability 
might partly explain the preservation of dendrite structure.   
Changes in dendritic excitability have been explored in several neurodegenerative 
diseases affecting non-Purkinje neuron populations.  Studies in rodent models of Alzheimer 
disease have revealed increased dendritic excitability (as measured by an increase in dendritic 
backpropagating action potential amplitude) in CA1 pyramidal neurons, and both have 
implicated these changes in dendritic excitability as contributors to symptomatic impairment
159, 
160
.  Interestingly, one study focused on changes in dendritic potassium channel trafficking
159
 
while the other focused on the impact of altered dendritic structure
160
, providing a nice 
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illustration of the multiple mechanisms by which dendritic excitability could be affected in 
neurodegenerative disease. 
Changes in dendritic excitability have been implicated in the dendritic pathology of 
neuronal populations affected in Parkinson disease.  When mice are treated with reserpine, 
profound striatal dopamine depletion and parkinsonism are induced
161
, and this treatment was 
found to produce spine and dendrite degeneration in D2-expressing medium spiny neurons 
(MSNs) but not D1-expressing MSNs
162
.  Study of the differences between D1-expressing and 
D2-expressing MSNs revealed that D2-expressing MSNs show dopamine-induced suppression 
and acetylcholine-induced enhancement of backpropagating action potential propagation into the 
dendrite
163
.  Backpropagating action potentials in dopaminergic neurons of the substantia nigra 
pars compacta produce dendritic calcium entry that triggers mitochondrial oxidant stress
164
, 
which the authors view as a potential driver of Parkinson disease neurodegeneration in this 
population of neurons.  Similar patterns of backpropagating action potential-induced calcium 
entry and oxidant stress have been observed in other neuronal populations that are affected in 
Parkinson disease, including neurons from the dorsal motor nucleus of the vagus
165
 and 
noradrenergic neurons of the locus coeruleus
166
.  Backpropagating action-potential-induced 
dendritic calcium entry through L-Type calcium channels has been suggested as a central risk 
factor of neurons which degenerate in Parkinson disease
167
, placing dendritic excitability as 
potentially central to dendrite pathology in this disease. 
1.3.4 Intracellular signaling systems operating downstream of altered Purkinje neuron 
excitability to mediate dendrite degeneration 
Neuronal excitability exerts its influence on dendritic structure through a host of 
intracellular signaling systems.  In this section I will provide a broad overview of these 
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regulators.  I will end by discussing studies where changes in these activity-dependent regulators 
have been observed or linked to dendrite remodeling in ataxia. 
As discussed in section 1.2.1, there are several activity-dependent transcriptional 
regulators which are known to be important for dendrite structure specification during 






, and chromatic remodeling 
complexes specific to terminally-differentiated neurons
169
, with genetic ablation or 
pharmacologic suppression of these factors producing stunted dendrites in cerebellar granule 
neurons
168
, cortical layer V pyramidal and hippocampal CA3 neurons
45
, cultured cortical 
neurons
46
, and cortical layer V pyramidal and cultured hippocampal neurons
169
, respectively.  
Work in Drosophila suggests that transcriptional regulators of dendritic structure operate much 
like transcription factors that specify cell fate, such that a neuron’s “dendritic specification” can 
be switched through exogenous expression of dendrite shape transcription factors from another 
neuronal population
43, 44
.  The dramatic and rapid impact that changes in these transcriptional 
regulators have on dendritic structure is at odds with the slowly-progressive dendritic 
degeneration observed in ataxia, arguing against the involvement of these factors, although 
subtle changes in the function of these  transcriptional regulators producing slowly-progressive 
remodeling cannot be ruled out.  As such, the remainder of this section will focus on regulators 
of dendrite structure that produce smaller-scale changes by acting on the dendritic cytoskeleton. 
 Within neuronal dendrites, the core scaffold of the dendritic shaft is composed of a 
tightly-packed network of microtubules
170
. It is important to note that dendritic structure is not 
strictly microtubule-based, since the microtubule core within the dendritic shaft is surrounded by 
an outer matrix of filamentous actin (F-actin) from which spine F-actin extends
171
 and the 
dendritic shaft also contains neurofilaments
172
.  Studies of axon growth cone development have 
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suggested that establishment of neurites is initiated through F-actin polymerization, with 
maturation of the neurite occurring through subsequent microtubule invasion
173
. Furthermore, in 
vitro studies have shown that treatment with drugs that influence only actin polymerization can 
produce changes in the structure of mature dendrites
174, 175
.  Finally, a study has suggested that 
alterations specific to neurofilaments can influence dendritic arborization
176
.  Importantly, there 
is cross-talk between all three classes of cytoskeletal filaments. These findings have led to an 
understanding of dendrite structure as most dependent on microtubule and actin dynamics
177
, 
with a likely (although less well-explored) contribution from neurofilaments, such that regulatory 
systems which impinge upon any of the three cytoskeletal systems are capable of producing 
remodeling of dendrites. 
 The activity-dependent regulators of the dendritic cytoskeleton are numerous.  Because 
the establishment and maintenance of dendritic structure involves locally-determined decisions 
about polymerization vs. depolymerization and branching vs. outgrowth, it is difficult to 
generalize about how perturbations to a specific regulator might affect dendritic structure, 
particularly given findings where differences in the cell-type, method, and timing of perturbation 
have produced opposite results
56, 178
.  Activity-dependent regulators of dendritic structure that act 
upon the cytoskeleton are outlined in Table 1.1.  For the remainder of this section, I will be 
focusing on studies that have explored specific activity-dependent regulators of the dendritic 
cytoskeleton in Purkinje neurons, ending with discussion of studies where changes in these 
regulators have been identified in spinocerebellar ataxias. 
 Among the Rho-family GTPases, the clearest role has been identified for Rac1 in 
Purkinje neurons, although RhoA and Cdc42 are also expressed
179
.  In a study where transgenic 
mice were generated expressing mutant constitutively-active Rac1 in Purkinje neurons, Purkinje 
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.  Furthermore, mice lacking the Rac1-
GEF P-Rex2 show smaller Purkinje neuron dendrite arbors
180
 while biolistic overexpression of 
the Rac1-GAP α1-chimaerin in slice cultures impairs Purkinje neuron dendrite outgrowth
57
, 
consistent with the fact that Rac-GEFs promote Rac1 activation while Rac-GAPs oppose Rac1 
activation.  These data together suggest that active Rac1 limits the elaboration of Purkinje neuron 
dendrites. 
 A separate study identified CaMKII-mediated regulation of stathmin as a crucial 
participant in activity-dependent dendritic outgrowth following the stellate phase (see section 
1.2.2).  Stathmin is a microtubule destabilizing protein, and overexpression of stathmin in 
developing Purkinje neurons prevents the development of a mature dendritic arbor.  This study 
demonstrated that neuronal activity stimulates CaMKII to phosphorylate stathmin, inactivating it 
and allowing for dendritic outgrowth
181
.  This study connects Purkinje neurons’ reliance on 
activity for dendritic outgrowth during development directly to the cytoskeleton. 
 Protein kinase C (PKC) isozyme activity has been demonstrated to be very important for 
mature Purkinje neuron dendrite structure, although the data are somewhat conflicting.  
Increased protein kinase C activity has been shown to impair dendritic outgrowth in developing 
Purkinje neurons from slice cultures
182
 in a manner that depends on the function of voltage-gated 
calcium channels
183
.  This would be consistent with the observation that mutations in the PKC 
substrate MARCKS that mimic PKC phosphorylation result in reduced dendritic complexity in 
cultured hippocampal neurons
184
.  However, spinocerebellar ataxia type 14 (SCA14) is caused by 
mutations in PRKCG, the gene which encodes PKCγ, and the vast majority of SCA14-causing 
mutations in PKCγ produce an enzyme with reduced in vivo kinase activity
185
, suggesting that 
the Purkinje neuron dendrite degeneration observed in SCA14
186
 is mediated by reduced PKCγ 
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function.  I propose that these data can be reconciled through a model where during development 
PKC activity promotes Purkinje neuron dendrite outgrowth but in mature Purkinje neurons PKC 
activity promotes dendrite stability.  However, this model remains to be tested. 
 There is indirect evidence to suggest that activity-dependent regulators of the dendrite 
cytoskeleton may play a role in Purkinje neuron dendrite remodeling in spinocerebellar ataxias.  
In addition to the studies of SCA14 and PKC isozymes’ role in dendritic remodeling, several 
studies in other forms of ataxia have hinted that there may be dysregulation of these systems.  
Studies in a SCA3 mouse have revealed that calpain family protease activity is an important 
modifier of Purkinje neuron dendrite degeneration
187
, although this could also be attributable to 
calpain-mediated cleavage of the pathogenic protein product ataxin-3
188
.  SCA5 is caused by 
mutations in SPTNB2 (the gene encoding βIII-spectrin), and βIII-spectrin knockout mice show 
increased calpain activation in Purkinje neurons
189
, a finding which follows the appearance of 
dendritic degeneration linked to reduced glutamate uptake
138
.  Outside of the cerebellum, studies 
in a SCA1 mouse model have suggested a role for GSK-3β in hippocampal dendritic 
degeneration
190
.  Although none of these studies makes a direct causal connection between 
neuronal activity, activity-dependent regulators, and Purkinje neuron dendrite remodeling, they 
do demonstrate that these systems are altered in multiple forms of ataxia, identifying potential 
pathways by which altered Purkinje neuron activity might drive dendritic remodeling in the 
SCAs. 
 
1.4 Summary and aims of dissertation 
 Dendritic degeneration is a ubiquitous feature of neurodegenerative disease, and mouse 
model studies suggest that Purkinje neuron dendritic degeneration may be particularly important 
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to progressive ataxia in spinocerebellar ataxias (SCAs).  Despite this, Purkinje neuron dendritic 
degeneration in spinocerebellar ataxias remains poorly understood.  Changes in Purkinje neuron 
activity have been linked to Purkinje neuron degeneration, in keeping with the substantial role 
that activity plays in specifying mature Purkinje neuron dendrite structure, but any possible role 
for changes in dendritic excitability have not yet been explored.  To address this, my dissertation 
sought to characterize any possible changes in the dendritic physiology of Purkinje neurons from 
the ATXN1[82Q] model of SCA1.  In addition to characterizing those changes, I sought to 
explore potential activity-dependent signaling pathways that might operate downstream of 
altered dendritic excitability to mediate dendritic remodeling in SCA1 and other degenerative 
ataxias. 
 My thesis was motivated by two hypotheses: 1) ATXN1[82Q] Purkinje neurons show an 
increase in intrinsic dendritic excitability that drives dendrite degeneration, and 2) changes in 
activity-dependent regulators of dendrite structure contribute to dendrite degeneration observed 
in SCA1 and other forms of cerebellar ataxia.  The first hypothesis was supported by the 
literature from ATXN1[82Q] mice which demonstrates reduced expression or function of 
potassium channels that should result in increased dendritic excitability and then also shows that 
reversing these changes is dendro-protective.  The second hypothesis was supported by the 
substantial role that activity-dependent pathways play in Purkinje neuron dendrite development, 
and also by the fact that SCA14 is caused by mutations in PKCγ, an activity-dependent 
regulators of Purkinje neuron dendrite structure.  These hypotheses fit together under a single 
hypothesis of dendritic degeneration, where I proposed that that increased dendritic excitability 
might be a major trigger for the hypothesized changes in activity-dependent regulators of 
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dendrite structure.  A schematic representation of the hypothesis explored in this dissertation is 
outlined in Figure 1.1. 
 This dissertation explores this hypothesis by addressing three specific aims.  The first aim 
is to assess whether there are abnormalities in ATXN1[82Q] Purkinje neuron dendritic 
physiology, to link observed abnormalities to changes in specific channels, and ultimately to 
assess whether there is a causal connection between altered dendritic physiology and dendritic 
remodeling.  The second aim is to explore activity-dependent pathways that could act 
downstream of alterations in dendritic excitability to drive Purkinje neuron dendritic 
degeneration in SCA1.  Work in this aim identified protein kinase C (PKC) isozyme activity as 
being an important modifier of Purkinje neuron dendritic degeneration, and suggested that the 
mechanism by which PKC activity regulates Purkinje neuron dendritic degeneration might also 
involve alterations in dendritic excitability.  The findings from this second aim led to the third 
and final aim of this dissertation, which is to assess whether PKC activity might participate in the 




Pathway Details Primary target 
Rho-family 
GTPases 
The important Rho-family GTPases regulating dendrite 
structure are RhoA, Rac1, and Cdc42
191
, although roles 
for other Rho-family GTPases have been demonstrated
192
. 
Activity is regulated by GAPs and GEFs, such that 
activity of these GAPs and GEFs can also influence 
dendrite structure
57, 193-195
.  Rho-family GTPase targets 










 regulate dendrite development and 







Arp2/3 Arp2/3 is a multi-protein complex that can stimulate actin 
nucleation.  PICK1, an inhibitor of Arp2/3, regulates 
NMDA-induced Arp2/3 function and is required for 
normal dendritic morphology
200
. Cobl has also been 
identified as an important  
Actin 
Cobl Cobl is an actin-nucleating protein that operates 
independent of Arp2/3 to regulate dendrite structure
201
.  





Caspase-3 Caspase-3 activity can be stimulated locally by synaptic 
activity
203
.  Rather than triggering cell death, local 
caspase 3 activation can trigger dendrite pruning
204
, 







Calpain proteases are calcium-responsive proteases that 

















GSK-3β facilitates activity-dependent regulation of 
dendrite structure
58












 participate in activity-dependent 





Ras family GTPases can be activated by neuronal calcium 
entry
211
 or membrane depolarization
212
.  Local activation 
of MAPK downstream of Ras can stabilize nascent 
dendrites
213





Stathmins Stathmins are microtubule destabilizing enzymes that 





Cypin Cypin binds to tubulin heterodimers and promotes 
microtubule polymerization in dendrites
215
. Activity 




The centrosome A surprising role for the centrosome was identified in 
dendrite development. Typically thought of as being 
important for spindle formation during mitosis, it was 
discovered that cdc20-dependent signaling at the 
















In addition to their well-established roles as activity-
dependent regulators of dendritic structure through their 
impact on transcription
46, 219
, they can also act through 
local phosphorylation of dendrite structure regulators, 









Table 1.1 Activity-dependent regulators of dendritic structure which act on cytoskeletal 
elements. Provided above is a list of activity-dependent pathways that operate by acting on 
dendritic cytoskeletal elements.  It is worth noting that there is cross-talk between the pathways 
outlined above
198, 222, 223






Figure 1.1 Hypothesis for the role that dendritic excitability and activity-dependent 
dendrite structure regulators play in Purkinje neuron dendrite degeneration in ataxia. 
Outlined above is the hypothesis explored in this dissertation.  In healthy adult Purkinje neurons 
(left), dendritic excitability is regulated by a host of channels including potassium channels, such 
that dendritic excitability is consistent and activity-dependent regulators of dendrite structure do 
not show significant changes in their activity.  This results in a stable dendritic arbor.  In 
contrast, Purkinje neurons in ataxia (right) undergo dendritic degeneration.  I hypothesize that 
this results from increased dendritic excitability and changes in activity-dependent regulators of 






Materials and Methods 
This chapter provides information on the materials and methods used in chapters 3, 4, and 5.  
Protocols are presented roughly in the order in which they will appear in later chapters.  Most of 
this information is in a publication which is currently under review. 
2.1 Animals and ethical use 
All animal procedures were approved by the University of Michigan Committee on the Use and 
Care of Animals. The ATXN1[82Q] transgenic mice
27
 overexpress mutant human ATXN1 with 
82 CAG repeats selectively in cerebellar Purkinje neurons under the Purkinje neuron-specific 
murine Pcp2 (L7) promoter and were maintained on an FVB/NJ background (Jackson Labs, 
001800). These mice were maintained homozygous for the transgene
116
 except as indicated 
below.  ATXN1[82Q] mice were used between two weeks old and fifteen weeks old. Age- and 
sex-matched wild-type FVB/NJ mice were used as controls for these studies.  The 
ATXN2[127Q] transgenic mice
11
 overexpress mutant human ATXN2 with 127 CAG repeats 
selectively in cerebellar Purkinje neurons under the Pcp2 (L7) promoter and were maintained on 
a mixed background. These mice were generated on a B6D2F1 hybrid background (Jackson 
Labs) and the line was maintained by crossing to this hybrid strain. Experiments using 
ATXN2[127Q] mice were done using hemizygous ATXN2[127Q] (tg/-) mice compared to wild-
type ATXN2[127Q] (-/-) littermate controls.  Mice used for these experiments were twelve 
weeks old.  PKCi mice
224
 express the pseudosubstrate PKC inhibitor (PKCi) peptide selectively 
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in Purkinje neurons under the Pcp2 (L7) promoter and were maintained on a C57B6J background 
(Jackson Labs). A balance of mice of both sexes were used in all studies. 
In all experiments where ATXN1[82Q] bigenic mice were used, animals were always 
compared to litter-mate controls.  Experimental mice originated from crosses between 
ATXN1[82Q] (tg/-) mice on an FVB/NJ background and PKCi (tg/-) mice on a C57B6J 
background, such that all experimental animals were F1 hybrids.  The genotypes of mice used 
are specified as follows: 
 Wild-Type: ATXN1[82Q] (-/-); PKCi (-/-) 
 PKCi: ATXN1[82Q] (-/-); PKCi (tg/-) 
 ATXN1[82Q]: ATXN1[82Q] (tg/-); PKCi (-/-) 
 ATXN1[82Q] Bigenic: ATXN1[82Q] (tg/-); PKCi (tg/-) 
All data presented from these experiments were from mice at twenty weeks of age. 
In all experiments where ATXN2[127Q] bigenic mice were used, animals were always 
compared to litter-mate controls.  Experimental mice originated from crosses between 
ATXN2[127Q] (tg/-) mice on a mixed background and PKCi (tg/-) mice on a C57B6J 
background, such that all experimental animals were on a mixed background.  The genotypes of 
mice used are specified as follows: 
 Wild-Type: ATXN2[127Q] (-/-); PKCi (-/-) 
 PKCi: ATXN2[127Q] (-/-); PKCi (tg/-) 
 ATXN2[127Q]: ATXN2[127Q] (tg/-); PKCi (-/-) 
 ATXN2[127Q] Bigenic: ATXN2[127Q] (tg/-); PKCi (tg/-) 





In all cases, DNA for genotyping was extracted from clipped mouse tails using a DNeasy 
Blood & Tissue Kit (Qiagen, Cat. no. 69504).  DNA was stored at -20ºC until a PCR was run for 
genotyping.  In all cases, products were run on a 1.5% agarose gel and visualized with ethidium 
bromide. 
For genotyping of the ATXN1[82Q] transgene, two primer sets were used 
simultaneously.  One primer set amplifies the transgene, producing an amplicon of size ~550 bp.  
The other primer set amplifies mouse genomic DNA from elsewhere in the genome, producing 
an amplicon of size ~220 bp and serving as a Taq and DNA control.  Mice expressing the 
ATXN1[82Q] transgene would have both bands, while mice not expressing the transgene would 
only have a single band at ~220 bp.  The PCR conditions for ATXN1[82Q] transgene genotyping 
are as follows: 1 cycle 94ºC for 5 minutes; 30 cycles of 94ºC for 1 minute, 60ºC for 1 minute, 
and 72ºC for 1 minute; 1 cycle of 72ºC for 8 minutes. Information on the primers is included in 
the table below: 
Primer Name Sequence Description 
Transgene Forward 
(5EX2B) 
5’ – AGGTTCACCGGACCAGGAAGG – 3’ Described previously
27
, 
located within Pcp2 exon 2 
Transgene Reverse 
(Ruby) 
5’ – AATGAACTGGAAGGTGTGCGGC – 3’ Binds to ATXN1 cDNA, 




5’ – AACTTTGGCATTGTGGAAGG – 3’   
Genomic Reverse 
(Gap60-2) 
5’ – ACACATTGGGGGTAGGAACA – 3’  
  
For genotyping of the ATXN2[127Q] transgene, one primer set was used.  This primer 
set amplifies the transgene, and the primers span the intron between exon 6 and exon 7 of the 
human and mouse gene and bind to the cDNA contained within the transgene.  This primer set 
produces an amplicon of size ~370 bp from the transgene, and is predicted to produce a mouse 
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genomic DNA amplicon of size ~68,000 bp (never seen).  Mice expressing the ATXN2[127Q] 
transgene will have a single band at ~370 bp, while mice not expressing the transgene will have 
no band.  The PCR conditions for ATXN1[82Q] transgene genotyping are as follows: 1 cycle 
94ºC for 3 minutes; 40 cycles of 94ºC for 30 seconds, 57ºC for 30 seconds, and 68ºC for 45 
seconds; 1 cycle of 68ºC for 5 minutes.  Information on the primers is included in the table 
below: 
Primer Name Sequence Description 
Transgene Forward 5’ - CGGGAAGCAAGGGCAAACCAGTTA – 3’ Within exon 6 of human 
ATXN2 refseq mRNA 
(NCBI ref no. 
NM_002973.3) 
Transgene Reverse 5’ – AGGAAGGAGATGGGCAAGGCGAT – 3’ Antisense to exon 7 of 
human ATXN2 refseq 
mRNA (NCBI ref no. 
NM_002973.3) 
 
For genotyping of the PKCi transgene, two primer sets were used, each of which share 
the same reverse primer.  One primer set has a forward primer sitting within the sequence for 
Pcp2 and the reverse primer also sitting within the sequence for Pcp2.  The other primer set has a 
distinct forward primer which sits at the 3’ end of the PKCi peptide inhibitor sequence. Wild-
type mice have a single amplicon of size 340 bp from the endogenous Pcp2 locus.  Mice 
expressing the transgene theoretically should have three bands, one from the endogenous Pcp2 
locus (340 bp), one which amplifies the transgene using Pcp2 primers but contains the PKCi 
sequence (~400 bp), and one which uses a forward primer within the PKCi sequence and the 
reverse primer for Pcp2 (~250 bp).  In practice, the 340 bp band is not seen, thus mice 
expressing the PKCi transgene appear to have two bands while wild-type mice only have one.  
The PCR conditions for PKCi transgene genotyping are as follows: 1 cycle 94ºC for 5 minutes; 
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30 cycles of 94ºC for 1 minute, 57ºC for 1 minute, and 72ºC for 1 minute and 30 seconds; 1 
cycle of 72ºC for 10 minutes.  Information on the primers is included in the table below: 
Primer Name Sequence Description 
Pcp2 Forward 
(L7 Primer 1) 
5’ – CACTTCTGACTTGCACTTTCCTTGG – 3’ Amplifies Pcp2 locus  
PKCi Forward 
(L7 PKC Primer) 
 
5’ – CTGAGGCAGAAGAACGTGTAAG – 3’ This primer is the last 22 bp 





(L7 Primer 2) 
5’ – TTCTTCAAGCTGCCCAGCAGAGCTC – 3’ Binds Pcp2 locus, is used as 
reverse primer for both 
forward primers 
 
2.3 Ex-vivo electrophysiology 
2.3.1 Solutions 
Artificial CSF (aCSF) contained the following (in mM): 125 NaCl, 3.5 KCl, 26 NaHCO3, 1.25 
NaH2PO4, 2 CaCl2, 1 MgCl2, and 10 glucose. For all recordings except for measurements of 
dendritic capacitance, pipettes were filled with internal recording solution containing the 
following (in mM): 119 K Gluconate, 2 Na gluconate, 6 NaCl, 2 MgCl2, 0.9 EGTA, 10 HEPES, 
14 Tris-phosphocreatine, 4 MgATP, 0.3 tris-GTP, pH 7.3, osmolarity 290 mOsm (somatic 
recordings) or 285 mOsm (dendritic recordings). For measurements of dendritic capacitance, 
pipettes were filled with internal recording solution containing the following (in mM): 140 CsCl, 
2 MgCl2, 1 CaCl2, 10 EGTA, 10 HEPES, 4 Na2ATP, pH 7.3, osmolarity 287 mOsm. In dendritic 
capacitance experiments where post-hoc visualization of neurons was performed, biocytin (Cat. 
No. B4261, Sigma-Aldrich) was added to CsCl internal recording solution to a final 
concentration of 3.03 mg/mL. 
 
2.3.2 Preparation of brain slices for electrophysiological recordings 
37 
 
Mice were anesthetized by isofluorane inhalation, decapitated, and the brains were submerged in 
pre-warmed (33°C) aCSF.  Slices were prepared in aCSF held at 32.5-34°C on a VT1200 
vibratome (Leica).  Slices were prepared to a thickness of 300 µm for somatic recordings and a 
thickness of 250 µm for dendritic whole-cell recordings. Once slices were obtained, they were 
incubated in continuously carbogen (95% 02/5% CO2)-bubbled aCSF for 45 minutes at 33°C. 
Slices were subsequently stored in continuously carbon-bubbled aCSF at room temperature until 
use.  For recordings, slices were placed in a recording chamber and continuously perfused with 
carbogen-bubbled ACSF at 33°C with a flow rate of 2–3 mls/min, excepting compartment-
specific capacitance measurements which were performed at room temperature (24-25°C). 
 
2.3.3 Patch-clamp recordings 
Purkinje neurons were identified for patch-clamp recordings in parasagittal cerebellar slices 
using a 40x water-immersion objective and Eclipse FN1 upright microscope (Nikon) with 
infrared differential interference contrast (IR-DIC) optics that were visualized using NIS 
Elements image analysis software (Nikon). Borosilicate glass patch pipettes were pulled with 
resistances of 3–5 MΩ for somatic recordings or 7-10 MΩ for dendritic whole-cell recordings.  
Recordings were made 1-5 hours after slice preparation in a recording chamber that was 
continuously perfused with carbogen-bubbled ACSF at 33°C at a flow rate of 2–3 mls/min.  Data 
were acquired using an Axon CV-7B headstage amplifier, Axon Multiclamp 700B amplifier, 
Digidata 1440A interface, and pClamp-10 software (MDS Analytical Technologies).  In all 
cases, acquired data were digitized at 100 kHz. Voltage data were acquired in current-clamp 
mode with bridge balance compensation and filtered at 2 kHz. Cells were rejected if the series 
resistance changed by >20% during the course of recording.  Whole-cell somatic recordings were 
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rejected if the series resistance rose above 15 MΩ, with the majority of recordings have a series 
resistance of <10 MΩ. Whole-cell dendritic recordings were rejected if the series resistance fell 
outside a range of 15-30 MΩ. The liquid gap junction potential for all voltage measurements was 
calculated to be 10 mV
116
.  All voltages are corrected for gap junction potential. 
Acquisition of data for compartment-specific capacitance measurements was performed 
in the presence of 50 µM picrotoxin at room temperature (24-25°C). Capacitative transients were 
obtained in voltage-clamp mode using 1 second steps to -70 mV from a holding potential of -80 
mV.  Recordings were excluded if the measured input resistance was <100 MΩ. 
Recordings to determine the current threshold for eliciting dendritic calcium spikes were 
performed as described previously, but in aCSF containing 1 µM tetrodotoxin (Tocris 
Bioscience).  In experiments where baclofen was used, baclofen (Cat. no. B5399, Sigma-
Aldrich) was used at a concentration of 2 µM. 
 
2.3.4 Analysis of cell capacitance 
 Determination of dendritic capacitance was performed using a well-established method 
for analysis of an equivalent circuit representing the Purkinje neuron
225
.  Input resistance was 
corrected offline, and the decay of the capacitative transient was fit using a two-exponential 








The constants from each cell’s decay function can then be used to obtain four parameters: C1 
(representing the capacitance of the soma and main proximal dendrites), C2 (representing the 
capacitance of the distal dendritic arbor), R1 (representing the pipette access resistance), and R2 
(representing the composite resistance of dendritic segments separating the distal dendritic arbor 
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In our measurement of dendritic capacitance in figure 1A, C2 was used to represent dendritic 
capacitance. 
In other experiments where whole-cell capacitance was measured, data were derived 
from experiments performed using K-gluconate-based internal and analyzed as described 
previously
116
.  Briefly, capacitative transients were obtained in voltage-clamp mode using 1 
second steps to -70 mV from a holding potential of -80 mV.  The whole-cell capacitance was 
calculated as the area underneath the capacitative transient following correction for input 
resistance.   
 
2.3.5 Analysis of dendritic calcium spike threshold 
Analysis of dendritic calcium spike threshold was performed in the whole-cell configuration in 
current clamp mode.  All spontaneous spiking was blocked with 1 µM tetrodotoxin, and +50 pA 
1 second current steps were imposed.  The current level of the first sweep where calcium spikes 
were elicited was reported.  In neurons which did not firing calcium spikes even up to a 
maximum of +3.5 pA, the current threshold for the neuron was reported at +3.5 pA. 
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At five weeks of age, the majority of ATXN1[82Q] Purkinje neurons have undergone 
depolarization block, and their membrane potential can be restored using 1 µM tetrodotoxin and 
100 µM CdCl2
116
.  We similarly observed non-firing cells in five week old ATXN1[82Q] 
Purkinje neurons. In non-firing ATXN1[82Q] Purkinje neurons, calcium spike measurements 
were performed, and subsequently the cells were exposed to 1 µM tetrodotoxin and 100 µM 
CdCl2. Cells whose membrane potential began the recording at a membrane potential greater 
than -45 mV and fell to a membrane potential below -55 mV upon exposure to 1 µM 
tetrodotoxin and 100 µM CdCl2 were deemed to be usable for subsequent analysis.  Cells which 
were not firing and were more depolarized than -45 mV or did not respond to 1 µM tetrodotoxin 
and 100 µM CdCl2 by hyperpolarization to below -55 mV were excluded. 
 Input resistance for each cell was calculated by generating an input-output curve for 
membrane potential vs. injected current.  This input-output curve encompassed only membrane 
potential measurements between -80 mV and -75 mV in an effort to minimize the influence of 
dendritic excitability on measurement of input resistance.  This method is consistent with 




2.3.6 Analysis of dendritic whole-cell patch clamp recordings 
Analysis of back-propagating action potential amplitude was performed by subtracting the peak 
and anti-peak of each spike across a single 10 second trace obtained during dendritic whole-cell 
patch clamp recording, with the mean of all such measurements reported as the back-propagating 
action potential amplitude for each cell.  Somatic peak-to-trough action potential amplitude was 
determined by subtracting the peak and anti-peak of each spike across a single 10 second trace 
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obtained during somatic whole-cell patch clamp recordings, with the mean of all such 
measurements reported as the peak-to-trough action potential amplitude for each cell. 
Soma-to-patch distance was determined using still IR-DIC images captured during recording, 
and measurement was done using shortest-distance free-form line measurements which originate 
at the center of an ellipse that just encloses the soma and end at the position where the patch 
pipette is in contact with the dendritic membrane.  Measurements were performed in NIS 
Elements (Nikon), and the experimenter was blind to the genotype of the visualized neuron 
during measurement. 
 
2.3.7 Analysis of baseline firing properties 
Analysis of baseline firing properties was performed using Clampfit 10.2 (MDS Analytical 
Technologies).  Firing frequency and coefficient of variation (CV) calculations were performed 
using a single 10 second trace obtained ~3 minutes after formation of a stable seal.  CV was 
calculated as follows: 
𝐶𝑉 =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐼𝑛𝑡𝑒𝑟𝑠𝑝𝑖𝑘𝑒 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙
𝑀𝑒𝑎𝑛 𝐼𝑛𝑡𝑒𝑟𝑠𝑝𝑖𝑘𝑒 𝐼𝑛𝑡𝑒𝑟𝑣𝑎𝑙
 
Analysis of the after-hyperpolarization (AHP) was performed using a single 10 second trace 
obtained ~1 minute after break-in.  To calculate the AHP for each neuron, the minima for each 
spike in the trace were determined using the antipeak function of Clampfit, and the mean of 
those minima was reported as the AHP for each neuron.  To calculate the AHP CV for each 
neuron, the following calculation was performed: 
𝐴𝐻𝑃 𝐶𝑉 =





Input resistance for each cell was calculated by generating an input-output curve for membrane 
potential vs. injected current.  This input-output curve encompassed only membrane potential 
measurements between -80 mV and -75 mV in an effort to minimize the influence of dendritic 
excitability on measurement of input resistance.  This method is consistent with previous studies 




2.4 Visualization and reconstruction of Purkinje neurons after recording 
2.4.1 Visualization of biocytin-filled Purkinje neurons from capacitance recordings 
Visualization of biocytin-filled Purkinje neurons was performed as described previously
226
.  
After recordings were complete, slices were immediately placed in 4% paraformaldehyde 
(Sigma-Aldrich) in phosphate-buffered saline (PBS) (pH 7.4) and refrigerated at 4ºC for at least 
24 hours and no longer than 1 wk. For biocytin visualization, slices were rinsed with PBS, and 
the endogenous peroxidase activity was quenched by incubation for ~30 minutes with 0.1% 
hydrogen peroxide in 10% methanol and PBS. After an additional wash in PBS, slices were 
permeabilized with 2% Triton X-100 (Sigma-Aldrich) in PBS and then incubated at room 
temperature in avidin/biotinylated enzyme complex (Cat. no. 32020, ThermoFisher). After 1–2 
days, slices were rinsed with PBS and then reacted with 3,3′-diaminobenzidine (Life 
Technologies Invitrogen). Slices were mounted and coverslipped.  
Visualized neurons were imaged using an Axiophot microscope (Zeiss) with attached 
motorized XYZ stage (MBF Bioscience). Images stacks were acquired at 20X.  After acquisition, 
image stacks were merged, and the merged image stacks were used for subsequent analysis. 
 
2.4.2 NeuroLucida reconstructions of biocytin-filled neurons 
43 
 
Reconstructions were performed on merged image stacks in Neurolucida 11.02 (MBF 
Bioscience) using the neuron tracing module.  Dendrites and somata were traced semi-manually 
with experimenter blind to sample genotype, and surface area measurements for individual 
dendritic segments were generated automatically using the surface area measurement function.  
For each neuron, composite dendritic surface area measurements for each neuron were obtained 
by taking the sum of all individual dendritic segment surface area measurements for that neuron.  
These composite measurements were used for subsequent analysis.  For each neuron, a sholl 
analysis
227
 was performed in Neurolucida using the sholl analysis tool and 10 µm concentric 
rings, with the number of dendrite crossings at each ring used for subsequent analysis. 
 
2.5 RNA isolation, cDNA synthesis, and quantitative real-time PCR 
Mice were euthanized following anesthesia with isoflurane, and cerebella were removed and 
flash-frozen in liquid nitrogen. Tissue was stored at −80°C until the time of processing.  Total 
RNA from each harvested mouse cerebellum was extracted using Trizol Reagent (Invitrogen) 
and subsequently purified using the RNeasy mini kit (Qiagen) following the manufacturer's 
instructions. cDNA was synthesized from 1 μg of purified RNA using the iScript cDNA 
synthesis kit (Cat. no. 1708891, Bio-Rad). Quantitative real-time PCR assays were performed 
using the iQ SYBR Green Supermix (Cat. no. 1708880, Bio-Rad) in a MyiQ Single Color Real-
Time PCR Detection System (Bio-Rad), with each reaction performed at a 20 μl sample volume 
in an iCycler iQ PCR 96-well Plate (Bio-Rad) sealed with Microseal optical sealing tape (Bio-
Rad). The relative amount of transcript mRNA was determined using the comparative Ct method 
for quantitation
228
 with ActinB mRNA serving as the reference gene. Ct values for each sample 
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were obtained in triplicate and averaged for statistical comparisons. The primers used for qRT-
PCR are listed below:  
Amplicon Forward Primer (5’ to 3’) Reverse Primer (5’ to 3’) 
Kcnma1 (C-Terminus) GGGCCAAGAAAAGAAATGGT GATCAGGCTGCTTGTGGATT 
Kcnma1 (N-Terminus) AGCCAACGATAAGCTGTGGT AATCTCAAGCCAAGCCAACT 
Kcnn2 ACCCTAGTGGATCTGGCAAA GGGTGACGATCCTTTTCTCA 
Itpr1 CAGCACAAATTGAGATTGTCAGA ATCCCGCTCTGTGGTGTAAT 
Cacna1g GTCGCTTTGGGTATCTTTGG TACTCCAGCATCCCAGCAAT 
Trpc3 GAGGTGAATGAAGGTGAACTGA CGTCGCTTGGCTCTTATCTT 
Kcnj3 TGTGGAAACCACAGGAATGA TTGCATGGAACTGGGAGTAA 
ActinB CGGTTCCGATGCCCTGAGGCTCTT CGTCACACTTCATGATGGAATTGA 
 
2.6 Adeno-associated virus (AAV) transduction of Purkinje neuron 
Adeno-associated virus injection was performed by David Bushart, another graduate student in 
the lab. Both AAV constructs used in this study (BK-AAV and GFP-AAV) have been described 
previously
116
.  Stereotaxic administration of AAV2/5 or sham PBS injection was performed on 
28 day old ATXN1[82Q] transgenic or wild-type mice placed under anesthesia using a mixture 
of O2 and isoflurane (dosage 4% for induction, 1.5% maintenance). Mice received bilateral 
intracerebellar injections (2 sites/hemisphere) of virus. For each injection site, ∼5.0 × 109 viral 
genomes per injection site (3 μl total volume) or an equal volume of PBS was delivered to the 
medial or lateral cerebellar nucleus at an infusion rate of 0.5 μl/min using a 10 μl Hamilton 
syringe (BD Biosciences). The number of viral genomes delivered was within a range capable of 
producing widespread viral transduction with a minimal gliosis response
229
.  One minute after 
the infusion was completed, the micropipette was retracted 0.3 mm and allowed to remain in 
place for 4 min before complete removal from the mouse brain. Anterior–posterior coordinates 
were calculated separately for medial and lateral injection into each cerebellar hemisphere. The 
coordinates for the medial injection were −6.4 mm anterior–posterior, ±1.3 mm medial-lateral, 
and 1.9 mm dorsal-ventral as measured from bregma. The coordinates for the lateral injection 
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were −6.0 mm anterior–posterior, ± 2.0 mm medial-lateral, and 2.2 mm dorsal-ventral as 
measured from bregma.  
 
2.7 Rotarod phenotype analysis 
Motor coordination was evaluated using a rotarod. The study was powered to detect a 25% 
improvement in motor performance, and estimated to require at least eight mice in each group. 
The groups were randomly allocated within cage and balanced with respect to sex, age, and 
number in each cohort, although some cohorts did not include animals treated with the 
combination of sham surgery and baclofen (Cat. no. B5399, Sigma-Aldrich).  Approximately 1 
week after virus injection or sham surgery, all mice were handled for four consecutive days. 
Once handling was complete, mice were trained for four consecutive days on the rotarod. The 
first 3 days were done on an accelerated protocol (4 to 40 rpm, at a rate of 0.12 rpm/s) and the 
last day was done at a constant speed of 24 rpm. Following the training period, mice were tested 
on the rotarod at a constant speed of 24 rpm on 5 consecutive days, with four trials per day. 
Latency score was recorded as the time taken before the animal either fell off the bar or if an 
animal made three full rotations on the rotating rod, to a maximum time of 300 s. During both 
training and testing, mice were given twice-daily intraperitoneal injections of either baclofen (10 
mg/kg in PBS) or an equal volume of PBS vehicle. After acute motor performance testing was 
complete, one cohort of mice was maintained on either baclofen-containing (150 mg/L) or 
vehicle drinking water until 14 weeks of age, with baclofen-containing or vehicle drinking water 
bottles replaced every 72 hours.  At 14 weeks of age, these mice were sacrificed and molecular 
layer thickness measurements were performed. The tester remained blinded to treatment 
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condition during experimentation. Performance on the rotarod was analyzed with a two-way 
repeated-measures ANOVA by trial with Holms-Sidak multiple comparison test. 
 
2.8 Tissue immunohistochemistry 
2.8.1 Paraformaldehyde-fixed mouse immunofluorescence 
Mice were anesthetized with isoflurane and brains were removed, fixed in 1% paraformaldehyde 
for 1 h, immersed in 30% sucrose in PBS and sectioned on a CM1850 cryostat (Leica). 14 μm 
parasagittal sections were processed for immunohistochemistry.  
For double immunofluorescence experiments, PKCα or PKCγ were labelled with mouse 
anti-PKCα (1:100, Cat. no. ab4124, Abcam) or mouse anti-PKCγ (1:500, Cat. no. ab71558, 
Abcam) and goat anti-mouse Alexa488-conjugated secondary antibody (1:200, Ref. no. A11001, 
Life Technologies Invitrogen), while Purkinje neurons were labeled with rabbit anti-calbindin 
(1:200, Cat. no. 13176, Cell Signaling) and goat anti-rabbit Alexa594-conjugated antibody 
(1:200, Ref. no. A11012, Life Technologies Invitrogen). Sections were imaged using a FV500 
Olympus Confocal Microscope at 60X magnification and single-plane images were obtained.  
Image acquisition settings were kept consistent for all samples prepared with a specific set of 
antibodies to allow for comparison between genotypes. Sample preparation was performed and 
images were obtained with experimenter blind to genotype. 
 For molecular layer thickness measurements, sections were prepared by the same method 
described above.  Purkinje neurons were labelled with mouse anti-calbindin (1:1000, Cat. no. 
C9848, Sigma-Aldrich) and goat anti-mouse Alexa488 conjugated secondary antibody (1:200, 
Ref. no. A11001, Life Technologies Invitrogen). Sections were imaged using an Axioskop 2 plus 
microscope (Zeiss) at either 10X or 20X magnification.  Measurements were performed using 
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cellSens Standard image analysis software (Olympus). Sample preparation was performed and 
images were obtained with experimenter blind to genotype. 
 
2.8.2 Molecular layer thickness measurements 
Measurement of molecular layer thickness was performed as previously described
116
. A line was 
drawn to measure 100 µm from the depth of the primary fissure along the length of the fissure.  
From the end of this line, a line was drawn to measure the distance to the nearest Purkinje neuron 
cell body in the appropriate lobule.  Measurements of molecular layer thickness were performed 
in two sections per animal, and reported molecular layer thickness for each animal is the mean of 
these two measurements. Molecular layer thickness measurement was performed with 
experimenter blind to genotype and/or treatment condition. 
 
2.8.3 Purkinje neuron cell counts 
Purkinje neuron cell counts reflect manual counts of the total number of neurons in lobule IV/V. 
Lobule IV/V was defined as having an anterior border formed by a line extending from the depth 
of the fissure between lobules III and IV and a posterior border formed by a line extending from 
the depth of the primary fissure between lobules V and lobule VI.  Purkinje cell counts were 
counted for two sections per animal, and the reported Purkinje cell count for each animal is the 
mean of these two measurements.  Purkinje cell counts were performed with experimenter blind 
to genotype. 
 
2.8.4 Paraffin-fixed mouse immunohistochemistry 
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Mice were anesthetized with isoflurane and brains were removed and fixed in 1% 
paraformaldehyde in PBS.  Subsequently, brains were embedded in paraffin. 4 μm parasagittal 
sections were prepared.  
Slides were hydrated by performing xylene rinses followed by ethanol gradient 
incubation.  Subsequently, 10 mM sodium citrate antigen retrieval was performed by microwave 
boiling for five minutes.  Tissue was then processed for immunohistochemistry.  PKC substrate 
phosphorylation was labelled with rabbit anti-Phospho-(Ser) PKC substrate antibody (1:200, Cat. 
no. 2261, Cell Signaling) and goat anti-rabbit Alexa488-conjugated secondary antibody (1:200, 
Ref. no. A11059, Life Technologies Invitrogen). Purkinje neurons were labelled with mouse 
anti-calbindin (1:1000, Cat. no. C9848, Sigma-Aldrich) and goat anti-mouse Alexa594-
conjugated secondary antibody (1:200, Ref. no. A11005, Life Technologies Invitrogen). Sections 
were imaged using a FV500 Olympus Confocal Microscope at 60X magnification and single-
plane images were obtained 
 
2.8.5 Paraffin-fixed human autopsy tissue immunohistochemistry 
For all immunohistochemistry using human autopsy tissue, 4 µm thick sections were prepared 
from paraffin-embedded human cerebellar tissue blocks.  11/12 SCA1 specimens were obtained 
from Arnulff Koeppen (Albany Medical College, Albany NY), 1/12 SCA1 specimens were 
obtained from the University of Michigan Brain Bank, and 7/7 age-matched healthy control 
specimens were obtained from the University of Michigan Brain Bank. Slides were hydrated by 
performing xylene rinses followed by ethanol gradient incubation.  Subsequently, 10 mM sodium 
citrate antigen retrieval was performed by microwave boiling for five minutes.  Tissue was then 
processed for immunohistochemistry.  PKC substrate phosphorylation was labelled with rabbit 
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anti-Phospho-(Ser) PKC substrate antibody (1:200, Cat. no. 2261, Cell Signaling) and goat anti-
rabbit Alexa488-conjugated secondary antibody (1:200, Ref. no. A11059, Life Technologies 
Invitrogen). Purkinje neurons were labelled with mouse anti-calbindin (1:1000, Cat. no. C9848, 
Sigma-Aldrich) and goat anti-mouse Alexa594-conjugated secondary antibody (1:200, Ref. no. 
A11005, Life Technologies Invitrogen). Sections were imaged using a FV500 Olympus 
Confocal Microscope at 60x magnification and single-plane images were obtained.  Image 
acquisition settings were kept consistent for all samples to allow for comparison between 
patients and controls. Sample preparation was performed and images were obtained with 
experimenter blind to patient disease status. 
For each patient and age-matched control, Purkinje neurons were identified as calbindin 
positive cells whose somata were located in the Purkinje neuron layer.  6 images of individual 
Purkinje neurons were obtained for each patient or control, although for some MSA patients 
there were few surviving Purkinje neurons and it was not possible to obtain 6 images, in which 
case no fewer than 4 images were obtained.  To reduce bias, images were obtained in areas were 
Purkinje neurons showed strong calbindin signal.  Images were obtained with experimenter blind 
to patient disease status.  
 
2.8.6 Analysis of human autopsy tissue immunohistochemistry images 
In SCA1 and age-matched healthy control tissue, measurements of average staining intensity for 
both phosphorylated PKC substrate staining and calbindin staining were performed in the soma 
and proximal dendrite.  Measurements in each cell reflect the average intensity of a circular area 
encompassing either the soma or proximal dendrite.  For MSA samples there were very few 
Purkinje neurons with visible dendrite, so MSA and AD tissue included only somatic 
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measurements, performed as described above.  Measurements were performed with experimenter 
blind to sample disease status. 
For each Purkinje neuron from a given individual, a phosphorylated PKC substrate-to-
calbindin intensity ratio was calculated, and in all graphs each data point represents the mean of 
these ratios calculated from the 4-6 images obtained from a single patient.  Error bars represent 
the standard error of the mean for those measurements within a given patient.  Lines indicating 
the mean intensity ratio value across all patients of a group are also included. Statistics reflect a 
two-way ANOVA analysis that revealed a statistically significant effect of disease state on 
phosphorylated PKC substrate-to-calbindin ratio, with no effect of sample number and no 
interaction. 
 
2.9 Western blotting 
2.9.1 Preparation of whole cerebellar samples 
Mice were euthanized following anesthesia with isoflurane, and cerebella were removed and 
flash-frozen in liquid nitrogen. Tissue was stored at −80°C until the time of processing. 
Igepal homogenization buffer was prepared as follows: 50 mM Tris HCl, 150 mM NaCl, 
5 mM EDTA, 1 mM EGTA, pH to 8.0, 1% Igepal CA-630 (Sigma-Aldrich).  EDTA-free 
protease inhibitor tablets (Cat. no. 11873580001, Sigma-Aldrich) and PhosSTOP phosphatase 
inhibitor tablets (Cat. no. 4906845001, Sigma-Aldrich) were added to homogenization buffer 
immediately before use. Whole cerebellar samples were homogenized using a Potter-Helvejm 
tissue grinder (Corning).  The supernatants (soluble protein fractions) were collected and total 
protein concentration was determined using the Pierce BCA protein assay kit (Prod. no. 23225, 
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ThermoFisher), at which point the supernatants were resuspended in Laemmli buffer.  Samples 
were then utilized immediately for Western blots. 
In all cases where ATXN1[82Q] and wild-type mice were compared, ATXN1[82Q] and 
wild-type mice were matched so that slices were prepared from matched mice on the same day 
with the same reagents, and all subsequent sample preparation and analysis was performed using 
matched samples.  In experiments where ATXN2[127Q] mice were compared with littermate 
controls, all samples were prepared on the same day with the same reagents, and all subsequent 
sample preparation and analysis was performed using matched samples. 
 
2.9.2 Preparation of organotypic slice culture samples 
Sagittal brain slices (300 µm thickness) were prepared as previously reported
116
.  5-6 slices per 
brain were used in each set of cultures, divided evenly between control medium and 
experimental medium.  After a quick wash in the corresponding medium, each slice was placed 
on a cell culture insert (0.4 μm pore size, 30 mm diameter; Millipore), which had been 
previously placed on a well (6-well plate) containing 1.2 ml of culture medium that had been 
pre-incubated at 37ºC in 95% O2 / 5% CO2. Control medium was prepared as follows: 50% 
minimal essential medium with Earle’s salts, 25% horse serum, 25% Hank’s balanced salts 
solution, 25 mM HEPES, 2 mM L-glutamine, 6.5 mg/ml glucose. EGTA-containing medium 
was prepared by starting with control medium, adding EGTA to a final concentration of 5 mM, 
and adjusting the pH to 7.4 with NaOH. Any slice-culture experiment involving treatment with a 
pharmacological agent was performed using experimental medium containing the 
pharmacological agent or control medium which contained an equivalent volume of vehicle.   
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 After 24 h of incubation at 37°C in 95% O2 / 5% CO2, lysates were prepared from brain 
slices for immunoblotting. For immunoblotting protein lysate preparation, the cerebellum from 
each slice was macrodissected, and all cerebellar samples exposed to a given condition from 
each mouse were pooled and placed in ice cold Igepal homogenization buffer containing 
protease and phosphatase inhibitors (40 µL per slice), prepared as described above. Samples 
were immediately homogenized by pipette trituration followed by sonication in a 500 watt sonic 
dismembranator with Misonix 3” cup horn attachment (Cat. no. FB505110, QSonica). The 
supernatants (soluble protein fractions) were collected and total protein concentration was 
determined using the Pierce BCA protein assay kit (Prod. no. 23225, ThermoFisher), at which 
point the supernatants were resuspended in Laemmli buffer.  Samples were then utilized 
immediately for Western blots. 
In all cases where ATXN1[82Q] and wild-type mice were compared, ATXN1[82Q] and 
wild-type mice were matched so that slices were prepared from matched mice on the same day 
with the same reagents, and all subsequent sample preparation and analysis was performed using 
matched samples. 
 
2.9.3 Electrophoresis and Western blotting 
Total protein from whole cerebellar extracts or slice culture extracts (30 μg) were resolved in 
either  6%, 8%, or 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) gels, and corresponding polyvinyl difluoride membranes were incubated overnight at 
4°C with primary antibodies: rabbit anti-Phospho-(Ser) PKC substrate antibody (1:1000, Cat. no. 
2261, Cell Signaling), rabbit anti-Phospho-GSK-3β (Ser9) (1:1000, Cat. no. 9323, Cell 
Signaling), rabbit anti-GSK-3β (1:1000, Cat. no. 9315, Cell Signaling), mouse anti-Spectrin 
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alpha chain (nonerythroid) (1:1000, Cat. no. MAB1622, Clone no. AA6, EMD-Millipore), rabbit 
anti-PKCα (1:1000, Cat. no. ab4124, Abcam), rabbit anti-PKCγ (1:2000, Cat. no. ab71558, 
Abcam), rabbit anti-α-Tubulin (11H10) (1:5000, Cat. no. 2125, Cell Signaling). Bound primary 
antibodies were visualized by incubation with a peroxidase-conjugated goat anti-mouse IgG 
secondary (1:10000, Code no. 115-035-146, Jackson ImmunoResearch Laboratories) or goat 
anti-rabbit IgG secondary antibody (1:10000; Code no. 111-035-003, Jackson ImmunoResearch 
Laboratories) followed by treatment with the Western Lightning ECL-plus reagent (Prod. no. 
NEL121001EA, PerkinElmer) and exposure to autoradiography films.   
 
2.9.4 Analysis of Western blot films 
Developed films were scanned and densitometry analysis was performed in ImageJ.  For analysis 
of phosphorylated PKC substrates, the intensity of the entire lane after phospho-(Ser) PKC 
substrate antibody blotting was normalized to the intensity of α-tubulin for each mouse. For 
analysis of αII-spectrin breakdown products (SBDPs) produced by the activity of calpain family 
proteases and caspase-3, intensity of the caspase-3-specific 120 kDa fragment  was normalized to 
full-length αII-spectrin at 280 kDa and intensity of the calpain-specific 145 kDa fragment was 
normalized  to full-length αII-spectrin at 280 kDa
230
. For analysis of all other proteins, intensity 
of the band of interest was normalized to the intensity of α-tubulin for each mouse. 
 
2.10 Statistical analysis 
Statistical tests are described in the figure legends for all data. Data are expressed as mean ± 
SEM unless otherwise specified.  Sample numbers are included in each panel, with the number 
of cells (n) or number of animals (N) included where appropriate. Studies were powered and 
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analysis was performed assuming unequal variance between groups. Statistical significance for 
all Student’s T-test analysis was defined as P<0.05. For one-way ANOVA with Holms-Sidak 
multiple comparison test, adjusted P<0.05 was considered statistically significant, and presented 
P values are adjusted P values.  For two-way ANOVA, statistical significance was defined as 
P<0.05.  For two-way ANOVA with Sidak multiple comparison test, adjusted P<0.05 was 
considered statistically significant, and presented P values are adjusted P values. For extra sum 
of squares F test, statistical significance was defined as a rejection of the null hypothesis that 
wild-type and ATXN1[82Q] data are better described by a single curve with P<0.05.  For two-
way repeated measures ANOVA without multiple comparisons, statistical significance was 
defined as P<0.05.  For two-way repeated measures ANOVA with Holms-Sidak multiple 
comparison test, adjusted P<0.05 was considered statistically significant, and presented P values 
are adjusted P values. Data were analyzed using SigmaPlot (Systat Software), GraphPad Prism 
(GraphPad), and Excel (Microsoft). 
 
2.11 Chemicals 







The ATXN1[82Q] model of SCA1 shows increased Purkinje neuron 
intrinsic dendritic excitability that drives dendrite degeneration 
3.1 Abstract 
Degeneration of Purkinje neuron dendrites is a prominent histopathologic feature 
observed in autopsy tissue from human spinocerebellar ataxias (SCAs), and studies in SCA 
mouse model have demonstrated that Purkinje neuron dendrite degeneration correlates with the 
onset of motor impairment.  While the evidence mediating dendrite degeneration in the SCAs 
remains poorly understood, studies of Purkinje neuron dendrite development and maintenance 
have demonstrated that mature dendritic structure is regulated heavily by synaptic and intrinsic 
activity.  Changes in synaptic transmission and autonomous pacemaking have been studied in 
multiple SCA models, but intrinsic dendritic excitability has not been explored.  To explore the 
role that changes in dendritic excitability might play in Purkinje neuron dendrite remodeling in 
the SCAs, we performed a characterization of dendritic physiology in Purkinje neurons from the 
ATXN1[82Q] model of SCA1, and assessed the role that those changes might have in dendritic 
remodeling.  We demonstrate that ATXN1[82Q] Purkinje neurons show increased intrinsic 
dendritic excitability throughout the course of dendritic degeneration.  Furthermore, we 
demonstrate that this increase in dendritic excitability is accompanied by changes in expression 
of a number of ion channels that are important for Purkinje neuron dendrite physiology.  Finally, 
we demonstrate that a therapeutic strategy which normalizes ATXN1[82Q] Purkinje neuron 
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intrinsic dendritic excitability is able to improve motor performance and preserve dendrite 
structure in vivo.  These findings identify changes in intrinsic dendritic excitability as a novel 
mechanism underlying Purkinje neuron dendrite degeneration in the SCAs, and adds to the 
literature from other neurodegenerative diseases implicating changes in dendritic physiology in 
dendritic pathology.  Most of the work of this chapter has been included in a paper that is 





Spinocerebellar ataxia type 1 (SCA1) is one of the more common and well-studied forms 
of spinocerebellar ataxia
231
.  SCA1 is caused by expansion of the repetitive CAG tract within the 
first coding exon (exon 8) of a single ATXN1 allele, such that healthy individuals have between 
6 and 42 CAG repeats (with those greater than 21 repeats being interrupted by several CAT 
exons) while individuals with SCA1 have a pure CAG tract ranging from 39 to 82 CAG 
repeats
232
.  The CAG exon encodes glutamine, and as such SCA1 is one of the so-called 
polyglutamine disorders.  Because expansion of the CAG tract beyond disease threshold is only 
required in a single allele, SCA1 is inherited in an autosomal dominant fashion, and de novo 
mutations have not been described. Like other polyglutamine disorders, SCA1 shows earlier age 
of onset and accelerated progression in individuals with longer CAG repeats, although the 
correlation is imperfect and suggests the presence of additional genetic modifiers
233
.  Also like 
other polyglutamine disorders, SCA1 shows instability of the CAG repeat tract, such that the 
length can vary with each intergenerational transmission event
232
. 
 Clinically, SCA1 presents with loss of motor coordination and balance, slurred speech, 
swallowing difficulties, spasticity, and cognitive impairment
231
.   These symptoms map well onto 
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the select brain regions where neurodegeneration is observed, with particularly prominent 
involvement of the cerebellar Purkinje neurons, neurons of the deep cerebellar nuclei, and 
pyramidal neurons of the motor cortex, as well as involvement of the basal forebrain, thalamus, 
and multiple brainstem nuclei
234
.  The selective pattern of neurodegeneration is observed despite 
widespread expression of ATAXIN-1, the protein product produced from the ATXN1 gene
235
. 
  The first animal model of SCA1 was the ATXN1[82Q] mouse, which was a transgenic 
model expressing full-length cDNA from an SCA1 patient (82 CAG repeats) specifically in 
Purkinje neurons under the control of the Pcp2 (L7) promoter
27
.  When maintained homozygous 
for transgene expression on the FvB/NJ background, these mice develop rota-rod impairment at 
5 weeks of age, and Purkinje neuron dendritic degeneration has been observed by 
immunohistochemistry at 6 weeks of age, with cell loss first apparent at 12 weeks but not 
achieving statistical significance until later
9
.  This model has been found to have abnormalities in 
Purkinje neuron spiking that correlate with the onset of motor impairment and dendritic 
degeneration
114, 116
.  This model has also been found to have a number of alterations in synaptic 
transmission from both parallel fibers and climbing fibers
134-136
.  The intrinsic excitability of 
Purkinje neuron dendrites in this model has not been explored. 
  Here, we examine changes in the intrinsic excitability of Purkinje neuron dendrites in 
ATXN1[82Q] mice.  We provide the first fine-grained analysis of the time course of dendritic 
remodeling in this model, using both electrophysiologic and morphologic measures.  We then 
identify increased intrinsic dendritic excitability by two methods, and we demonstrate that the 
increase is correlated with the onset of dendritic degeneration.  Subsequently, we use expression 
analysis to demonstrate changes in expression of multiple ion channels that are important for 
regulating intrinsic dendritic excitability.  Then we show that improving the expression of large-
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conductance calcium-activated potassium (BK) channel and pharmacologically activating 
subthreshold-activated potassium channels (subthreshold K) can normalize ATXN1[82Q] 
Purkinje neuron dendrite excitability, suggesting that reduced expression of these channels might 
account for observed changes in intrinsic dendritic excitability.  Finally we assess the impact of 
normalizing intrinsic dendritic excitability on motor performance and dendrite degeneration in 
vivo.  The work described here outlines a novel mechanism underlying Purkinje neuron dendrite 
remodeling in ataxia, and it adds to the body of literature exploring alterations in dendritic 
physiology in neurodegenerative disease.  This provides a new conceptual framework for 
understanding dendritic remodeling in ataxia, and it also highlights novel therapeutic targets that 
could be pursued. 
3.3 Results 
In all experiments outlined below, ATXN1[82Q] mice are maintained homozygous for 
the ATXN1[82Q] transgene.  Age- and sex-matched FvB/NJ mice were used as wild-type 
controls. 
3.3.1 ATXN1[82Q] Purkinje neuron dendrite degeneration begins at 5 weeks of age  
Previous studies have demonstrated that ATXN1[82Q] mice have a rota-rod phenotype at 
five weeks of age
9, 114
.  Several studies in this mouse have used the thickness of the molecular 
layer (where Purkinje neuron dendrites reside) as an indicator of when dendrite degeneration 
begins, and these studies have identified molecular layer thinning as beginning no earlier than 
ten weeks of age
9, 114
.  Qualitative observations of dendrite structure in calbindin-stained tissue 
found that evidence of dendrite degeneration could be seen as early as six weeks of age
9
.  
Visualization and reconstruction of single Purkinje neurons from this model showed dramatic 
dendrite degeneration by twelve weeks of age, suggesting that looking at a population of 
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individual Purkinje neurons’ dendrites might provide a more sensitive measure for the time 
course of ATXN1[82Q] Purkinje neuron dendrite degeneration. 
We assessed the capacitance of ATXN1[82Q] and wild-type Purkinje neurons in acute 
cerebellar slices at 2, 3.5, 5, and 15 weeks of age using a CsCl internal, which dramatically 
increases input resistance by blocking potassium channels and thereby improves the ability to 
clamp the extensive dendritic arbor.  Using a well-established model based on an equivalent 
circuit model of a Purkinje neuron (see section 2.3.4), we separated the capacitative current into 
two capacitance values, one reflecting the capacitance of the distal dendritic arbor while the 
other reflects the capacitance of the proximal dendrite and soma.  Using these measurements, we 
were able to establish that ATXN1[82Q] Purkinje neuron dendrite atrophy is first apparent at 5 
weeks and progresses until it is nearly complete at 15 weeks (Figure 3.1A).  Notably, 
developmental pruning of the Purkinje neuron dendrite in mature wild-type neurons can also be 
resolved with this technique, a process which has been described previously
72
.  By contrast, at no 
age was the capacitance of the soma and proximal dendrite different between ATXN1[82Q] 
Purkinje neurons and wild-type Purkinje neurons .  Based on the trajectory of dendrite 
capacitance in ATXN1[82Q] Purkinje neurons it appears that dendrite degeneration may begin 
before the dendritic arbor reaches its maximal surface area.  The ATXN1[82Q] transgene begins 
to express at around P12, and it has been noted that later onset of transgene expression results in 
significantly less Purkinje neuron pathology
236
, raising the possibility that this reflects 
developmental rather than neurodegenerative pathology associated with transgene expression.  
However, there is no clear evidence that SCA1 has a neurodevelopmental component in humans, 
calling into question the relevance of this observation to human disease. 
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Biocytin was included in the recording pipette when capacitance measurements were 
performed, allowing for post-hoc visualization of Purkinje neurons after recording (Figure 3.1C).  
Digital reconstructions of these neurons were created in NeuroLucida, and analysis of the 
dendrite surface area in reconstructions matched what was observed with capacitance 
measurements (Figure 3.1D), including the observation of developmental pruning in wild-type 
neurons.  Sholl analysis performed on reconstructions revealed decreased dendritic complexity in 
ATXN1[82Q] Purkinje neurons at 5 weeks of age (Figure 3.1E) and 15 weeks of age (Figure 
3.1F).  All of these findings are consistent with Purkinje neuron dendrite degeneration beginning 
at 5 weeks of age, coinciding with the onset of motor symptoms
9, 114, 116
. 
3.3.2 Measurement of dendritic calcium spike threshold suggests increased intrinsic 
dendritic excitability in ATXN1[82Q] Purkinje neurons at 5 weeks of age, but not 15 weeks 
of age 
 In order to explore potential alterations in Purkinje neuron dendritic physiology that 
might relate to dendritic degeneration in ATXN1[82Q] mice, we performed experiments to look 
at the intrinsic excitability of the Purkinje neuron dendrite arbor.  Using the terminology outlined 
in section 1.3.3, evidence of more dramatic spatial decay of depolarization along the dendrite 
shaft will be referred to as reduced intrinsic dendritic excitability.  Conversely, evidence of more 
faithful propagation of depolarization along the dendritic shaft will be considered increased 
intrinsic dendritic excitability. 
Previously, a study examined intrinsic dendritic excitability in the Kcnc3 knockout mouse 
by blocking spiking with bath application of tetrodotoxin (TTX) and then injecting current into 
the soma in order to elicit a dendritic calcium spike
152
.   A reduced level of injected current 
required to elicit a dendritic calcium spike was viewed as a reflection of increased intrinsic 
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dendritic excitability, in this case due to the absence of the KV3.3 channel encoded by Kcnc3.  
The underlying assumption of this experiment is that the local membrane potential required to 
achieve the threshold of a dendritic calcium spike is unchanged; thus, the level of injected 
current required to elicit a spike would be a reflection of the extent to which depolarization 
produced by somatic current injection is spreading into the dendritic arbor, making it a valid 
measure of the intrinsic excitability of the dendritic arbor. 
We performed similar studies in ATXN1[82Q] Purkinje neurons at 5 weeks of age 
(Figure 3.2A).  Relative to wild-type Purkinje neurons, ATXN1[82Q] Purkinje neurons required 
significantly less injected current in order to elicit a dendritic calcium spike (Figure 3.2B).  The 
input resistance of ATXN1[82Q] Purkinje neurons used in these experiments was modestly but 
not statistically significantly increased relative to wild-type Purkinje neurons (Figure 3.2C), 
suggesting that the reduced threshold was not simply a reflection of more somatic depolarization 
in response to current injection.  These findings suggest that ATXN1[82Q] Purkinje neurons 
have increased intrinsic dendritic excitability at 5 weeks of age. 
To assess whether increased dendritic excitability was a consistent feature of disease in 
ATXN1[82Q] Purkinje neurons, we performed the same experiment at 15 weeks of age (Figure 
3.2D).  Surprisingly, ATXN1[82Q] Purkinje neurons required significantly more injected current 
to elicit a dendritic calcium spike (Figure 3.2E), although 6/9 ATXN1[82Q] Purkinje neurons 
showing no calcium spikes even after +3.5 nA of injected current and were incorporated into 
analysis as firing a calcium spike at +3.5 nA (see section 2.3.5).  Additionally, the input 
resistance of the neurons used in these experiments was significantly increased for ATXN1[82Q] 
Purkinje neurons relative to wild-type Purkinje neurons. 
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This finding was somewhat perplexing, as it suggested a dramatic reversal of the 
observation at 5 weeks.  This finding raised several possibilities: 1) there is a paradoxical 
decrease in intrinsic dendritic excitability in ATXN1[82Q] Purkinje neurons at 15 weeks, or 2) 
there is an experimental confound that prevents this assay from effectively measuring intrinsic 
dendritic excitability in ATXN1[82Q] Purkinje neurons at 15 weeks of age.  In order to explore 
this possibility further, I thought it would be best to utilize an additional technique to measure 
intrinsic dendritic excitability in ATXN1[82Q] Purkinje neurons. 
3.3.3 Measurement of dendritic action potential backpropagation suggests increased 
intrinsic dendritic excitability in ATXN1[82Q] Purkinje neurons at 5 weeks and 15 weeks 
of age 
 As discussed in section 1.3.3, action potentials initiated at the axon initial segment also 
spread into the dendritic arbor, but in Purkinje neurons they attenuate strongly as they 
backpropagate into the dendrite
95
.  This is thought to be a function of both the highly-branched 
structure of Purkinje neuron dendrites and dendritic potassium channels.  Measurement of 
backpropagating action potential amplitude is another method for measure the intrinsic 
excitability of neuronal dendrites, and a study in Purkinje neurons has used this method to 
demonstrate that synaptic plasticity protocols also induce plastic changes in intrinsic dendritic 
excitability that are input-specific
237
. 
 We performed direct whole-cell patch clamp dendritic recordings in Purkinje neurons at 5 
weeks of age.  Because Purkinje neurons spike spontaneously, the amplitude of the 
spontaneously-generated action potentials could be measured at the site of recording in the 
dendritic arbor (Figure 3.3A).  In both wild-type and ATXN1[82Q] Purkinje neurons, the 
relationship between patch distance and peak-to-trough backpropagating action potential 
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amplitude was fit with a single-exponential decay function.  The ATXN1[82Q] distance-to-
amplitude function showed a statistically significant right shift (Figure 3.3.B), indicating that 
action potentials were attenuating less as they backpropagate into the dendritic arbor.  This did 
not appear to be a function of the order of dendrite from which recordings were performed, as 






 order dendrites sampled in wild-type and 
ATXN1[82Q] Purkinje neurons. Because the peak-to-trough amplitude of the action potential 
when measured at the soma does not differ between wild-type and ATXN1[82Q] Purkinje 
neurons (Figure 3.3C-D), this indicates that ATXN1[82Q] Purkinje neuron dendrites have 
increased intrinsic dendritic excitability at 5 weeks of age.  This is consistent with what was 
observed with somatically-evoked dendritic calcium spikes (see section 3.3.2). 
 We also performed direct whole-cell patch clamp dendritic recordings in Purkinje 
neurons at 15 weeks of age (Figure 3.3E).  At this age, we also found that ATXN1[82Q] Purkinje 
neurons showed increased intrinsic dendritic excitability, as indicated by a statistically 
significant right-shift in the relationship between recording location and peak-to-trough 
backpropagating action potential amplitude (Figure 3.3F).  Also similar to 5 weeks of age, the 
peak-to-trough amplitude of the action potential when measured at the soma does not differ 
between wild-type and ATXN1[82Q] Purkinje neurons at 15 weeks, despite changes in the shape 
of the spike (Figure 3.3G-H).  These findings suggest that ATXN1[82Q] Purkinje neuron 
dendrites have increased intrinsic dendritic excitability at 15 weeks, in contrast to what was 
observed with somatically-evoked dendritic calcium spikes (see section 3.3.2).  The discrepancy 
between these two methods for measuring dendritic excitability remains unclear, although we 
will postulate possible reasons behind this discrepancy in the discussion section. 
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 In summary, measurement of backpropagating action potentials showed less attenuation 
in the dendritic arbor of ATXN1[82Q] Purkinje neurons relative to wild-type Purkinje neurons at 
5 weeks and 15 weeks of age.  This finding is consistent with an increase in intrinsic dendritic 
excitability from the onset of dendritic degeneration through its entire course.  This finding could 
be attributable to changes in dendritic structure, changes in dendritic channels, or both.  We 
focused on changes in dendritic channels, and specifically looked at changes in expression of 
mRNA for ion channels that play an important role in Purkinje neuron dendrites. 
3.3.4 ATXN1[82Q] cerebella show changes in mRNA expression for many ion channels that 
play important roles in dendritic physiology 
 Studies in both the ATXN1[82Q] transgenic and Atxn1
154Q
 knock-in model have 
demonstrated profound changes in expression of a number of mRNAs
238, 239
, suggesting that 
disease pathogenesis might derive from changes in gene expression.  It is particularly likely that 
mutant ATAXIN-1 exerts its effect by perturbing transcription, as it was found that the 
polyglutamine-expanded ATAXIN-1 forms functional complexes with the transcriptional 
repressor Capicua
124
 and that the ATXN1[82Q] transgene produces no pathology in the mouse 
when its nuclear localization sequence is ablated
240
.  Because of the proposed role that altered 
transcription plays in SCA1 pathology, we hypothesized that the observed increases in dendritic 
excitability might be due to changes in expression of mRNA for ion channels important in 
Purkinje neuron dendrites. 
 As discussed in section 1.3.3, calcium-activated potassium channels are important 
regulators of Purkinje neuron dendritic excitability, and their action reduces intrinsic dendritic 
excitability, resulting in reduced electrical coupling between the dendrite and the soma
101, 154
, 
attenuation of backpropagating action potentials
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activated potassium channels, we focused on expression of the small-conductance calcium-
activated potassium channel isoform 2 (SK2) and the large-conductance calcium activated 
potassium channel (BK), as a role for these channels in limiting Purkinje neuron dendritic 
excitability has been well-characterized
101, 149, 154, 237
.  We found that expression of Kcnma1, the 
gene encoding the α subunit for BK, shows a progressive reduction in expression with 67.7% of 
wild-type expression at 5 weeks of age and 26.2% of wild-type expression at 15 weeks of age 
(Figure 3.4A).  Surprisingly, expression of Kcnn2, the gene encoding SK2, showed increased 
expression at both 5 and 15 weeks (Figure 3.4B).  These data demonstrate that there is 
dysregulated expression of calcium-activated potassium channels important for Purkinje neuron 
dendritic physiology, although the direction of those changes is not consistent. 
 Upstream of calcium-activated potassium channels are a number of potential dendritic 
calcium sources.  Purkinje neurons have an unusually high endogenous calcium buffering 
capacity relative to other neurons
243
 and show significant attenuation of backpropagating action 
potentials, such that Purkinje neurons show very modest dendritic cytosolic [Ca
2+
] increases 
associated with backpropagating simple spikes
244, 245
.  In contrast, Purkinje neurons show more 
substantial dendritic cytosolic [Ca
2+
] increases in response to synaptic input, with parallel fiber 
input producing localized dendritic calcium transients in response to parallel fiber input and 
more widespread dendritic cytosolic [Ca
2+
] increases in response to climbing fiber stimulation
246
.  
This synaptically-evoked calcium increase is largely attributable to glutamate binding to and 
activating mGluR1 receptors on Purkinje neurons
247-250
.  This mGluR1-mediated cytosolic [Ca
2+
] 
increase arises as follows: 1) glutamate binding to mGluR1 activates the Gq subclass of G 
proteins
251
, 2) Gq proteins activate PLCβ, which cleaves phosphatidylinositol 4,5-bisphosphate 
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(PIP2) to form diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), and 3)  IP3 binds to 
IP3 receptors on the dendritic endoplasmic reticulum (ER) to trigger release of ER-receptor 
mediated stores, which contribute substantially to synaptically-driven mGluR1-mediated calcium 
release
252
, with additional contributions from the transient receptor potential channel 3 (Trpc3) 
channel
253
 and voltage-gated calcium channels
150
 that are activated by an incompletely 
understood non-canonical G-protein mediated pathway
254
.  These calcium sources have all been 
shown to be coupled to calcium-activated potassium channels in Purkinje neurons or other cell 
types
255, 256
; as such, cytosolic [Ca
2+
] increases through these sources has the effect of activating 
calcium-activated potassium channels.  
Because the IP3 receptor, Trpc3, and voltage-gated calcium channels each serve as 
important calcium sources in the dendrite, and because those calcium sources are coupled to 
calcium-activated potassium channels, we were interested in assessing whether increased 
dendritic excitability could be linked to changes in any of these channels.  As such, we examined 
the expression of Itpr1 (Figure 3.4C), which encodes the major IP3 receptor subtype expressed in 
Purkinje neurons
257
, Trpc3 (Figure 3.4 D), and Cacna1g (Figure 3.4E), which encodes the α 
subunit of the voltage-gated calcium channel Cav3.1.   In all cases, mRNA levels are 
dramatically reduced at 5 weeks and 15 weeks, with no apparent progression between the two 
ages.  It is important to note that reduced expression of Itpr1 and Trpc3 has been described 
previously as early as four weeks of age in this mouse
258
, in agreement with our findings. These 
data suggests that multiple calcium sources for calcium-activated potassium channels show 
reduced expression, which could contribute to increased intrinsic dendritic excitability. 
 In addition to calcium-activated potassium channels, subthreshold-activated potassium 
channels (subthreshold K channels) play an important role in regulating dendritic excitability in 
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other neuronal subtypes, although a role has not been explored in Purkinje neurons
259
.  Previous 
work in the ATXN1[82Q] mouse identified reduced expression of several subthreshold K 
channel genes by RNAseq and suggested a role for dysregulation of subthreshold potassium 
channels in ATXN1[82Q] Purkinje neuron dendrite degeneration
116
.  This study found reduced 
expression of Kncj3, the gene encoding the G-protein-coupled inward rectifier potassium channel 
type 1 (GIRK1), and we attempted to recapitulate this finding with qRT-PCR.  Surprisingly, we 
did not find any change in expression of Kncj3 at 5 weeks or 15 weeks (Figure 3.4F).  This 
experiment was repeated with many other primers for Kcnj3 and a difference was never 
identified (data not shown). 
3.3.5 Adeno-associated viral expression of BK in combination with baclofen normalizes 
dendritic calcium spike threshold in ATXN1[82Q] Purkinje neurons at 5 weeks of age 
In order to assess the role that dendritic excitability might play in ATXN1[82Q] Purkinje 
neuron dendritic degeneration, we aimed to identify a strategy which could normalize dendritic 
excitability.  We decided to employ a strategy which acted to normalize BK channel function and 
increase subthreshold K channel function, as both of these channels act to limit intrinsic dendritic 
excitability and our expression data demonstrated reduced expression of Kcnma1.  We utilized 
an adeno-associated virus to drive expression of BK in Purkinje neurons (referred to as BK-
AAV) in combination with the GABAB agonist baclofen, which strongly activates an inwardly-
rectifying potassium current in Purkinje neurons
260
.   
Based on the data described in sections 3.3.2 and 3.3.3, evoking dendritic calcium spikes 
is an effective measure of intrinsic dendritic excitability at 5 weeks of age.  Because dendritic 
degeneration also begins at 5 weeks of age, we decided to test the proposed treatment strategy 
and its effect on dendritic excitability using this method (Figure 3.5A).  Purkinje neurons 
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transduced with BK-AAV or treated with 2µM baclofen each required more injected current to 
elicit a dendritic calcium spike, suggesting that normalizing BK expression or potentiating 
subthreshold K channels could each improve dendritic excitability (Figure 3.5B).  Importantly, it 
was only the combination that was able to normalize the current required for eliciting dendritic 
calcium spikes in ATXN1[82Q] Purkinje neurons, and the observed rescue indicated a 
synergistic effect of concurrent BK-AAV transduction and baclofen treatment.  None of the 
groups showed statistically significant differences in their input resistance during these 
experiments (Figure 3.5C), indicating that any observed changes in threshold reflect changes in 
the intrinsic excitability of Purkinje neuron dendrites. 
3.3.6 Treatment with both BK-AAV and baclofen improves motor performance and 
preserves Purkinje neuron dendrite structure in ATXN1[82Q] mice 
 As demonstrated in section 3.3.5, ATXN1[82Q] Purkinje neurons transduced with BK-
AAV and treated with baclofen showed a normalization of intrinsic dendritic excitability.  Next 
we examined the consequences of normalizing dendritic excitability on motor impairment and 
dendritic degeneration.  We analyzed the motor performance of four groups of animals: 1) 
ATXN1[82Q] mice injected with BK-AAV and simultaneously treated with baclofen;  2) 
ATXN1[82Q] mice that received baclofen and sham surgery; 3) ATXN1[82Q] mice that 
received vehicle and sham surgery; 4) wild-type control mice.  Motor impairment was assessed 
by rotarod performance two weeks after initiation of therapy, a time point where BK-AAV 
treatment by itself produces no detectable improvement in motor performance
116
.  Combined 
treatment with BK-AAV and baclofen significantly improved motor performance of 
ATXN1[82Q] mice (Figure 3.6A). These mice also showed preservation of the thickness of the 
cerebellar molecular layer (Figure 3.6B-C), demonstrating that this combined treatment also 
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significantly reduced dendritic degeneration. Mice treated with baclofen alone did not show 
significant improvement in either motor behavior or molecular layer thickness, and our previous 
work demonstrates that BK-AAV alone does not acutely improve motor performance or prevent 
thinning of the molecular layer in ATXN1[82Q] mice
116
.  The fact that normalizing dendritic 
excitability protects ATXN1[82Q] Purkinje neuron dendrites suggests that increased intrinsic 
dendritic excitability drives dendritic degeneration in SCA1. 
3.4 Discussion 
 Here we report that Purkinje neurons from the ATXN1[82Q] model of SCA1 show 
increased intrinsic dendritic excitability in association with dendritic degeneration, and we also 
demonstrate that a treatment strategy which normalizes intrinsic dendritic excitability can 
improve motor performance and preserve Purkinje neuron dendrite structure in vivo.  Using 
electrophysiologic and single-cell morphologic reconstruction, we demonstrate that dendritic 
degeneration is first detectable in ATXN1[82Q] Purkinje neurons at 5 weeks of age and that the 
dendrite is markedly attenuated by 15 weeks of age.  We show that ATXN1[82Q] Purkinje 
neurons require less current to induce dendritic calcium spikes at 5 weeks but not 15 weeks, and 
also show that ATXN1[82Q] Purkinje neurons show less backpropagating action potential 
attenuation in the dendritic arbor at 5 and 15 weeks of age.  We show that in association with 
these changes in dendritic physiology there are changes in expression of many channels 
important for dendritic physiology in wild-type Purkinje neurons.  Finally, we show that the BK-
AAV and baclofen treatment normalizes intrinsic dendritic excitability and is able to improve 
motor performance and preserve ATXN1[82Q] Purkinje neuron dendrites in vivo.  These data 
support the hypothesis that changes in dendritic excitability contribute to degenerative dendrite 
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remodeling in SCA1, and they also present a therapeutic strategy for symptomatic and 
neuroprotective therapy. 
 In section 3.3.2, we demonstrated that ATXN1[82Q] Purkinje neurons require less 
injected current than wild-type neurons to elicit a dendritic calcium spike at 5 weeks of age, but 
at 15 weeks of age the majority of ATXN1[82Q] Purkinje neurons never fired calcium spikes.  In 
contrast, in section 3.3.3 we demonstrated that ATXN1[82Q] Purkinje neurons show less 
attenuation of backpropagating action potentials in the dendritic arbor at both 5 and 15 weeks of 
age.  While both assays support the conclusion that ATXN1[82Q] Purkinje neurons have 
increased intrinsic dendritic excitability at 5 weeks of age, the calcium spike and dendritic 
recording experiments point to opposite conclusions at 15 weeks of age.  I would argue that the 
dendritic recording experiment is a more reliable measure of intrinsic dendritic excitability, as 
we have measurement of both the input signal (the somatic action potential) and the measured 
output (the dendritic backpropagating action potential), in contrast to the dendritic calcium spike 
experiment where the measure of intrinsic dendritic excitability is more indirect.  Furthermore, 
the fact that 6/9 ATXN1[82Q] Purkinje neurons would not fire a dendritic calcium spike even up 
to a peak current injection of +3.5 nA raises the possibility that those neurons are much less 
capable of firing calcium spikes in general, making the assay invalid at this time point.  Without 
further study, it is difficult to understand the reasons for this paradoxical finding.  Nevertheless, 
the dendritic calcium spike experiment and backpropagating action potential measurements 
provide independent measures of increased intrinsic dendritic excitability at 5 weeks of age, and 
backpropagating action potential measurements at 15 weeks of age confirm that ATXN1[82Q] 




 One larger question that remains outstanding from this study is to understand the 
molecular basis for increased intrinsic dendritic excitability in ATXN1[82Q] Purkinje neurons.  
The observation that Kcnma1 expression is reduced and that BK-AAV treatment partially 
rescues the dendritic calcium spike threshold implicates reduced BK as being involved.  
However, changes in other channels must be involved, as BK-AAV treatment did not produce 
full rescue.  One possibility is that reduced transcript levels for subthreshold K channels, 
identified previously
116
 but not recapitulated here, accounts for the remaining increase in 
intrinsic dendritic excitability that can then be rescued with baclofen.  The second possibility is 
that other as-of-yet unidentified channels acting in parallel with BK are affected, producing an 
impact on dendritic excitability, with baclofen acting on existing subthreshold K channels.  I 
propose instead a third possibility: the reduction in Cacna1g, Itpr1, and Trpc3 transcripts 
represents a second “hit” upstream of BK.  In support of this hypothesis, it has been shown that 
ATXN1[82Q] Purkinje neurons show reduced mGluR1-dependent cytosolic [Ca
2+
] increases at 5 
weeks of age and treatment with baclofen can rescue this deficit
135
, consistent with data showing  
potentiation of mGluR1 signaling by GABAB
261
.  Furthermore, our own study found a 
synergistic relationship between BK-AAV and baclofen on calcium spike threshold, which 
would be more consistent with two interventions operating on a single pathway than operating on 
parallel pathways.  Within this framework, the increased dendritic excitability is a combination 
of 1) reduced BK expression, and 2) reduced cytosolic [Ca
2+
] to activate BK.   These three 
potential pathways for increased dendritic excitability and the targets engaged by our therapeutic 
strategy are outlined in Figure 3.7.  Further study will be required to dissect the molecular 
underpinnings of increased intrinsic dendritic excitability, including identifying specific channel 
blockers than can occlude the effect of baclofen in vitro and in vivo. 
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As discussed in section 1.3, a number of studies have reported abnormalities of Purkinje 
neuron spiking in ataxia models, and several studies have identified neuroprotective 
interventions that normalize aberrant spiking.  Other studies have focused on Purkinje neuron 
synaptic function in models of ataxia, and several have suggested that changes at synapses onto 
Purkinje neurons influence Purkinje neuron pathology.  Notably, changes in dendritic excitability 
have not been explored.  The current study suggests that changes in dendritic excitability are not 
merely a read-out of cell-wide neuronal dysfunction, but instead reflect a specific driver of 
neurodegeneration.  In previous studies of ataxia, pharmacologic modulation of spiking resulted 
in neuroprotection
114-116
; however, the channels targeted in these studies also regulate dendritic 
excitability, raising the possibility that some or all of the neuroprotective effect could reflect 
excitability changes in the dendritic compartment.  It is important to acknowledge that even in 
our current study, the effect of increasing BK and subthreshold K channel function was not 
restricted to the dendritic compartment. A definitive demonstration of the role for dendritic 
excitability in SCA1 Purkinje neuron dendrite degeneration would require intervening only in the 
excitability of the dendritic compartment while leaving synapses and somatic spiking unchanged.  
Although the tools do not currently exist to perform this experiment, improvements in the 
understanding of how ion channels are trafficked to specific compartments of the neuron may 
allow for development of channel constructs whose expression is restricted only to the dendritic 
arbor, allowing for such a targeted intervention
262
. 
The findings from this study are likely to have implications for other forms of cerebellar 
ataxia.  As discussed previously, studies of Purkinje neuron spiking in many models of ataxia 
have revealed changes in the excitability of the soma, and in most cases the channels that are 
implicated are expressed and functionally important in Purkinje neuron dendrites. Additionally, 
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the human ataxias Spinocerebellar ataxia type 13 (SCA13) and Spinocerebellar ataxia type 19/22 





, respectively, and studies of these channels or their paralogs 
have demonstrated that they limit dendritic excitability
152, 263
.  Focusing on intrinsic dendritic 
excitability in Purkinje neurons from models of these other ataxias may yield important insights, 
and these ataxias may similarly respond to agents that target dendritic excitability. 
Alterations in intrinsic dendritic excitability may extend to other neurodegenerative 
diseases.  The studies of neuronal populations affected in Parkinson disease
162-164, 264
 and CA1 
pyramidal neurons in Alzheimer disease mouse models
159, 160
 point to increased intrinsic 
dendritic excitability as a potentially common feature of neurodegenerative disease.  To the best 
of our knowledge, our study is the first to identify changes in the excitability of the dendritic 
compartment and to link those changes to neuropathology in a rodent model of 
neurodegenerative disease. Our study also identifies a strategy for normalizing dendritic 
excitability that has motor performance benefits as well as neuroprotective benefits.  These data 
present an exciting possibility: that targeting dendritic excitability is an attractive therapeutic 
strategy to both improve neurologic symptoms and produce long-term benefits by slowing 
disease progression in ataxias and other neurodegenerative diseases. 
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Figure 3.1 Characterization of Purkinje neuron dendritic degeneration in ATXN1[82Q] 
Purkinje neurons. (A) Dendritic capacitance measurements reveal ATXN1[82Q] Purkinje 
neuron dendritic degeneration starting at five weeks of age.  (B) Somatic and proximal dendrite 
capacitance measurements reveal no significant differences in somatic and proximal dendrite 
surface area.  (C) Visualized neurons Representative biocytin-filled Purkinje neurons used for 
dendritic capacitance measurements and for Neurolucida reconstruction and surface area 
measurement. (D) Measurement of dendritic surface area in reconstructed Purkinje neurons 
match surface area measurements using capacitance. (E) Sholl analysis at 5 weeks of age reveals 
reduced dendritic complexity in ATXN1[82Q] Purkinje neurons.  (F) Sholl analysis at 15 weeks 
of age reveals reduced dendritic complexity in ATXN1[82Q] Purkinje neurons.  Throughout, 
data are mean ± SEM.  ** = P<0.01; *** = P<0.001. Statistical significance derived by two-way 
ANOVA with Sidak’s multiple comparison test with statistically significant differences after 





Figure 3.2 Measuring intrinsic dendritic excitability using dendritic calcium spikes in wild-
type and ATXN1[82Q] Purkinje neurons. (A) Representative traces where dendritic calcium 
spikes were evoked with somatic current injection (injected current amount indicated on the 
trace) from five week old wild-type Purkinje neurons (left) and ATXN1[82Q] Purkinje neurons 
(right).  ATXN1[82Q] Purkinje neurons require less injected current to elicit a dendritic calcium 
spike than wild-type Purkinje neurons, summarized (B). (C) At five weeks of age, the input 
resistances of wild-type and ATXN1[82Q] Purkinje neurons do not differ when measured in 
normal aCSF with 1 µm TTX. (D) Representative traces where dendritic calcium spikes were 
evoked with somatic current injection (injected current amount indicated on the trace) from 
fifteen week old wild-type Purkinje neurons (left) and ATXN1[82Q] Purkinje neurons (right).  In 
this case, the ATXN1[82Q] Purkinje neuron did not elicit a dendritic calcium spike up to a 
maximum of +3.5 nA.  The current threshold for a calcium spike is higher in ATXN1[82Q] 
Purkinje neurons, summarized in (E).  (F) At fifteen weeks of age, the input resistance of 
ATXN1[82Q] Purkinje neurons is significantly greater than wild-type Purkinje neurons when 
measured in normal aCSF with 1 µm TTX.   Throughout, data are mean ± SEM.  NS = not 
significant, *** = P<0.001. Statistical significance derived by unpaired two-tailed Student’s T-





Figure 3.3 Measuring intrinsic dendritic excitability using backpropagating action 
potentials in wild-type and ATXN1[82Q] Purkinje neurons. (A) Representative dendritic 
whole-cell patch clamp recordings from a five week old wild-type Purkinje neuron (soma-to-
patch distance: 53.9 µm) and five week old ATXN1[82Q] Purkinje neuron (soma-to-patch 
distance:  58.2 µm). (B) Scatter-plots with single-exponent decay best-fit lines for back-
propagating action potential (bAP) amplitude measurements in wild-type and ATXN1[82Q] 
Purkinje neurons at five weeks of age show less attenuation of back-propagating action 
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potentials in ATXN1[82Q] mice. Each data point represents a recording from a separate cell, and 
the color of the data point represents the order of the dendrite from which the recording was 
performed. (C) Representative action potential from a somatic whole-cell recording in wild-type 
and ATXN1[82Q] Purkinje neurons at five weeks of age.  The peak-to-trough amplitude of 
action potentials does not differ significantly between wild-type and ATXN1[82Q] Purkinje 
neurons at five weeks of age, summarized in (D). (E) Representative dendritic whole-cell patch 
clamp recordings from a fifteen week old wild-type Purkinje neuron (soma-to-patch distance: 
45.0 µm) and fifteen week old ATXN1[82Q] Purkinje neuron (soma-to-patch distance: 48.6 
µm). (F) Scatter-plots with single-exponent decay best-fit lines for back-propagating action 
potential (bAP) amplitude measurements in wild-type and ATXN1[82Q] Purkinje neurons at 
fifteen weeks of age show less attenuation of back-propagating action potentials in ATXN1[82Q] 
mice. Each data point represents a recording from a separate cell, and the color of the data point 
represents the order of the dendrite from which the recording was performed. (G) Representative 
action potential from a somatic whole-cell recording in wild-type and ATXN1[82Q] Purkinje 
neurons at fifteen weeks of age.  The peak-to-trough amplitude of action potentials does not 
differ significantly between wild-type and ATXN1[82Q] Purkinje neurons at fifteen weeks of 
age, summarized in (H). Where there are error bars, data are mean ± SEM. Throughout, NS = not 
significant; * = P < 0.05. Statistical significance derived by unpaired two-tailed Student’s T-Test 
(D, H) or extra sum of squares F test to determine whether one should reject the null hypothesis 







Figure 3.4 Measuring mRNA transcript expression for ion channels important in dendritic 
physiology. mRNA transcript levels for Kcnma1 (A), Kcnn3 (B), Itpr1 (C), Trpc3 (D), Cacna1g 
(E), Kcnj3 (F),Throughout, data are mean ± SEM. Throughout, NS = not significant; ** = P < 
0.01; *** = P < 0.001. Statistical significance derived by unpaired two-tailed Student’s T-Test 





Figure 3.5 Measuring the effect of BK-AAV and baclofen treatment on dendritic calcium 
spike threshold in ATXN1[82Q] Purkinje neurons at 5 weeks of age.  (A) Representative 
traces from Purkinje neurons at 5 weeks of age where dendritic calcium spikes were evoked with 
somatic current injection (injected current amount indicated on the trace).  Recordings are from 
wild-type mice treated with GFP-AAV (left), ATXN1[82Q] mice treated with GFP-AAV 
(middle), and ATXN1[82Q] mice treated with BK-AAV and recordings were performed in the 
presence of 2 µm baclofen (right).  (B) At five weeks of age, Purkinje neurons from 
ATXN1[82Q] mice which had been injected with BK-AAV with recordings performed in the 
presence of 2 µm baclofen show a normalization of their dendritic calcium spike threshold. (A) 
Input resistances are plotted from Purkinje neurons from five week old wild-type mice injected 
with GFP-AAV, Purkinje neurons from five week old ATXN1[82Q] mice injected with GFP-
AAV, Purkinje neurons from five week old ATXN1[82Q] mice injected with BK-AAV, Purkinje 
neurons from five week old ATXN1[82Q] mice injected with GFP-AAV and exposed acutely to 
2 µm baclofen, and Purkinje neurons from five week old ATXN1[82Q] mice injected with BK-
AAV and exposed acutely to 2 µm baclofen.  Throughout, data are mean ± SEM. Throughout, 
NS = not significant, * = P<0.05.  Statistical significance derived by one-way ANOVA with 






Figure 3.6 Measuring the effect of BK-AAV and baclofen treatment on rota-rod 
performance and dendritic degeneration in ATXN1[82Q] mice.  (C) Rotarod performance 
was improved in ATXN1[82Q] mice injected with BK-AAV and treated with baclofen. * = 
statistically significant difference from wild-type and ATXN1[82Q] BK-AAV + Baclofen 
groups; # = statistically significant difference from all other groups. Statistical significance 
derived by repeated-measures two-way ANOVA with Holms-Sidak multiple comparison test. 
(D) Molecular layer thickness was preserved at fifteen weeks in ATXN1[82Q] mice injected 
with BK-AAV and treated with baclofen. * = statistically significant difference from wild-type 
and ATXN1[82Q] BK-AAV + Baclofen groups; # = statistically significant difference from all 
other groups.  Statistical significance derived by one-way ANOVA with Holms-Sidak multiple 
comparison test. (E) Representative images at the cerebellar primary fissure in wild-type mice, 
ATXN1[82Q] mice exposed to sham surgery and vehicle, ATXN1[82Q] mice exposed to sham 







Figure 3.7 Possible pathways underlying increased intrinsic dendritic excitability.  (A) 
Pathway outlining increased dendritic excitability in ATXN1[82Q] Purkinje neurons as arising 
from reduced transcript levels for subthreshold K channel genes and the BK channel.  In this 
model, baclofen acts on remaining subthreshold K channels and BK-AAV restores expression of 
BK to normalize dendritic excitability.  (B) Pathway outlining increased dendritic excitability in 
ATXN1[82Q] Purkinje neurons as arising from reduced transcript levels for BK and reduced 
function or expression of unknown channels in a parallel pathway.  In this model, baclofen acts 
on unaffected subthreshold K channels and BK-AAV restores expression of BK to normalize 
dendritic excitability. (C) Pathway outlining increased dendritic excitability in ATXN1[82Q] 
Purkinje neurons as arising from two hits: 1) reduced transcript levels for BK, and 2) reduced 
expression of mGluR1-dependent dendritic calcium sources (IP3 receptor, Trpc3, and CaV3.1).  
In this model, baclofen acts by potentiating mGluR1 and BK-AAV restores expression of BK to 
normalize dendritic excitability.  In all cases, channels whose transcript levels are reduced in 






The ATXN1[82Q] model of SCA1 shows increased protein kinase C 
(PKC) substrate phosphorylation that opposes increased Purkinje 
neuron dendritic excitability and dendritic degeneration 
4.1 Abstract 
Purkinje neuron dendrite degeneration is a common histopathologic finding in ataxia, and 
models of spinocerebellar ataxias suggest that dendritic degeneration is an important structural 
correlate of motor impairment.  Establishment and maintenance of mature Purkinje neuron 
dendrite structure depends heavily on neuronal activity and downstream activity-dependent 
pathways that act on the dendritic cytoskeleton to specify dendritic structure.  Although a role for 
altered Purkinje neuron physiology in dendritic degeneration has been demonstrated in some 
models of spinocerebellar ataxia, the activity-dependent pathways that would act downstream of 
these changes to execute pathogenic dendrite remodeling are not well understood.  To address 
this issue, we investigated activity-dependent regulators of dendritic structure in the 
ATXN1[82Q] model of SCA1, motivated in part by the finding that ATXN1[82Q] Purkinje 
neurons show increased intrinsic dendritic excitability that drives dendritic degeneration (chapter 
3).  We began by exploring changes in several pathways that respond to neuronal activity and 
regulate dendrite structure, and found a persistent increased in phosphorylation of PKC 
substrates throughout the course of dendritic degeneration, indicating that there is increased PKC 
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activation in ATXN1[82Q] Purkinje neurons.  Increased PKC substrate phosphorylation was 
observed in Purkinje neurons from SCA1 patient autopsy tissue, confirming the relevance of this 
observed finding to human disease.  Study of the cause for this increase in PKC substrate 
phosphorylation revealed that it depends on calcium, implicating conventional PKC isozymes.  
Suppression of PKC activation in ATXN1[82Q] mice by interbreeding with a mouse expressing 
a PKC peptide inhibitor in Purkinje neurons (the PKCi mouse) resulted in accelerated dendritic 
degeneration in ATXN1[82Q] mice, suggesting that increased PKC activity prevents dendrite 
degeneration.  Analysis of dendritic physiology in ATXN1[82Q] mice expressing the PKCi 
transgene revealed increased intrinsic dendritic excitability, suggesting that increased PKC 
activity may exert its dendroprotective role by limiting increases in dendritic excitability.  These 
findings identify PKC isozymes as novel protective modifiers of dendritic degeneration in SCA1, 
and they also suggest PKC isozymes may influence dendritic degeneration in ataxia through 
regulation of dendritic excitability.  The findings from this chapter are included in a paper that is 
currently under review. 
4.2 Introduction 
Much is known about the pathways that regulate dendritic structure in developing and 
mature Purkinje neurons, but little is understood about how these pathways are affected in 
spinocerebellar ataxias.  Purkinje neuron dendrite development depends significantly on Purkinje 
neuron electrophysiologic activity
84, 85
 and there are many studies identifying changes in 
Purkinje neuron physiology in ataxia (see section 1.3.1-1.3.3).  These findings suggest that 
activity-dependent pathways regulating dendrite structure might be implicated in dendrite 
degeneration in cerebellar ataxia.   
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Among the many activity-dependent regulators of dendrite structure (see section 1.3.4), 
several candidates have already been implicated in different forms of spinocerebellar ataxia.  
Studies of SCA3 and SCA5 have demonstrated that there is increased activation of calpain 
family proteases
188, 189
, and in SCA3 calpain activity has been demonstrated to be a modifier of 
Purkinje neuron dendrite degeneration
187
.  Studies of hippocampal neurons in the Atxn1
154Q
 have 
suggested that increased activation of GSK-3β plays a role in dendrite degeneration.  Finally, 
protein kinase C activity has been demonstrated to modulate Purkinje neuron dendrite 
development in an activity-dependent fashion
183
, and several studies have suggested that SCA14-
causing mutations result in a mutant PKCγ with reduced function and a reduced capacity to 
phosphorylate targets
185, 265
.  We therefore sought to determine whether any of these pathways 
were altered in the ATXN1[82Q] model of SCA1. 
We began by assessing whether there were consistent changes in activation of GSK-3β, 
calpain family proteases, and PKC isozymes.  Having only identified a consistent increase in 
PKC substrate phosphorylation in ATXN1[82Q], we investigated PKC substrate phosphorylation 
in autopsy tissue from patients with SCA1 and found that SCA1 patient Purkinje neurons also 
showed increased PKC substrate phosphorylation.  We explored the causes for increased PKC 
activation in ATXN1[82Q] Purkinje neurons and demonstrated that it required calcium, 
implicating the conventional PKC isozyme subfamily, and also demonstrated that it was likely a 
change in activity of these isozymes rather than expression.  In order to investigate the 
consequence for increased PKC activity on dendritic structure in ATXN1[82Q] Purkinje 
neurons, we inhibited PKC activity in ATXN1[82Q] mice in vivo by interbreeding them with 
PKCi mice that express a pseudosubstrate peptide inhibitor, and we found that inhibition of PKC 
activity accelerated dendritic degeneration.  In our efforts to understand the mechanisms by 
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which PKC activity modulated dendritic degeneration, we identified increased intrinsic dendritic 
excitability in ATXN1[82Q] mice expressing the PKCi transgene, suggesting that PKC isozymes 
may act to limit the pathological increases in dendritic excitability identified in chapter 3.  In 
summary, we have found that increased PKC activation in ATXN1[82Q] mice is dendro-
protective, potentially by limiting increases in intrinsic dendritic excitability.  
4.3 Results 
In experiments outlined in sections 4.3.1, 4.3.2, and 4.3.4, ATXN1[82Q] mice
27
 were 
maintained homozygous for the ATXN1[82Q] transgene.  Age- and sex-matched FvB/NJ mice 
were used as wild-type controls. 
In experiments outlined in sections 4.3.5-4.3.7, experimental mice originated from 
crosses between ATXN1[82Q] (tg/-) mice on an FVB/NJ background and PKCi (tg/-) mice on a 
C57B6J background, such that all experimental animals were F1 hybrids.  The genotypes of mice 
used are specified as follows: 
 Wild-Type: ATXN1[82Q] (-/-); PKCi (-/-) 
 PKCi: ATXN1[82Q] (-/-); PKCi (tg/-) 
 ATXN1[82Q]: ATXN1[82Q] (tg/-); PKCi (-/-) 
 ATXN1[82Q] Bigenic: ATXN1[82Q] (tg/-); PKCi (tg/-) 
It is important to note that in the experiments discussed in sections 4.3.5-4.3.7, ATXN1[82Q] 
mice are on a different genetic background and are ATXN1[82Q](tg/-), rather than being 
ATXN1[82Q](tg/tg) on a pure FvB background as the mice are in section 4.3.1, 4.3.2, and 4.3.4.  
ATXN1[82Q] mice used for sections 4.3.5-4.3.7 show a slower progression of 
neurodegeneration (compare molecular layer measurements from Figure 4.5B to molecular layer 
measurements from Figure 3.6B), which we hypothesize is a result of the lower transgene dose 
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and different genetic background.  All data presented using these mice are from mice at 20 
weeks of age.  In all experiments, animals were compared to littermate controls. 
4.3.1 ATXN1[82Q] cerebella show increased PKC substrate phosphorylation throughout 
the course of dendritic degeneration 
 We investigated activation of four activity-dependent dendrite remodeling pathways in 
ATXN1[82Q] mice: GSK-3β, calpain family proteases, caspase-3, and PKC isozymes.  In 
hippocampal neurons, activity-dependent dendrite remodeling through GSK-3β involves loss of 
constitutive inhibitory phosphorylation on Serine 9
58
.   Investigation of serine 9 phosphorylation 
on GSK-3β in ATXN1[82Q] cerebella did not reveal a decrease in phosphorylation at 15 weeks 
(Figure 4.1A-B), suggesting that such activity-dependent disinhibition of GSK-3β is not taking 
place in ATXN1[82Q] Purkinje neurons.  This finding suggests that activity-dependent dendrite 
remodeling is likely not occurring through GSK-3β. 




 have been identified as important 
activity-dependent regulators of the dendritic cytoskeleton.  Activation of calpain family 
proteases and caspase-3 can both be assessed by looking at cleavage of αII-spectrin: calpain 
activity will produce a unique 145 kDa cleavage product, while caspase-3 activity will produce a 
unique 120 kDa cleavage product
230
.  Investigation of αII-spectrin breakown products in fifteen 
week old ATXN[82Q] cerebella did not reveal an increase in production of either the caspase-3-
specific 120 kDa fragment or the calpain-specific 145 kDa fragment (Figure 4.1C-E), suggesting 
that there is not increased activation of either pathway.  These findings indicate that activity-




 Activity-dependent PKC isozyme function profoundly influences Purkinje neuron 
dendrite development
183
, and mutations in PKCγ result in SCA14, a spinocerebellar ataxia with 
prominent Purkinje neuron dendrite degeneration
186
. Using an antibody that recognizes 
phosphorylated serine residues within the PKC consensus motif on substrates
266
, we assessed 
whether phosphorylation of PKC substrates was altered in ATXN1[82Q] cerebella at 15 weeks, 
and found a striking increase in PKC substrate phosphorylation (Figure 4.1F-G).  We then 
assessed PKC substrate phosphorylation at 5 weeks of age to determine whether this change was 
observed throughout the course of dendritic degeneration, and found a similar increase in PKC 
substrate phosphorylation (Figure 4.1H-I).  These findings demonstrate that PKC substrate 
phosphorylation is increased throughout the course of ATXN1[82Q] Purkinje neuron dendrite 
degeneration, suggesting an increase in activation of PKC isozymes.  These findings support a 
potential role for PKC isozyme activation in activity-dependent dendrite remodeling in 
ATXN1[82Q] Purkinje neurons. 
4.3.2 Increased PKC substrate phosphorylation likely represents increased PKC isozyme 
activity in ATXN1[82Q] Purkinje neurons 
 The ATXN1[82Q] model of SCA1 is a transgenic model expressing cDNA for human 
ATXN1 with 82 CAG repeats, and the expression is limited to Purkinje neurons with the Pcp2 
(L7) promoter.  This suggests that the observed changes in PKC substrate phosphorylation might 
originate from cell-autonomous effects of ATXN1[82Q] expression on Purkinje neurons; 
however, the data presented in Figure 4.1 are from whole cerebellar extracts, raising the 
possibility that observed increases in PKC substrate phosphorylation reflect a cell non-
autonomous effect such as gliosis
267
.  To assess the cell type from which phosphorylated PKC 
substrate signal originates, immunohistochemistry was performed with the same antibody used to 
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detect phosphorylated PKC substrates by immunoblotting (Figure 4.2A).  Signal is visible in all 
cell types, consistent with the widespread expression and function of PKC isozymes in the 
cerebellum; however, the strongest signal originates from Purkinje neurons.  The fact that the 
most robust PKC substrate phosphorylation is observed in Purkinje neurons relative to other cell 
types suggests that a significant proportion of the observed immunoblot signal originates from 
Purkinje neurons.   
In addition to assessing the cell type in PKC substrate phosphorylation is observed, we 
aimed to assess whether the increase in substrate phosphorylation represented a true increase in 
activity, as opposed to changes in the expression of PKC substrates.  This is particularly 
important given that the identity of substrates detected by immunoblotting is not known.  Use of 
protein kinase C inhibitors in organotypic cerebellar slice cultures largely eliminated the 
immunoblot signal (Figure 4.2B), supporting the conclusion that signal detected using this 
antibody is an indicator of steady-state PKC activity.  We concluded from this that the observed 
immunoblot signal in figure 4.1F-I represents an increase in PKC activity in ATXN1[82Q] 
Purkinje neurons. 
4.3.3 Increased PKC substrate phosphorylation is observed in Purkinje neurons from 
SCA1 patient autopsy tissue 
In order to ensure that observed increases in PKC activity from the ATXN1[82Q] model 
are relevant to human SCA1, immunohistochemistry experiments were performed in autopsy 
tissue from SCA1 patients and age-matched controls (demographic information for patient and 
control tissue is outlined in Table 4.1).  Purkinje neurons were identified with calbindin, and 
phosphorylated PKC substrates were visualized using the same antibody employed in figures 
4.1F-I and 4.2.  Consistent with the findings in ATXN1[82Q] mice, there was a significant 
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increase in PKC substrate phosphorylation (Figure 4.3A) in the dendritic (Figure 4.3B) and 
somatic (Figure 4.3C) compartments of SCA1 Purkinje neurons compared to healthy controls. 
Among the SCA1 patient samples, 4/11 SCA1 samples showed strikingly high PKC 
substrate phosphorylation.  The significance of this heterogeneity is unclear: there is no 
correlation between increased PKC substrate phosphorylation and CAG repeat length or age of 
death, and clinical information is not available to determine whether increased PKC substrate 
phosphorylation predicts worse or improved cerebellar function.  Additionally, subjective 
assessment of Purkinje neuron degeneration (specifically with respect to the number of Purkinje 
neurons per high power field and apparent dendritic integrity) did not suggest that SCA1 samples 
with higher PKC activity in Purkinje neurons showed more or less pathology. Additional studies 
are required to understand the reasons behind the significant variability in SCA1 Purkinje neuron 
PKC activity observed in patient autopsy tissue.  Nevertheless, these studies recapitulate the 
findings in the ATXN1[82Q] model, supporting the use of this model for understanding any role 
that increased PKC activity may play in SCA1 Purkinje neuron dendrite degeneration. 
4.3.4 Increased PKC substrate phosphorylation reflects increased conventional PKC 
isozyme activation in ATXN1[82Q] Purkinje neurons 
The PKC family of enzymes is subdivided into four sub-families that are distinguished by 
the regulatory signals to which they respond
268
.  The conventional PKC isozyme sub-family 




activation.  Cerebellar organotypic 
slice culture experiments from ATXN1[82Q] and wild-type mice revealed that the increased 
PKC activity which was observed in SCA1 Purkinje neurons at fifteen weeks could be 
eliminated by using 5 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
(EGTA) to chelate extracellular Ca
2+
 ions (Figure 4A-B).  This suggests that the observed 
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changes in PKC substrate phosphorylation reflect increased function of one of the conventional 
PKC isozymes.  Purkinje neurons express both PKCα and PKCγ
269, 270
.  ATXN1[82Q] Purkinje 
neurons show unchanged PKCα expression and reduced PKCγ expression, consistent with 
previous reports
32
 (Figure 2C-G).  These data indicate that the observed steady-state increases in 
conventional PKC activity are due to increased activation rather than increased isozyme 
expression. 
The trigger for increased conventional PKC isozyme activity remains unclear.  Multiple 
calcium sources and PKC activation pathways were inhibited in ATXN1[82Q] organotypic 
cerebellar slices, including mGluR1, AMPA receptors, and the P/Q-, T-, and L-type voltage-
gated calcium channels, but none of these inhibition strategies were able to recapitulate the 
observed reduction in PKC substrate phosphorylation when slices were treated with EGTA (data 
not shown).  As such, the mechanism by which PKC activity is increased in ATXN1[82Q] 
Purkinje neurons remains as yet unknown. 
4.3.5 Normalizing PKC activity in ATXN1[82Q] Purkinje neurons accelerates dendrite 
degeneration  
As discussed previously, PKC activity plays a major role in determining Purkinje neuron 
dendritic structure
182, 185
.  However, the data from studies of Purkinje neuron dendrite 
development demonstrate that use of phorbol esters to activate PKC isosymes results in atrophic 
dendrites
182
, while studies of SCA14 suggest that mutations in PKCγ produce an enzyme which 
is functionally defective
185
 or even exerts dominant negative effects
265
 to drive Purkinje neuron 
dendrite degeneration, making it difficult to predict how increased PKC activity might contribute 
to dendrite degeneration in SCA1 Purkinje neurons. To assess the significance of increased PKC 
activity in SCA1 Purkinje neurons, we aimed to normalize PKC activity in ATXN1[82Q] mice 
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and assessed the effect on Purkinje neuron dendritic integrity.  We inhibited PKC activity by 
intercrossing ATXN1[82Q] mice with PKCi mice that express a pseudosubstrate PKC inhibitor 
peptide under the control of the Purkinje neuron-specific L7/Pcp2 promoter
224
 (mice expressing 
both transgenes are hereafter referred to as ATXN1[82Q] bigenic mice).  ATXN1[82Q] bigenic 
mice showed a normalization of cerebellar PKC substrate phosphorylation (Figure 4.5A).  
Importantly, dendrite degeneration at twenty weeks was accelerated in ATXN1[82Q] 
bigenic mice. Molecular layer thickness, a measure of Purkinje neuron dendritic integrity, was 
significantly decreased in ATXN1[82Q] bigenic mice compared to both wild-type and PKCi 
mice (Figure 4.5B&D).  The increased dendrite loss in ATXN1[82Q] bigenic mice was also 
confirmed with whole-cell capacitance measurements, which revealed that the severity of 
Purkinje neuron atrophy was significantly greater in ATXN1[82Q] bigenic mice compared to 
ATXN1[82Q] mice (Figure 4.5C). In both molecular layer thickness measurements and whole-
cell capacitance measurements, no dendrite surface area changes were observed in PKCi mice, 
suggesting that the observed effect is specific to increased PKC activation in the disease state.  
These data suggest that the increased PKC activity observed in ATXN1[82Q] mice protects 
against dendritic degeneration. 
4.3.6 Increased PKC activity does not protect Purkinje neuron dendrites in SCA1 by 
modulating somatic spiking  
Previous studies have suggested that altered spiking is an important driver of 
neurodegeneration in the ATXN1[82Q] model of SCA1
114, 116
 and in other models of cerebellar 
ataxia
115, 271
.  Protein kinase C family members influence the function of a number of ion 
channels that regulate membrane excitability
272-275
.  We therefore sought to investigate whether 
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increased PKC activity might exert its dendro-protective effect on ATXN1[82Q] Purkinje 
neurons by altering Purkinje neuron spiking. 
To assess this possibility, cell-attached and whole-cell patch clamp somatic recordings 
were performed from ATXN1[82Q] bigenic and litter-mate control Purkinje neurons in acute 
cerebellar slices at twenty weeks of age. Baseline firing properties were abnormal in both 
ATXN1[82Q] bigenic mice and ATXN1[82Q] mice as compared to litter-mate wild-type and 
PKCi controls (Figure 4.6A). Both ATXN1[82Q] and ATXN1[82Q] bigenic Purkinje neurons 
exhibited reduction in firing frequency (Figure 4.6B) and increased spike irregularity (Figure 
4.6C).  Analysis of spikes from whole-cell patch clamp recordings of baseline spiking (Figure 
4.6E) revealed reduced amplitude (Figure 4.6F) and increased variability (Figure 4.6G) of the 
anti-peak after-hyperpolarization potential (AHP) reached during each spike, and abnormalities 
in the AHP have been previously demonstrated to underlie irregular spiking in Purkinje 
neurons
105, 276
. The alterations in spiking in ATXN1[82Q] Purkinje neurons are consistent with 
our prior work in this model of SCA1
116
 identifying altered spiking and a reduction in the AHP 
due to reduced expression and function of the large-conductance calcium-activated potassium 
(BK) channel.  Consistent with these data, we observed reduced expression of Kncma1, the gene 
that encodes the BK channel (Figure 4.6D). 
Importantly, all of these spiking parameters were similarly altered in both ATXN1[82Q] 
and ATXN1[82Q] bigenic Purkinje neurons.  The lack of differences in basal Purkinje neuron 
spiking between ATXN1[82Q] and ATXN1[82Q] bigenic Purkinje neurons indicate that PKC 




4.3.7 Increased PKC activity may protect Purkinje neuron dendrites in SCA1 by reducing 
intrinsic dendritic excitability  
 The studies outlined in section 4.3.6 demonstrate that PKC activity is unlikely to exert its 
dendroprotective effect in SCA1 by regulating somatic spiking. Importantly, studies presented in 
chapter 3 demonstrate that increased intrinsic dendritic excitability is a driver of Purkinje neuron 
dendrite degeneration in SCA1.  Protein kinase C isozymes phosphorylate a number of channels 





raising the possibility that increased PKC activity may protect ATXN1[82Q] Purkinje neuron 
dendrites by influencing dendritic excitability. 
 Despite the similarity in basal spiking between ATXN1[82Q] and ATXN1[82Q] bigenic 
Purkinje neurons, ATXN1[82Q] bigenic Purkinje neurons could not sustain spiking in response 
to depolarizing current injection to the same level as ATXN1[82Q] Purkinje neurons (Figure 
4.7A-B).  This abnormality occurred despite a similar input resistance for ATXN1[82Q] bigenic 
Purkinje neurons and ATXN1[82Q] Purkinje neurons (Figure 4.7C).  Importantly, in some 
Purkinje neurons from ATXN1[82Q] bigenic mice, dendritic calcium spikes appeared after a 
small number of sweeps and appeared to compete with somatic sodium action potentials (Figure 
4.7A).  It is known that dendritic calcium spikes can influence somatic spiking in Purkinje 
neurons
154, 278
, raising the possibility that  ATXN1[82Q] bigenic Purkinje neurons required less 
injected current to elicit a dendritic calcium spike than ATXN1[82Q] Purkinje neurons. As 
discussed in section 3.3.2, this would suggest an increase in intrinsic dendritic excitability. 
To directly test the intrinsic dendritic excitability of ATXN1[82Q] bigenic Purkinje 
neurons, the same calcium spike experiment utilized in section 3.3.2 was performed in 
ATXN1[82Q] bigenic and ATXN1[82Q] Purkinje neurons (Figure 4.7D).  Consistent with the 
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conclusion that ATXN1[82Q] Purkinje neurons show increased intrinsic dendritic excitability, 
they  required less injected current to elicit dendritic calcium spikes (Figure 4.7E) in the absence 
of changes in input resistance (Figure 4.7F).  As discussed in chapter 3, a reduced threshold to 
dendritic calcium spikes suggests increased intrinsic dendritic excitability.  Because of the role 
established in chapter 3 for increased intrinsic dendritic excitability as a driver of ATXN1[82Q] 
Purkinje neuron dendrite degeneration, these data raise the possibility that increased PKC 
activity opposes SCA1 Purkinje neuron dendrite degeneration by reducing intrinsic dendritic 
excitability. 
4.4 Discussion 
 Here we report that Purkinje neurons from the ATXN1[82Q] model of SCA1 show 
increased activation of PKC isozymes, which are important regulators of Purkinje neuron 
dendrite structure that are responsive neuronal activity.  Increased PKC isozyme activity is 
recapitulated in Purkinje neurons from SCA1 patient post-mortem tissue, demonstrating that 
observations in the ATXN1[82Q] model recapitulate human disease.  Investigation of the 
mechanism behind increased PKC activity reveal that it is specifically the conventional PKC 
isozymes which are activated in ATXN1[82Q] Purkinje neurons.  Importantly, normalizing PKC 
activity in ATXN1[82Q] mice by interbreeding with mice expressing a PKC pseudosubstrate 
inhibitor in Purkinje neurons results in accelerated dendrite degeneration, demonstrating that 
increased PKC activity protects ATXN1[82Q] Purkinje neuron dendrite structure.  Efforts to 
understand the mechanism behind this dendroprotection revealed that increased PKC activity 
opposes intrinsic dendritic excitability but has no effect on somatic spiking, further supporting a 
role for dendritic excitability independent of somatic spiking as a driver of dendrite degeneration 
in SCA1 Purkinje neurons. 
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 As discussed in section 1.3.4, studies of Purkinje neuron development have found that 
PKC activation suppresses dendrite outgrowth
182
, while studies of SCA14 have suggested that 
the Purkinje neuron dendrite degeneration observed in SCA14
186
 arises from a mutated PKCγ 
with reduced in vivo kinase activity
185
 or even dominant negative action
265
. These data have 
suggested that PKC activity might have distinct roles in developing vs. mature neurons, with 
PKC activity inhibiting dendrite outgrowth in developing Purkinje neurons but supporting 
dendrite stability in mature Purkinje neurons.  The findings from this study lend support to the 
idea that increased PKC activity stabilizes mature Purkinje neuron dendrites, and they suggest 
that increased PKC activation in ATXN1[82Q] Purkinje neurons is an induced protective 
pathway that slows the rate of dendrite degeneration.  These findings are not only relevant to 
SCA1, but they also provide insight into the Purkinje neuron degeneration observed in 
SCA14
186
, suggesting that the adult-onset dendrite degeneration in this disease reflects the loss of 
a factor (PKCγ) that sustains mature Purkinje neuron dendrites. 
 How increased PKC activity opposes dendritic degeneration in ATXN1[82Q] Purkinje 
neurons is at this point not clear.  However, it is very likely a Purkinje cell-autonomous effect, as 
both the ATXN1[82Q] transgene and the PKCi transgene are expressed only in Purkinje neurons.  
As such, the ATXN1[82Q] bigenic mouse lends itself to –omics approaches for exploring the 
dendro-protective pathway(s) downstream of PKC in SCA1.  PKC isozymes act not just on 
direct substrates but also influence transcription
279
, suggesting that there may be utility in both 
phosphoproteomic and transcriptomic approaches.  Ideally, such a study might identify novel 
modifiers of dendritic degeneration relevant to SCA1 and other SCAs. 
 Because of the data in chapter 3 indicating that increased dendritic excitability drives 
SCA1 Purkinje neuron dendrite degeneration, the reduced threshold to calcium spikes in 
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ATXN1[82Q] bigenic Purkinje neurons suggests that increased PKC activity in ATXN1[82Q] 
Purkinje neurons protects Purkinje neuron dendrites by limiting increases in dendritic 
excitability.  If this were confirmed to be the mechanism, the fact that no other changes in 
baseline spiking were identified between ATXN1[82Q] and ATXN1[82Q] bigenic Purkinje 
neurons would demonstrate that increased intrinsic dendritic excitability can drive dendrite 
degeneration independent of changes in spiking.  This would add more weight to the arguments 
put forth in chapter 3, and it would address the lack of dendrite specificity for the BK-AAV and 
baclofen experiment.   
 Further exploration of this mechanism would require identification of the channel(s) 
acted on by PKC to limit dendrite degeneration.  Among the many channel targets of PKC, three 
channel candidates are of particular interest because they are expressed at high levels in PN 
dendrites and are affected by PKC phosphorylation in a manner which would be predicted to 
reduce dendritic excitability.  The first channel of interest is the Slack channel, which is a 
sodium-activated potassium channel whose current is increased two- to three-fold in response to 
PKC phosphorylation at Ser407
280, 281
.  The second channel of interest is Kv3.3, a channel which 
has been shown to suppress dendritic excitability
152
 and which shows slowing of inactivation 
upon PKC phosphorylation at either Ser3 or Ser9
272
.  The final channel candidate is the T-Type 
voltage-gated calcium channel subfamily, which shows a two- to three-fold increase in peak 
current upon PKC phosphorylation
277
; the prediction would be that increased T-Type channel 
activity would reduce excitability by activating calcium-activated potassium channels, since the 
predominant effect of calcium channel function in Purkinje neurons is to produce a 
hyperpolarizing current through activation of calcium-activated potassium channels
96
.  
Identifying which of these channels are modulating dendritic excitability downstream of PKC 
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will not only reveal dendro-protective channel targets for SCA1 and possibly SCA14, but will 
also provide insight into how specific channels regulate activity-dependent dendrite remodeling 
in Purkinje neurons. 
 An important question not answered in this study is the mechanism by which increased 
PKC activity is triggered in SCA1 Purkinje neurons.  The fact that calcium chelation eliminates 
PKC substrate phosphorylation in ATXN1[82Q] cerebella demonstrates that increased PKC 
activity is mediated by conventional PKC isozymes; however, conventional PKC isozymes 
expressed in Purkinje neurons (PKCα and PKCγ) are not increased in expression, and PKCγ in 
fact has significantly reduced expression.  Furthermore, a well-characterized pathway for 
activation of conventional PKC isozymes is from studies of parallel fiber LTD, wherein Purkinje 
neuron cPKC isozymes (most likely PKCα
282
) are activated downstream of mGluR1 through the 
action of both DAG and IP3-mediated calcium
283
; however, ATXN1[82Q] Purkinje neurons 




.  These findings 
demonstrate that to explain increased PKC activity in ATXN1[82Q] Purkinje neurons, one 
cannot invoke changes in expression of PKCα or PKCγ and also cannot invoke increased 
mGluR1-dependent activation. 
We propose several hypotheses for increased PKC activity in ATXN1[82Q] Purkinje 
neurons. One possibility is that despite reduced expression of calcium sources downstream of 
mGluR1 (section 3.3.4), cytosolic [Ca
2+
] might still be increased from another calcium source 
that has not yet been tested, resulting in secondary DAG production and consequent PKC 
activation
284
.  A second possibility is that the observed increase in PKC activity reflects ectopic 
expression of PKCβI or PKCβII in Purkinje neurons as a result of ATXN1[82Q] transgene 
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expression, a possibility best assessed by immunohistochemistry analysis of PKCβI and PKCβII 
expression in ATXN1[82Q] Purkinje neurons. 
A third possibility is that as PKCγ expression is suppressed, signals for activation of both 
PKCγ and PKCα result in disproportionate activation of PKCα, with the differences in 
phosphorylation efficiency and substrate pool that have been reported for individual PKC 
isozymes
285
 resulting in the observed increase in PKC substrate phosphorylation.  Several lines 
of evidence support this hypothesis.  In studies of Purkinje neuron dendrite development it has 
been suggested that PKCα forms a “reserve pool” that is only activated in response to strong 
stimuli
286
, and in ATXN1[82Q] Purkinje neurons it might be possible that this reserve pool is 
recruited more readily as PKCγ expression is reduced.  Furthermore, immunohistochemistry 
experiments in ATXN1[82Q] Purkinje neurons (see figure 4.4F-G) show that PKCγ is 
particularly suppressed in the dendritic arbor and PKCα expression is intact throughout both the 
soma and dendrite, such that if such a mechanism were active it might arise through regional 
differences in the availability of each isozyme. This possibility would be best assessed by 
crossing ATXN1[82Q] mice to PKCα knockout mice; if this hypothesis were correct then 
ATXN1[82Q] mice interbred with PKCα knockout mice should also have accelerated dendritic 
degeneration.  
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Figure 4.1 Activity-dependent dendrite remodeling pathways in whole cerebellar lysates 
from ATXN1[82Q] mice. (A) Representative Western blot for phospho-Ser9 GSK-3β at fifteen 
weeks of age showing unchanged phosphorylation of serine 9 on GSK-3β in ATXN1[82Q] 
cerebella, summarized in (B). (C) Representative Western blot for αII-spectrin breakdown 
products (SBDPs) produced by the activity of calpain family proteases and caspase-3.  These 
blots show unchanged levels of the caspase-3-specific 120 kDa fragment  relative to full-length 
αII-spectrin (summarized in (D)) and unchanged levels of the calpain-specific 145 kDa fragment 
relative to full-length αII-spectrin (summarized in (E)) at fifteen weeks of age in ATXN1[82Q] 
cerebella. (F) Representative Western blot for phosphorylated PKC substrates at fifteen weeks of 
age showing increased PKC substrate phosphorylation in cerebella from ATXN1[82Q] mice, 
summarized in (G). (H) Representative Western blot for phosphorylated PKC substrates at five 
weeks of age show increased PKC substrate phosphorylation in cerebella from ATXN1[82Q] 
mice, summarized in (I). Throughout, data are mean ± SEM.  ** = P<0.01; *** = P<0.001. 




Figure 4.2 Increased PKC substrate phosphorylation in ATXN1[82Q] mice reflects 
increased PKC isozyme activity in Purkinje neurons. (A) Representative 
immunohistochemistry experiment showing PKC substrate phosphorylation in Purkinje neurons 
from a fifteen week old ATXN1[82Q] mice. Scale bars, 50 µm. (B) Western blot demonstrating 
the effect of the PKC inhibitor Go6983 on PKC substrate phosphorylation in cerebellar slice 





Patient No Age Repeat Size (pathogenic allele) Sex 
S1 47 47 Male 
S2 52 Not Available Male 
S3 54 50 Male 
S4 59 47 Male 
S5 61 46 Male 
S6 63 41 Female 
S7 64 45 Male 
S8 64 44 Male 
S9 65 42 Male 
S10 66 46 Female 
S11 73 Not Available Female 
S12 81 38 Female 
    Control Samples 
Patient No Age Repeat Size Sex 
C1 48 N/A Female 
C2 59 N/A Male 
C3 61 N/A Male 
C4 65 N/A Male 
C5 70 N/A Male 
C6 73 N/A Female 
C7 80 N/A Female 
 
Table 4.1 Demographic information on SCA1 patients and age-matched healthy controls.  
Presented above is relevant demographic information from SCA1 patients and age-matched 







Figure 4.3 Increased PKC substrate phosphorylation is observed in Purkinje neurons from 
SCA1 patient autopsy tissue. (A) Representative images of phosphorylated PKC substrate 
staining (green) in Purkinje neurons (red) from SCA1 patient samples and age-matched healthy 
controls. Scale bars, 50 µm. Summarized data show increased phosphorylated PKC substrate 
staining relative to calbindin staining in the dendritic (B) and somatic (C) compartment of 
Purkinje neurons from SCA1 patient samples and age-matched healthy control samples.  Each 
data point represents an individual patient, with error bars representing SEM for measurements 
from multiple Purkinje neurons in that individual.  ** = P<0.01; *** = P<0.001.  Statistical 
significance derived by two-way ANOVA demonstrating an independent impact of disease state 






Figure 4.4 Conventional PKC isozyme activity is increased in ATXN1[82Q] Purkinje 
neurons. (A) Representative Western blot for phosphorylated PKC substrates in organotypic 
cerebellar slice cultures treated with 5 mM EGTA from fifteen week old mice. Calcium chelation 
with EGTA reduced PKC substrate phosphorylation in ATXN1[82Q] slice cultures but not wild-
type slice cultures, summarized in (B).  (C) Representative Western blot for PKCα and PKCγ in 
fifteen week old mice. Unchanged expression of PKCα in ATXN1[82Q] cerebella at fifteen 
weeks of age is summarized in (D), while reduced expression of PKCγ in ATXN1[82Q] 
cerebella at fifteen weeks of age is summarized in (E).  (F) Representative image of PKCα 
expression (green) in ATXN1[82Q] and wild-type Purkinje neurons (labelled with calbindin, 
red) at fifteen weeks of age.  Scale bars, 50 µm (G) Representative image of PKCγ expression 
(green) in ATXN1[82Q] and wild-type Purkinje neurons (labelled with calbindin, red) at fifteen 
weeks of age. Scale bars, 50 µm. Throughout, data are mean ± SEM.  NS = Not Significant; * = 
P<0.05; *** = P<0.001. Statistical significance derived by two-way ANOVA with Sidak’s 
multiple comparison test with statistically significant differences after multiple comparisons 






Figure 4.5 Increased PKC activity protects against dendritic degeneration in ATXN1[82Q] 
mice.  (A) Representative Western blot for PKC substrate phosphorylation in wild-type, 
ATXN1[82Q], and ATXN1[82Q] bigenic mice at twenty weeks of age demonstrating 
normalization of PKC substrate phosphorylation in ATXN1[82Q] bigenic mice. (B) Reduced 
molecular layer thickness in lobule V of ATXN1[82Q] bigenic mice at twenty weeks of age. (C) 
Whole-cell capacitance measurements in ATXN1[82Q] bigenic Purkinje neurons show a greater 
reduction in cell size relative to ATXN1[82Q] Purkinje neurons, which are atrophied relative to 
wild-type and PKCi Purkinje neurons at twenty weeks of age. (D) Representative images at the 
cerebellar primary fissure in wild-type, PKCi, ATXN1[82Q], and ATXN1[82Q] bigenic mice 
stained with calbindin at twenty weeks of age. Scale bar, 100 µm. Throughout, data are mean ± 
SEM.  * = P<0.05. Statistical significance derived by one-way ANOVA with Holms-Sidak 






Figure 4.6 Increased PKC activity does not influence baseline action potential firing in 
ATXN1[82Q] Purkinje neurons.  (A) Representative firing from wild-type, PKCi, 
ATXN1[82Q], and ATXN1[82Q] bigenic (expressing both the ATXN1[82Q] and PKCi 
transgenes) Purkinje neurons.  ATXN1[82Q] and ATXN1[82Q] bigenic mice show irregular 
spiking, with abnormal pauses marked with     . (B) ATXN1[82Q] and ATXN1[82Q] bigenic 
Purkinje neurons show reduced firing frequency. (C) ATXN1[82Q] and ATXN1[82Q] bigenic 
Purkinje neurons show more irregular firing, indicated by a higher coefficient of variation. (D) 
ATXN1[82Q] and ATXN1 [82Q] bigenic mice show reduced expression of Kcnma1, the gene 
encoding the BK channel. (E) Representative spontaneous action potentials from wild-type, 
PKCi, ATXN1[82Q], and ATXN1[82Q] bigenic Purkinje neurons.  ATXN1[82Q] and 
ATXN1[82Q] bigenic Purkinje neurons have an AHP which does not achieve the same degree of 
hyperpolarization as wild-type and PKCi Purkinje neurons, summarized in (F). (G) During 
spontaneous spiking, the membrane potential reached by the AHP of each spike varies more in 
ATXN1[82Q] and ATXN1[82Q] bigenic Purkinje neurons relative to wild-type and PKCi 
Purkinje neurons, indicated by a higher coefficient of variation for AHP measurements.  
Throughout, data were acquired from Purkinje neurons in mice at twenty weeks of age. 
Throughout, data are mean ± SEM.  NS = not significant; * = P < 0.05. Statistical significance 





Figure 4.7 Increased PKC activity opposes increases in dendritic excitability in 
ATXN1[82Q] Purkinje neurons.  (A) Representative traces from ATXN1[82Q] and 
ATXN1[82Q] bigenic Purkinje neurons injected with +700 pA of current.  Dendritic calcium 
spikes in the ATXN1[82Q] bigenic Purkinje neuron are marked with arrows. ATXN1[82Q] 
bigenic Purkinje neurons undergo depolarization block of repetitive spiking at lower levels of 
injected current than ATXN1[82Q] Purkinje neurons, summarized in (B). (C) Representative 
traces where dendritic calcium spikes were evoked with somatic current injection (injected 
current amount indicated on the trace) from ATXN1[82Q] (left) and ATXN1[82Q] bigenic 
(right) Purkinje neurons treated with 1 µm TTX. ATXN1[82Q] bigenic Purkinje neurons require 
less injected current to elicit a dendritic calcium spike than ATXN1[82Q] Purkinje neurons, 
summarized in (D).  Throughout, data were acquired from Purkinje neurons in mice at twenty 
weeks of age. Throughout, data are mean ± SEM.  NS = not significant; * = P < 0.05. Statistical 






Increased protein kinase C (PKC) substrate phosphorylation is a 
shared modifier of Purkinje neuron degeneration in some forms of 
ataxia 
5.1 Abstract 
Purkinje neuron dendrite degeneration is a common histopathologic finding in many 
spinocerebellar ataxias and sporadic forms of ataxia.  Purkinje neuron dendrite structure is 
heavily regulated by the activity of PKC isozymes in developing Purkinje neurons and the 
studies outlined in chapter 4 demonstrate that altered PKC function modulates Purkinje neuron 
dendrite degeneration in spinocerebellar ataxia type 1 (SCA1).  We were interested in exploring 
the extent to which a role for PKC isozymes in regulating dendrite degeneration was common to 
inherited and sporadic ataxias.  To explore a role for PKC in another spinocerebellar ataxia, we 
assessed whether there were changes in PKC activity in the ATXN2[127Q] model of 
spinocerebellar ataxia type 2 (SCA2), and found that there was increased PKC activity at the 
onset of Purkinje neuron dendrite degeneration.  Suppression of PKC activation in 
ATXN2[127Q] mice by interbreeding with a mouse expressing a PKC peptide inhibitor in 
Purkinje neurons (the PKCi mouse) resulted in accelerated dendrite degeneration and cell loss in 
ATXN2[127Q]  mice, suggesting that increased PKC activity is also neuroprotective in SCA2.  
Analysis of PKC substrate phosphorylation in multiple system atrophy (MSA), a sporadic 
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neurodegenerative disease that can involve Purkinje neurons, revealed that post-mortem human 
MSA tissue with heavy Purkinje neuron involvement showed increased Purkinje neuron PKC 
substrate phosphorylation, raising the possibility that dendro-protective increases in PKC activity 
may be observed in sporadic forms of ataxia as well.  These data support increased PKC activity 
as an important neuroprotective pathway in some forms of inherited and sporadic ataxia.  Some 
of the findings from this chapter are included in a paper that is currently under review. 
5.2 Introduction 
As discussed in section 1.1.1, cerebellar ataxia is a clinical entity rather than a discrete 
disease, and there are a large number of causes of ataxia, including ischemic, toxic, metabolic, 
paraneoplastic, or genetic etiologies.  For many
4, 5, 287
 but not all
288
 forms of progressive ataxia, 
autopsy studies suggest degeneration of Purkinje neuron dendrites preceding cell death.  From 
studies of spinocerebellar ataxias there is evidence to suggest that progressive dendrite 
degeneration is capable of contributing substantially to motor impairment, underlining the 
importance of understanding this phase in Purkinje neuron pathology. 
In exploring this diverse set of diseases, each of which show varying amount of clinical 
and histopathologic overlap, an important question emerges: are there common mechanisms of 
disease across multiple forms of ataxia?  Studies of protein-protein interaction networks
289
 and 
distinguishing features of specific brain regions’ transcriptomes
290
 have demonstrated that there 
are relatively small clusters of interacting proteins or pathways that emerge when one considers 
ataxias as a group.  These findings suggest that distinct pathogenic insults may ultimately feed 
into constrained pathways by which Purkinje neurons can degenerate.  They also suggest that 
common features of disease, such as dendrite degeneration, may be executed through a similarly 
constrained set of intracellular actors. 
111 
 
As discussed in chapter 4, our studies have identified increased PKC activation as a 
modifier of Purkinje neuron dendrite degeneration in SCA1.  Given the role that PKC activity 
plays as a potent regulator of normal Purkinje neuron dendrite development
182
, we were 
interested in investigating whether this role for PKC extended beyond SCA1.  We began with 
studies of SCA2, a form of ataxia that appears to be closely linked to SCA1. 
SCA2 is caused by CAG tract expansions in ATXN2
291
, resulting in a protein product 
(Ataxin-2) with an expanded polyglutamine tract.  All patients with SCA2 present with ataxia 
and many with eye movement abnormalities, while additional symptoms such as dementia, 
neuropathy, and chorea can be observed
292
.  As with SCA1, patients with more CAG repeats in 
ATXN2 will show an earlier onset of disease
292
.  Severe Purkinje neuron dendrite degeneration 
has been observed in autopsy tissue from SCA2 patients
5
, and studies in a mouse model of SCA2 




In addition to both being polyglutamine diseases, SCA1 and SCA2 appear 
mechanistically linked.  A study in a drosophila model of SCA1 revealed that increasing levels 
of the drosophila homologue of ATXN2  (dAtx2) results in accelerated pathology and 
demonstrated a direct protein-protein interaction between dAtx2 and Ataxin-1
293
.  Importantly, 
changes in Purkinje neuron excitability have been described in models of both diseases
11, 114, 116
 
and treatments which improve spiking but also reduce dendritic excitability have been shown to 




.  Because Purkinje neuron pathology 
appears to be realized through similar pathways in SCA1 and SCA2, we aimed to investigate a 
potential role for PKC activity as a modulator of Purkinje neuron dendrite pathology in SCA2. 
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We began by assessing PKC substrate phosphorylation in the ATXN2[127Q] model of 
SCA2
11
 and found that PKC activity was increased at the onset of Purkinje neuron dendrite 
degeneration.  We found that as with SCA1, calcium chelation with EGTA resulted in a 
significant reduction in PKC substrate phosphorylation in ATXN2[127Q] cerebella, implicating 
conventional PKC isozymes.   Suppression of PKC activation in ATXN2[127Q] mice by 
interbreeding with a mouse expressing a PKC peptide inhibitor in Purkinje neurons (the PKCi 
mouse) resulted in accelerated dendrite degeneration and cell loss in ATXN2[127Q]  mice, 
suggesting that increased PKC activity is also neuroprotective in SCA2. 
We also explored a role for PKC activation in other forms of cerebellar ataxia.  Analysis 
of PKC substrate phosphorylation in the sporadic neurodegenerative disease MSA revealed that 
post-mortem human MSA tissue with heavy Purkinje neuron involvement showed increased 
Purkinje neuron PKC substrate phosphorylation, raising the possibility that dendro-protective 
increases in PKC activity may be observed in this disease.  Our findings shed light on a role for 
increased PKC activity as a modifier of Purkinje neuron degeneration beyond SCA1, but they 
also highlight the fact that this role is not universal to diseases affecting Purkinje neurons. 
5.3 Results 
In experiments outlined in section 5.3.1, ATXN2[127Q] mice were maintained by 
crossing to the B6D2F1 hybrid background (Jackson Labs) on which the mouse was originally 
generated. Experiments using ATXN2[127Q] mice were done using hemizygous ATXN2[127Q] 
(tg/-) mice compared to wild-type ATXN2[127Q] (-/-) littermate controls.  Mice used for these 
experiments were twelve weeks old. 
In the experiments outlined in section 5.3.2, experimental mice originated from crosses 
between ATXN2[127Q] (tg/-) mice on a mixed background and PKCi (tg/-) mice on a C57B6J 
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background, such that all experimental animals were on a mixed background.  The genotypes of 
mice used are specified as follows: 
 Wild-Type: ATXN2[127Q] (-/-); PKCi (-/-) 
 PKCi: ATXN2[127Q] (-/-); PKCi (tg/-) 
 ATXN2[127Q]: ATXN2[127Q] (tg/-); PKCi (-/-) 
 ATXN2[127Q] Bigenic: ATXN2[127Q] (tg/-); PKCi (tg/-) 
All data presented from these experiments were from mice at twenty-five weeks of age. In all 
experiments, animals were compared to littermate controls. 
 5.3.1 ATXN2[127Q] cerebella show increased conventional PKC isozyme activity at the 
onset of Purkinje neuron dendrite degeneration 
 The ATXN2[127Q] mouse
11
 is a transgenic model which overexpresses mutant human 
ATXN2 with 127 CAG repeats selectively in cerebellar Purkinje neurons under the Pcp2 (L7) 
promoter.  In this model, thinning of the cerebellar molecular layer is first detected at twelve 
weeks
11
.  Although thinning of the molecular layer is a relatively crude measure of dendritic 
degeneration, we explored PKC substrate phosphorylation at this age, since it is well before the 
onset of cell loss (previously reported to be forty weeks
11
) such that any observed changes would 
be occurring during the dendrite degeneration phase. 
 As was observed with ATXN1[82Q] cerebella (see section 4.3.1), ATXN2[127Q] 
cerebellar extracts show a significant increase in PKC substrate phosphorylation (Figure 5.1A-
B).  Organotypic cerebellar slice culture experiments at this age reveal that treatment with 5 mM 
EGTA produces a reduction in PKC substrate phosphorylation in ATXN2[127Q] samples which 
is trending towards significance, while producing a noticeable but less substantial reduction in 
wild-type samples (Figure 5.1C-D).  Although the observed effect on wild-type samples in this 
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experiment is much more striking, these trends are otherwise consistent with what was observed 
in experiments with ATXN1[82Q] mice (see figure 4.4A-B).  The fact that EGTA treatment 
appears to have a similar effect on PKC substrate phosphorylation suggests that increased PKC 
substrate phosphorylation is likely attributable to the action of conventional PKC isozymes.  
Together, these data suggest that there is increased conventional PKC activity in ATXN2[127Q] 
cerebella at the onset of dendritic degeneration, raising the possibility that a similar mechanism 
is at work in regulating ATXN2[127Q] Purkinje neuron dendrite degeneration as was observed 
in ATXN1[82Q] mice. 
5.3.2 Normalizing PKC activity in ATXN2[127Q] Purkinje neurons accelerates Purkinje 
neuron dendrite degeneration 
As discussed in section 4.3.5, normalizing PKC activity in ATXN1[82Q] mice by 
interbreeding with PKCi mice expressing a PKC pseudosubstrate inhibitor results in accelerated 
dendrite degeneration, suggesting that increased PKC activity in ATXN1[82Q] Purkinje neurons 
is neuroprotective. We crossed ATXN2[127Q] mice with PKCi mice to generate ATXN2[127Q] 
bigenic progeny.  At twenty-five weeks, ATXN2[127Q] bigenic mice showed significantly 
greater thinning of the molecular layer in the intermediate zone relative to litter-mate 
ATXN2[127Q] mice (Figure 5.2A, 5.2C). There was significant cell death in the anterior 
cerebellum in both ATXN2[127Q] bigenic and litter-mate ATXN2[127Q] mice, but with more 
prominent disruption of the organization of Purkinje neurons in ATXN2[127Q] bigenic mice 
(Figure 5.2B). These data demonstrate that increases in PKC activity oppose Purkinje neuron 
dendrite degeneration in both SCA1 and SCA2. 
Based on this analysis, it is clear that at twenty-five weeks of age, ATXN2[127Q] 
Purkinje neuron pathology is already quite advanced, as there is already robust cell loss detected 
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in the anterior cerebellum.  This is in contrast to previous studies in the ATXN2[127Q] model, 
which have suggested that statistically significant cell loss is first detected at 40 weeks of age
11
.  
This discrepancy may have arisen because of the mixed background on which our experiments 
were performed, or because of differences in the cell counting method utilized.  Nevertheless, 
these data suggest that analysis of dendritic degeneration in ATXN2[127Q] bigenic mice should 
be performed at an earlier point before cell loss has begun, in order to more accurately isolate 
any potential role for PKC as a modulator of Purkinje neuron dendrite degeneration in SCA2. 
5.3.3 Increased PKC substrate phosphorylation is observed in Purkinje neurons from 
multiple system atrophy (MSA) patient autopsy tissue 
Multiple system atrophy (MSA) is an adult-onset, sporadic neurodegenerative disease 
characterized by autonomic dysfunction and variable combinations of parkinsonism, cerebellar 
ataxia, lower motor neuron disease, and brainstem dysfunction
294
.  MSA is clinically divided into 
a Parkinsonian subtype (MSA-P) or a cerebellar subtype (MSA-C), depending on whether the 
predominant motor symptom is Parkinsonism or cerebellar ataxia.  Although the causes and 
mechanisms of MSA remain poorly understood, it is thought that pathology originates in 
oligodendrocytes
295
 and involves the accumulation of α-synuclein, which deposits in both 
oligodendroglia and neurons
296
.  As with the clinical presentation, the neuropathology can be 
varied, and a subset of patients will have prominent involvement of Purkinje neurons
297
.    
As outlined in chapter 4 and sections 5.3.1-5.3.2, PKC activity may be a modifier of 
Purkinje neuron pathology that extends beyond PKCγ mutations in SCA14 to include other 
forms of inherited ataxia.  We were interested in assessing whether PKC might modify disease 
pathogenesis in sporadic forms of ataxia, and to that end we examined PKC substrate 
phosphorylation in surviving Purkinje neurons from post-mortem MSA samples that were noted 
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at autopsy to have significant Purkinje neuron involvement (demographic information is outlined 
in Table 5.1). MSA samples were compared to age-matched samples from patients with 
Alzheimer disease (AD), a neurodegenerative disease with limited cerebellar involvement
298, 299
.  
Subjective assessment of MSA tissue revealed substantial pathology, such that calbindin-positive 
Purkinje neurons were in some samples difficult to find, with those Purkinje neurons that were 
identified often lacking visible dendrite.  Importantly, surviving MSA Purkinje neurons showed a 
significant increase in PKC substrate phosphorylation relative to age-matched AD controls 
(Figure 3A-3B).   
It is important to note that as with the SCA1 patient tissue (see section 4.3.4), there was 
substantial heterogeneity in PKC substrate phosphorylation both within and between MSA 
samples.  Also as with the SCA1 patient tissue, there was no correlation between increased PKC 
substrate phosphorylation and subjective assessment of Purkinje neuron degeneration.  However, 
there was an apparent association between clinical features and PKC substrate phosphorylation, 
with those patients defined clinically as having both MSA-C and MSA-P showing a significantly 
higher phosphorylated PKC substrate-to-calbindin ratio than those defined as having MSA-C 
alone (Figure 3C).  With such a small number of patients it is difficult to draw firm conclusions 
from these data, but they raise the possibility that PKC activity correlates with differences in 
clinical presentation.  As such, this study raises the possibility that PKC substrate 
phosphorylation may act as a disease modifier in MSA as was observed in SCA1 and SCA2.  
Given the apparent association between clinical presentation and Purkinje neuron PKC substrate 
phosphorylation, this activity also appears to correlate with clinical presentation, suggesting that 




 Here we report that increased PKC activity may be a more general feature of 
degenerative ataxias.  As in ATXN1[82Q] mice, increased PKC substrate phosphorylation is 
observed in cerebellar extracts from the ATXN2[127Q] model of SCA2, and the increase in PKC 
substrate phosphorylation appears to reflect increases in activity of conventional PKC isozymes.  
Also as was observed in ATXN1[82Q] mice, normalizing PKC activity in ATXN2[127Q] mice 
by interbreeding with mice expressing a PKC pseudosubstrate inhibitor in Purkinje neurons 
results in accelerated dendrite degeneration, demonstrating that increased PKC activity protects 
ATXN2[127Q] Purkinje neuron dendrite structure.  These studies demonstrate that 
dendroprotective increases in PKC activity are a common feature of SCA1 and SCA2, 
underscoring the shared pathogenic features of these diseases.  Finally, study in autopsy tissue 
from patients with MSA revealed increased PKC substrate phosphorylation in Purkinje neurons, 
suggesting that PKC activity may act as a clinically-relevant modifier of disease not just in 
inherited ataxias but also sporadic forms of ataxia.  The mechanism by which PKC activity 
modulates Purkinje neuron degeneration in these other forms of ataxia warrants further study. 
 The data outlined in section 5.3.3 suggest not only that PKC substrate phosphorylation is 
increased in Purkinje neurons from patients with MSA, but they also establish a correlation 
between PKC substrate phosphorylation and clinical presentation.  These data raise the exciting 
possibility that Purkinje neuron PKC substrate phosphorylation may not only modulate cellular 
neuropathology but also clinical course. Clinical data on the autopsy samples utilized were 
limited, and more information on initial presentation and clinical course could provide further 
information regarding a possible role for PKC activity as a modifier of disease. Additional 
studies with more patients are required to test this relationship more definitively and to explore 
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other reasons behind the variability observed in MSA Purkinje neuron PKC activity observed in 
patient autopsy tissue.   
 The fact that similar acceleration of dendrite degeneration is observed in ATXN2[127Q] 
bigenic mice and ATXN1[82Q] bigenic mice presents an exciting opportunity for the application 
of the –omics approaches discussed in section 4.4.  Using either phosphoproteomics or 
transcriptomics, comparisons both within and between models will allow dendro-protective 
pathways to be more easily separated from spurious changes by identifying only those pathways 
that are changed by PKCi expression in both ATXN1[82Q] and ATXN2[127Q] mice (see Figure 
5.4).  In theory, such an approach has the capacity to identify novel modifiers of Purkinje neuron 
dendrite degeneration, and these modifiers will not only apply to SCA1 and SCA2 but may apply 
MSA and potentially to SCA14.  Future studies will aim to not only identify these pathways, but 
to then validate them in SCA1 and SCA2 and then subsequently assess the extent to which those 
pathways are affected in MSA and potentially other forms of inherited and sporadic ataxia. 
 In section 4.3.7, it was proposed that PKC activity may exert its dendroprotective effect 
in ATXN1[82Q] Purkinje neurons by limiting increases in dendritic excitability. There are 
several reasons to believe that a similar mechanism could be at work in ATXN2[127Q] Purkinje 
neurons.  The first is that abnormalities of Purkinje neuron spiking have been described in 
models of SCA2
11, 115
, indicating that SCA2 is also a condition where Purkinje neuron intrinsic 
excitability is perturbed.   Although intrinsic dendritic excitability has not been explored directly, 
it has been shown that an activator of SK2 channels, which are highly expressed in Purkinje 
neuron dendrites
153
 and act to reduce intrinsic dendritic excitability
237
, is able to improve late-
stage Purkinje neuron pathology in a model of SCA2
115
.  It is important to note that unlike 
studies where improvement of spiking produced neuroprotection in SCA1
114, 116
, this study did 
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not assess dendrite pathology at baseline or with SK2 modulation in this model, so there is not a 
necessary connection between the observed effect on late-stage pathology and dendrite 
degeneration in SCA2.  However, it does establish a role for abnormal intrinsic excitability in 
SCA2, and it raises the possibility that modulation of dendritic excitability could influence 
Purkinje neuron dendrite degeneration.  Future studies will aim to assess whether ATXN2[127Q] 
mice have abnormalities in intrinsic dendritic excitability, at which point the difference between 
ATXN2[127Q] bigenic mice and ATXN2[127Q] mice can also be assessed to determine if PKC 
activity suppresses dendritic excitability in SCA2 as it does in SCA1. 
 As with the ATXN1[82Q] model, it is not clear from the studies presented above why 
PKC activity is increased in ATXN2[127Q] cerebella.  The role for conventional PKC isozymes 
in ATXN2[127Q] mice appears similar to what was observed in ATXN1[82Q] mice, although 
studies of PKCα and PKCγ protein expression have not yet been performed in ATXN2[127Q] 
mice.  Future studies will aim to determine whether increases in PKCα or PKCγ protein 
expression might explain the observed increased in ATXN2[127Q] cerebellar PKC activity.  If 
no increase is identified, the same hypotheses proposed for the ATXN1[82Q] model of SCA1 
can be pursued in the ATXN2[127Q] mouse, allowing for a more complete understanding of this 
shared pathway between SCA1, SCA2, and potentially MSA. 
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Figure 5.1 ATXN2[127Q] cerebella show increased PKC substrate phosphorylation by 
conventional PKC isozymes. (A) Representative Western blot for phosphorylated PKC 
substrates at twelve weeks of age showing increased PKC substrate phosphorylation in cerebella 
from ATXN2[127Q] mice, summarized in (B). (C) Representative Western blot for 
phosphorylated PKC substrates in organotypic cerebellar slice cultures treated with 5 mM EGTA 
from twelve week old mice. Calcium chelation with EGTA reduced PKC substrate 
phosphorylation in ATXN2[127Q] slice cultures but not wild-type slice cultures, summarized in 
(D).   Throughout, data are mean ± SEM.  NS = not significant; * = P<0.05. Statistical 
significance derived by unpaired two-tailed Student’s T-Test (B) or two-way ANOVA with 





Figure 5.2 Increased PKC activity protects against dendritic degeneration in ATXN1[82Q] 
mice.  (A) ATXN2[127Q] bigenic mice and ATXN2[127Q] mice show significant cell loss in 
lobule IV/V at twenty-five weeks of age. (B) Reduced molecular layer thickness in lobule VI of 
ATXN2[127Q] bigenic mice at twenty-five weeks of age. (C) Representative images at the 
cerebellar primary fissure in wild-type, PKCi, ATXN2[127Q], and ATXN2[127Q] bigenic mice 
stained with calbindin at twenty-five weeks of age. Scale bar, 100 µm. Throughout, data are 
mean ± SEM.  NS = not significant; * = P<0.05. Statistical significance derived by one-way 





Patient No Age Sex MSA-C vs. MSA-P 
BB1427 49 Male MSA-C 
BB666 54 Male MSA-C 
BB39 61 Female MSA-C & MSA-P 
BB822 65 Female MSA-C & MSA-P 
BB1679 72 Female MSA-C 
BB658 72 Male Not Reported 
BB1358 75 Male MSA-C 
   
 
AD Samples 
Patient No Age Sex MSA-C vs. MSA-P 
BB787 51 Female N/A 
BB1302 52 Male N/A 
BB1235 69 Female N/A 
BB325 72 Female N/A 
BB1520 72 Female N/A 
BB460 73 Male N/A 
BB209 77 Female N/A 
 
Table 5.1 Demographic information on MSA patients and age-matched Alzheimer disease 
controls.  Presented above is relevant demographic information from MSA patients and age-






Figure 5.3 Increased PKC substrate phosphorylation is observed in Purkinje neurons from 
MSA patient autopsy tissue. (A) Representative images of phosphorylated PKC substrate 
staining (green) in Purkinje neurons (red) from MSA patient samples and age-matched 
Alzheimer disease (AD) controls. In phosphorylated PKC substrate images, Purkinje neurons are 
marked with arrows.  Scale bars, 50 µm. Data showing increased phosphorylated PKC substrate 
staining relative to calbindin staining in the somatic compartment of Purkinje neurons from MSA 
patient samples and age-matched healthy control samples is summarized in (B).  Each data point 
represents an individual patient, with error bars representing SEM for measurements from 
multiple Purkinje neurons in that individual.  (C) Comparison of phosphorylated PKC substrate 
staining relative to calbindin staining in patients defined clinically as MSA-C vs. patients defined 
as both MSA-C & MSA-P; data are from (B).  ** = P<0.01.  Statistical significance derived by 
two-way ANOVA detecting an effect of disease state on PKC substrate phosphorylation (B) or 






Figure 5.4 Conceptual framework for discovery of PKC-dependent dendro-protective 
pathways in SCA1 and SCA2. Proteomic or transcriptomic tools are likely to reveal changes 
between mice expressing the SCA transgene alone vs. mice expressing the SCA transgene and 
PKCi transgene.  If the mechanism for PKC-dependent dendrite protection is shared between 
SCA1 and SCA2, identifying the area of overlap between PKC-modulated pathways in SCA1 
and SCA2 will allow for elimination of spurious hits and foreground those pathways which are 
likely to be biologically relevant.  Those pathways can then be validated biochemically in SCA1 








Conclusions and Future Directions 
 The results described in this dissertation lead to four main conclusions.  The first is that 
Purkinje neuron dendrite degeneration is associated with increased intrinsic dendritic excitability 
in the ATXN1[82Q] model of SCA1.  Secondly, normalizing intrinsic dendritic excitability by 
targeting channels whose transcript levels are suppressed by ATXN1[82Q] transgene expression 
is able to improve motor performance and preserve Purkinje neuron dendrites, establishing a 
novel role for increased intrinsic dendritic excitability as a driver of Purkinje neuron dendrite 
degeneration in SCA1.  Thirdly, increased PKC activity is observed in the ATXN1[82Q] mouse 
and SCA1 patient tissue, and the action of this increase in PKC activity is to preserve Purkinje 
neuron dendrite structure and limit increases in intrinsic dendritic excitability.  Finally, increased 
PKC activity is neuroprotective in the ATXN2[127Q] model of SCA2 and is observed in MSA 
patient tissue, suggesting that a role for PKC in dendrite degeneration may extend beyond SCA1 
to other forms of inherited and sporadic ataxia.  Together, the findings of this thesis provide a 
novel conceptual framework for understanding Purkinje neuron dendrite degeneration in ataxia: 
instead of being a passive response to toxic insult, it may instead reflect a regulated process 
where electrophysiologic activity and PKC activity regulate degenerative dendrite remodeling. 
However, important gaps remain in our understanding of Purkinje neuron dendrite physiology 
and PKC activity in these diseases.  In this section, I will outline what I see as important 
opportunities for future studies extending from this work. 
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6.1 Dendritic calcium homeostasis in SCA1 Purkinje neurons 
 In any discussion of excitability and its relationship to neurodegeneration, considerable 
thought must be given to calcium dynamics.  Ionic Ca
2+
 acts not just as a charge carrier but also 
an extremely powerful second messenger that impinges upon a myriad of cellular processes
300
.  
Among these, the importance of calcium as a driver of dendrite remodeling
301
 and cell death
302
 
position it as an essential consideration in neurodegenerative disease.   
 There is an extensive literature for many neurodegenerative diseases that views 
neurodegeneration as a consequence of increased cytosolic calcium
167, 303-305
.  Additionally, 
many studies which link increases in membrane excitability to neurodegeneration invoke ionic 
Ca
2+
 as the second messenger by which abnormalities at the membrane ultimately exert their 
degenerative effect
306, 307
.  Although I do not necessarily disagree with this hypothesis in its 
relevance to other neurodegenerative diseases, I propose a different hypothesis for Purkinje 
neuron degeneration in SCA1: dendrite degeneration is driven in part by reduced cytosolic 
calcium availability, which contributes to increased intrinsic dendritic excitability that ultimately 
exerts its effect on dendrite structure by a different mechanism. 
 In the soma of Purkinje neurons, the effect of voltage-gated calcium channel opening is 
actually to hyperpolarize membrane potential because of the action of calcium-activated 
potassium channels
96
.  Indirect evidence suggests that the same principle applies in Purkinje 
neuron dendrites, because local dendritic perfusion of cadmium chloride to block voltage-gated 
calcium channels has the same effect on spontaneous spiking as dendritic perfusion of specific 
blockers of SK2 or BK
101, 308
.  These findings have demonstrated that under normal conditions, 
voltage-gated calcium channels function as stabilizers of Purkinje neuron membrane potential. 
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 calcium entry through voltage-gated calcium channels, 
demonstrating that this operates as a negative feedback loop.  Our prior work had demonstrated 
reduced BK channel expression and increased somatic excitability in ATXN1[82Q] Purkinje 
neurons
116
, and our studies showing increased dendritic excitability (see chapter 3) led us to 
hypothesize that increased calcium dendritic calcium entry might be a driver of dendrite 
degeneration in SCA1.  Our hypothesis was complicated, however, by an early study 





.  Three findings clarified our understanding: 1) 
we observed that the combination of BK-AAV and baclofen could normalize dendritic 
excitability and preserve dendrites, 2) we observed reduced expression of the mGluR1-dependent 
calcium sources, and 3) a study was published demonstrating that ATXN1[82Q] Purkinje 
neurons show reduced mGluR1-mediated cytosolic [Ca
2+
] increases after parallel fiber 
stimulation that can be normalized by treatment with baclofen
135
.  This led us to revise our 
model, such that reduced expression of calcium sources would limit dendritic calcium entry 
while simultaneously exacerbating increases in dendritic excitability, such that a strategy 
targeting both the calcium sources and BK (through the use of baclofen and BK-AAV, 
respectively) was required to normalize dendritic excitability and preserve dendrite structure. 
 This “two-hit” model of increased dendritic excitability motivates several future lines of 
study.  The first is to do a thorough and complete analysis of dendritic cytosolic [Ca
2+
] in 
ATXN1[82Q] Purkinje neurons.  Dendritic cytosolic [Ca
2+
] should be assessed at five weeks and 
fifteen weeks during baseline spiking, somatic current injection-evoked spiking, parallel fiber 
stimulation, and climbing fiber stimulation.  Distal and proximal segments should be assessed, in 
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order to provide a more granular picture of how calcium signaling might be perturbed. 
Furthermore, the effects of BK-AAV and baclofen treatment on all of these measures should be 
assessed.  Without such a complete characterization of ATXN1[82Q] Purkinje neuron dendritic 
calcium homeostasis, it will be difficult to generate biologically realistic models of the role that 
calcium plays in SCA1 dendrites.  We currently have the tools for Oregon Green BAPTA-based 
confocal calcium imaging in slices, and efforts to optimize and then apply the technique are 
ongoing. 
A second key area for further research will be to test a role for mGluR1 and downstream 
calcium sources in increased dendritic excitability and dendritic degeneration.  The role for these 
calcium sources can be assessed by repeating the BK-AAV + baclofen calcium spike experiment 
but in the presence of either mGluR1 antagonists or antagonists for one of the calcium sources; if 
the hypothesis is correct, the effect of baclofen should be occluded entirely by mGluR1 
antagonists and partially blocked by IP3 receptor, T-Type calcium channel, or TRPC3 channel 
blockers.  Conversely, activators of mGluR1 should be able to substitute for baclofen and reduce 
intrinsic dendritic excitability either by themselves or in conjunction with BK-AAV.  If mGluR1 
is determined to be upstream of BK in modulation of dendritic excitability in vitro, then an in 
vivo experiment should be performed using a specific mGluR1 agonist in conjunction with BK-
AAV to assess whether the behavioral and dendrite rescue can be recapitulated in ATXN1[82Q] 
mice. 
Yet another question that arises from this hypothesis is the following: if ionic Ca
2+
 is not 
the signal by which increased excitability produces changes in dendrite structure, how is it that 
changes at the membrane are ultimately converted into degenerative changes in the neuron?  One 
possibility is that the signaling occurs through membrane potential-dependent changes in the flux 
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of another ion; although less well-studied than Ca
2+
, changes in flux or concentration of other 
ions has been linked to biological processes as diverse as cell cycle transitions
310, 311





, and even neural circuit activity
314
.  Another possibility 
is that membrane potential itself is the signal: for example, a recent study demonstrated that 
membrane potential modulates K-Ras signaling in a manner that is independent of Ca
2+
 by 
altering the clustering of charged plasma membrane phospholipids
212
.  Future studies in this area 





, and transition metal biology
317
, to identify candidate pathways that respond to 
changes in membrane potential or non-Ca
2+
 ion flux and trigger either cytoskeletal remodeling or 
transcriptional changes.  Validation of pathway activation using downstream gene expression 
changes or phosphorylation of pathway targets can then serve as a foundation for more 
comprehensive investigation.  Although time-consuming and significant in scope, such studies 
may lead to significant insights, including identification of novel pathways for regulating 
dendrite structure not yet considered in neuroscience.  
 Beyond this, there is an important question not explored in this thesis: by what 
mechanism is ATXN1[82Q] suppressing transcript levels for these genes?  As discussed in 
section 3.3.4, polyglutamine-expanded Ataxin-1 likely exerts its effect by perturbing 
transcription, indicating that transcriptional regulators for these genes likely hold the answer.  I 
propose that there are at least two separate transcriptional systems impacted by ATXN1[82Q]: 
one controlling the expression of Itpr1, Cacna1g, and Trpc3, with another controlling expression 
of Kcnma1.  This hypothesis is based on the kinetics of mRNA transcript suppression for these 
genes (see figure 3.4): Itpr1, Cacna1g, and Trpc3, are all completely suppressed at five weeks of 
age and remain suppressed, while Kncma1 shows progressive reduction of expression from five 
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weeks of age to fifteen weeks of age.  Future studies to investigate this hypothesis will require a 
combination of bioinformatic analysis of gene regulatory elements for identification of candidate 
regulators and biochemical approaches to validate whether those candidates bind to Ataxin-1 
and/or regulatory sequences.  
6.2 Dendrite structure and its relationship to dendritic excitability in SCA1 
 Chapter 4 focuses primarily on the role for reduced ion channel expression as a driver of 
increased dendritic excitability and downstream dendrite degeneration.  A question not explored 
by this thesis is the extent to which structural changes in the dendrite then feed back to influence 
dendritic excitability.  Cable theory would predict that the substantial changes described in 
ATXN1[82Q] Purkinje neuron dendrite structure should produce some kind of impact on 
dendrite signal propagation.  We propose two opposing hypotheses for the impact that dendrite 
remodeling has on ATXN1[82Q] Purkinje neuron dendrite physiology: 1) dendrite degeneration 
further amplifies increases in dendrite excitability, or 2) dendrite degeneration is homeostatic 
from the perspective of excitability in that it opposes increases in dendritic excitability. 
   The first hypothesis is essentially a positive feedback model.  Structural changes in 
dendrite shafts that would be predicted as part of this model include reduced branching, 
increased cross-sectional surface area, and reduced length for each dendrite segment.  If this 
hypothesis were validated, it would suggest that early intervention would be critical for 
achieving maximal clinical benefit, as the establishment of structural changes that increase 
excitability would not only ensure the continued progression of disease but would also frustrate 
therapeutic strategies which relied solely on targeting dendritic channels. 
 The second hypothesis is a negative feedback model.  Structural changes in dendrite 
shafts that would be predicted as part of this model include increased branching, reduced cross-
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sectional surface, and increased length for each dendrite segment.  This hypothesis is interesting 
because of the robust literature demonstrating that neurons exert homeostatic control over 
excitability
318
.  Although the study of so-called homeostatic plasticity has only demonstrated 
functional changes through receptors or channels
318
 and structural changes up to the level 
dendritic spines
319
, it does provide a framework for considering how changes in dendrite 
structure could oppose increases in intrinsic dendritic excitability in ATXN1[82Q] Purkinje 
neurons.  If this hypothesis were validated, it would imply that targeting dendrite structure 
without also improving dendrite physiology might actually be detrimental to performance of the 
neuron within the circuit. 
 Dissociating the impact of changes in channels vs. changes in dendrite structure on 
dendrite physiology would require an experimental paradigm where structure could be held 
constant while channels were perturbed and vice-versa.  While the molecular tools for 
performing such experiments do not yet exist, such a study is ideally suited for a computational 
modeling approach.  Using the NEURON environment
320
, experiments could be performed using 
biologically realistic representations of Purkinje neurons derived from Neurolucida 
reconstructions (see chapter 3) and ion channel gene expression data from publicly-available 
RNAseq data on ATXN1[82Q] transcripts at five and twelve weeks of age
239
.  As an initial 
experiment, backpropagating action potentials could be assessed in 1) neurons where channel 
conductances per unit membrane are progressively changed proportional to the RNAseq data 
while structure is held consistent, 2) neurons where channels are held consistent while dendrite 
structure is changed according to the Neurolucida reconstructions.  Although it would be 
important to validate some of the assumptions of this model (i.e. can a proportional relationship 
be assumed between transcript abundance and conductance per unit membrane surface area for a 
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specific channel), such an approach would provide proof-of-principle for the possibility that 
changes in dendrite structure could themselves influence the evolution of dendritic pathology in 
SCA1. 
6.3 Towards a multi-compartment model of Purkinje neurons in ataxia 
 As discussed in section 1.3, changes in Purkinje neuron spiking and synaptic physiology 
have been explored in models of many spinocerebellar ataxias, while dendritic physiology has 
been largely overlooked.  This thesis focused specifically on dendritic physiology in SCA1, and 
revealed significant changes that impacted both motor performance and neurodegeneration.  
Sitting between the synapse and the spike, the dendrite mediates the influence of synaptic input 
onto the soma and also has its own influence on somatic spikes.  Now that there is a growing 
literature identifying changes in spiking, synaptic physiology, and (with this thesis) dendritic 
excitability, an important priority for the field will be integrating our understanding of these 
three compartments such that a comprehensive picture of SCA1 Purkinje neuron physiology can 
be developed. 
  In considering the literature on synaptic physiology in SCA1, it is difficult at this point 
to identify clearly any influence that the alterations we have described in dendritic physiology 
may have on synaptic integration.  This is in part due to the conflicting data which already exist 
regarding Purkinje neuron synaptic function in the ATXN1[82Q] mouse.  In vivo studies using 
flavoprotein autofluorescence (a very indirect measure of Purkinje neuron synaptic responses) 
suggest reduced climbing fiber and parallel fiber responsiveness
134
, while in vitro studies suggest 
there is no difference parallel or climbing fiber-evoked AMPA current
135
 but a significant 
reduction in parallel fiber-induced mGluR1 current amplitude
135
 or slowed mGluR1 current 
decay
136
.  To complicate things further, in vitro measurements of synaptic currents in these 
134 
 
studies were performed with cesium chloride in the pipette, such that the properties of the 
dendrite are necessarily obscured in pursuit of more accurate current measurements.  Based on 
the data outlined in chapter 3, we would predict that synaptic PSPs should spread more readily 
along ATXN1[82Q] Purkinje neuron dendrites than wild-type dendrites.  This should mean a 
given synaptic PSP will produce a larger effect on somatic spiking (as has been observed during 
blockade of Kv1 channels in wild-type Purkinje neurons
278
), and would also suggest that PSPs 
originating from nearby dendritic branches might influence one another more than they might in 
a wild-type Purkinje neuron.  Future studies to assess the impact of altered dendritic excitability 
on synaptic integration could be done in a rudimentary fashion through multi-site stimulation and 
somatic recording, but would be done best using confocal microscopy with genetically-encoded 
voltage sensors
321, 322
 to monitor the spread of depolarization throughout the dendritic tree in 
response to different types of input.  Ideally, dendritic integration of synaptic input will be 
monitored in vivo
245
, as it is very likely that the properties of the dendrite differ substantially in a 
slice preparation where much of the synaptic input is severed
323
. 
 It is clear from studies of wild-type Purkinje neurons that the dendrite influences somatic 
spiking, providing an active contribution linked to the function of dendritic conductances
101, 308
 
as well as a passive contribution stemming from the significant capacitance of the Purkinje 
neuron dendrite
324
.  This influence extends beyond baseline spiking frequency
325
 to produce 
changes in spike shape, such that elimination of the dendrite’s influence by pinching it with 
pipettes results in increased spike height and a larger AHP
324
.  Importantly, changes in somatic 
spiking have been described in several studies of the ATXN1[82Q] mouse, including changes in 
the AHP
116
, reduced baseline firing frequency
114, 116
, and altered spiking in response to 
somatically-injected current
114, 116, 309
.  It is reasonable to consider the possibility that some of 
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these changes, such as the observed rescue of the BK-mediated fast AHP in aged ATXN1[82Q] 
Purkinje neurons
116
, could arise in part as a result of changes in the dendrite.  Future studies 
could address any contribution that altered dendritic physiology may have on somatic spiking, 
either through the use of local dendritic sucrose perfusion
325
 to eliminate active contributions or 
the use of dendrite pinching
324
 to eliminate active and passive contributions. 
 It is important to note that while the work of this thesis adds the dendrite as a third 
compartment for consideration in SCA1 Purkinje neuron physiology, future studies should 
acknowledge that a three-compartment Purkinje neuron is itself an oversimplification, as the 
Purkinje neuron is not really three compartments but many.  Experiments performed in chapter 3 
and 4 to examine intrinsic dendritic excitability only demonstrate that signal propagation is 
altered in the Purkinje neuron dendrite arbor generally, without much consideration given to 
dendrites of different orders, dendrites receiving different inputs, or state-dependent 
characteristics of the dendrite, all of which confer significant complexity to dendritic 
computation in Purkinje neurons
245
 and many other neuronal subtypes
326-329
.   Computational 
modeling can be used to generate hypotheses, but these questions can also be addressed 
experimentally through imaging of neuronal activity, as imaging provides significantly wider 
spatial coverage (at a cost of temporal and spatial resolution) than patch clamp 
electrophysiology.  As discussed previously, our lab currently has the capacity for laser-scanning 
confocal microscopy, allowing for in vitro calcium or voltage imaging.  There are also other 
techniques being used that could provide even better information.  Multiphoton calcium imaging 
has been used effectively in vitro
330
 to perform studies with high temporal resolution and wide 
spatial coverage across the Purkinje neuron dendrite arbor, revealing complex signal processing 
rules such as mGluR1-dependent gating of calcium spike spread
150
.  Similarly, two-photon 
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calcium imaging has been used in vivo to demonstrate further complexity in Purkinje neuron 
dendrites, including the observation that individual dendrite segment responses to climbing fiber 
stimulus are tuned by local interneurons
245
 and the observation that dendritic calcium spikes can 
serve as analogue signals encoding stimulus strength
331
.  Although calcium flux may be a poor 
proxy for membrane potential in ATXN1[82Q] Purkinje neurons due to changes in calcium 
channel expression, it will be important to assess the extent to which these rules are intact or 
altered in ATXN1[82Q] Purkinje neurons, and ideally changes will be connected to clinically-
meaningful outcomes.      
6.4 Understanding the relationship between physiology, structure, and motor 
impairment in spinocerebellar ataxias 
 To move beyond a descriptive characterization of dendritic physiology in ATXN1[82Q] 
Purkinje neurons, this thesis identified specific ion channels mediating those changes and also 
identified treatment strategies which targeted dendritic physiology to produce relatively rapid 
improvement of motor performance (within two weeks of initiating treatment) and long-term 
dendroprotection.  These studies move towards establishing increased intrinsic dendritic 
excitability as an immediate cause of motor impairment and also a driver of neurodegeneration.  
They also raise a question: in SCA1 and neurodegenerative ataxias more generally, is it the 
structural change in the network that causes symptoms, the functional changes in the neurons, or 
both? 
 It is clear from studies of ion channel mutant mice that changes in Purkinje neuron 
physiology can produce profound ataxia without any changes in Purkinje neuron structure
104-107
.   
It has also been demonstrated in a model of Niemann-Pick disease, Type C1 that Purkinje neuron 





demonstrating that structural changes in the network are also sufficient to produce motor 
impairment.  In SCA models where both electrophysiologic and structural changes in the 
network are observed, it is vital to understand in what way each contributes to motor impairment.  
This is a clinically-meaningful question because it will identify whether normalizing physiology 
or normalizing structure will have a greater impact on patient symptoms, although it is worth 
noting that our work suggests that physiology and structure are linked. 
 I propose that early in disease progression, altered physiology may play a proportionally 
more significant role in motor impairment, but that in more advanced disease there is a 
significant contribution from structural changes in the network.   This is best supported by a 
study examining aminopyridine treatment for improving Purkinje neuron physiology in 
ATXN1[82Q] mice
114
.  This study found that chronic aminopyridine treatment in vivo could 
produce neuroprotection and long-term behavioral improvement.  Importantly, short-term 
treatment with aminopyridines could only improve motor behavior in young mice but not old 
mice, despite the fact that aminopyridines could improve Purkinje neuron spiking in both young 
and older ATXN1[82Q] Purkinje neurons.  These findings are consistent with ongoing studies in 
our own lab which suggest that treatments which improve spiking are effective if administered 
short-term in young but not old ATXN1[82Q] mice (data not shown).  Taken together, these data 
suggest that alterations in Purkinje neuron physiology are a consistent feature of disease, but that 
treatments which target physiology may only be effective for motor symptoms over the short 
term when the network architecture is relatively intact.  
 This hypothesis presents several important experiments that can be performed with BK-
AAV and baclofen.  Future studies will assess whether BK-AAV and baclofen is able to produce 
motor improvement if viral delivery, treatment, and testing occur at fifteen weeks of age.  If no 
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motor rescue is observed (as we would predict), baclofen treatment can continue until a later 
time point to assess whether treatment can halt further dendrite degeneration or even allow for 
dendrite regrowth.  Studies where ATXN1[82Q] was knocked down in SCA1 mice using 
synthetic microRNAs or doxycycline-based conditional knockdown revealed that late-stage 
knockdown could produce significant (although incomplete) reversal of motor impairment
229, 333
 
and partial recovery of dendrite structure
333
, so if the mechanism of dendrite degeneration 
continues to depend on changes in dendritic excitability it should be possible to prevent or 
reverse further dendrite degeneration if treatment is initiated in older animals.  Important insights 
could also be gained through employing these tools or antisense oligonucleotide-based 
knockdown
334
 and comparing the kinetics of rescue in expression of channels of interest (Itpr1, 
Trpc3, Cacna1g, and Kcnma1) to the kinetics of rescue in dendrite structure as far as how closely 
they coincide with behavioral rescue.  Such studies could provide important caveats for clinical 
pursuit of physiology-based therapies, and therefore represent a meaningful research priority.   
6.5 Exploring and expanding the dendroprotective PKC pathway in ataxia 
 The findings outlined in chapter 5 demonstrate increased PKC activity in SCA1 Purkinje 
is dendroprotective and opposes increases in dendritic excitability.  The findings in chapter 6 
demonstrate that increased PKC is also dendroprotective in a model of SCA2 and is observed in 
post-mortem MSA tissue, suggesting that PKC activity is a critical modifier of 
neurodegeneration in SCA1, SCA2, and potentially beyond.  These findings represent an 
important first step in characterizing a neuroprotective mechanism in ataxia that has not yet been 
described.  However, important questions remain unanswered that must be addressed to better 
understand this mechanism and potentially leverage it for clinical application. 
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 One of the most pressing questions relates to why PKC activity is increased in SCA1, 
SCA2, and MSA.  It is possible that the activation of PKC is regulated in a manner that is in 
some way specifically linked to these disease entities; alternatively, it may be a non-specific 
protective response induced by Purkinje neurons during neurodegeneration.  These possibilities 
are best addressed by exploring PKC activation in other models of ataxia with robust Purkinje 




.  Future studies will perform Western 
blots to assess PKC substrate phosphorylation at the onset of Purkinje neuron dendrite 
degeneration in these models.  A consistent finding of increased PKC substrate phosphorylation 
across all models favors the interpretation that it is a non-specific protective pathway, whereas a 
finding that only some ataxia models show increased PKC substrate phosphorylation would 
suggest disease-specific regulation. 
 Regardless of which result is obtained, the question of what triggers the increase in 
activity remains. The fact that EGTA can eliminate the increased PKC substrate phosphorylation 
in ATXN1[82Q] and ATXN2[127Q] slice cultures implicates conventional PKC isozymes, and 




, it suggests that 
pathways which regulate cytosolic calcium, DAG production, or both might be involved.  The 
presumed role for calcium as a trigger for increased conventional PKC activity is at odds with 
the hypothesis outlined in section 6.1, which proposes that ATXN1[82Q] Purkinje neurons 
actually have reduced cytosolic [Ca
2+
].  There are several possibilities: 1) there is sufficient 
calcium available under baseline conditions to allow for conventional PKC activation, but the 
increase in activation occurs through changes in DAG processing, 2) the hypothesis that there is 
decreased cytosolic [Ca
2+
] in ATXN1[82Q] Purkinje neurons is incorrect or at least imprecise, or 
3) conventional PKC isozymes are being activated by  some other mechanism.   
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The first possibility would involve some mechanism by which DAG in the membrane 
would be increased.  It is intriguing to note that diacylglycerol lipase-α (DAGLα), an enzyme 
which breaks down DAG to the endocannabinoid 2-Arachidonoyl-glycerol, is highly expressed 
in Purkinje neuron dendrites
335
 and promotes neurite outgrowth
336
 but is suppressed at the 
mRNA transcript level starting at five weeks of age in ATXN1[82Q] cerebella
239
.  Future studies 
to investigate this hypothesis will begin by characterizing expression of DAGLα and other key 
players in membrane lipid metabolism, as well as determining whether there are in fact changes 
in DAG levels in the membrane.  The second possibility can be confirmed or ruled out based on 
experiments described in section 6.1.  The third possibility is difficult to assess, in part because 
there are many mechanisms by which PKC activity could be increased, although experiments to 
investigate the possibility of ectopic expression of PKCβI or PKCβII have been discussed in 
section 5.4. 
Beyond the question of what triggers neuroprotective increases in PKC activity, it is also 
important to identify mechanisms by which PKC activity exerts its protective effect.  As 
discussed in sections 4.4 and 5.4, this can be most easily investigated using –omics approaches 
and leveraging the fact that the neuroprotective effect has been observed in both the 
ATXN1[82Q] model and the ATXN2[127Q] model.  PKC targets that consistently correlate with 
neuroprotection will not only provide mechanistic insight for PKC neuroprotection, but may also 
represent therapeutic targets in their own right, particularly if increased PKC activity is identified 
as a protective pathway induced only in some forms of ataxia. 
In summary, much remains to be understood regarding the increased PKC activity and 
neuroprotection identified in this thesis.  Events both upstream and downstream of PKC remain 
unclear, and a more complete understanding of this pathway could yield scientifically or 
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clinically important insights.  These insights may be applied beyond SCA1, SCA2, and MSA to 
other forms of ataxia, and therefore represent a significant research priority.  
6.6 Concluding remarks 
Dendrite degeneration is a ubiquitous feature of neurodegenerative diseases, including 
degenerative cerebellar ataxias.  Studies of spinocerebellar ataxias, a disabling and currently 
untreatable subset of genetic ataxias, have suggested that Purkinje neuron dendrite degeneration 
contributes meaningfully to motor impairment.  Despite this, Purkinje neuron dendrite 
degeneration in ataxia remains poorly understood.  My work in this thesis helps establish that 
Purkinje neuron dendrite degeneration is regulated by intrinsic dendritic excitability and protein 
kinase C activity in SCA1, and also demonstrates a role for protein kinase C activity in SCA2 
and MSA.  Contrary to conceptions of dendrite degeneration as a passive response to toxic insult, 
these data imply that dendrite degeneration in ataxia may be a regulated process mediated by 
some of the same systems that regulate dendrite development and maintenance in healthy 
neurons. 
This thesis provides several important contributions to the field.  First, it demonstrates 
that dendritic excitability and protein kinase C activity are capable of regulating adult Purkinje 
neuron dendrite remodeling, which is itself a novel finding.  Second, it identifies both dendritic 
excitability and PKC activity as being important for disease progression in SCA1 and likely also 
for SCA2 and MSA, suggesting that these processes may be amenable to therapeutic 
intervention.  Finally, this thesis provides a novel conceptual framework for understanding 
dendrite degeneration in cerebellar ataxia and potentially other neurodegenerative diseases.  
Future studies could expand upon the studies presented here to identify channel targets, PKC 
regulators, and downstream effectors that link both excitability and PKC to dendrite remodeling.  
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The work of this thesis, as well as the research it motivates, could bring about the development 
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